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11 innate and adaPtiVe immune cellS
Our cellular immune system consists of an innate part that quickly responds to environmental 
cues and an adaptive component that is shaped and fine-tuned during immune responses and 
expands upon the presence of antigen. The first part is represented by antigen presenting cells 
(APC) that pick up antigen and signals from the environment and instruct T cells that belong to 
the second part; the adaptive compartment.
1.1  t cells
T cells express the T-cell receptor (TCR, CD3) that recognizes antigen in an MHC-dependent 
fashion. T cells develop in the bone marrow and by re-arrangement of the TCR genes, random 
specificities of the TCR are generated. Subsequently the cells are selected for recognition in the 
thymus. T cells that are able to recognize MHC and therefore express a functional receptor with 
a useful specificity get a survival signal but the cells that too strongly recognize self-antigens 
(and are potentially harmful for the body) are programmed to die by apoptosis. Alternatively, 
CD4+ T cells with weak affinity can differentiate into regulatory T cells (natural Tregs, expressing 
transcription factor FoxP3). After selection naïve CD4+ and CD8+ T cells enter the blood and 
cycle through the body between blood and lymph nodes (LN).
Upon their first encounter with antigen in the periphery, T cells develop in distinct 
functional phenotypes, depending on the second and third signal. Classically the CD8+ T cells 
were designated as the cytotoxic T cells (CTL), producing IFNg, TNFa and granzymes to directly 
kill infected or transformed target cells. However, recently data emerged that also helper CD8+ 
T cells (TC2) and regulatory CD8+ T cells exist that suppress other T cells in infectious disease 
as well as in tumors [1,2].  
CD4+ T cells have been named ‘helper’ cells in the past but are now known to comprise a 
number of distinct subsets. Their main characteristics are secreting cytokines and expressing 
CD40-L on their surface upon antigen recognition. Main functions of the CD40-CD40-L 
interaction are the class-switch in B cells and activation of APC. However keratinocytes also 
express CD40 and can interact with CD4+ T cells [3,4]. The CD4+ T cells are defined by their 
function and recently by the expression of transcription factors [5], although the latter is mostly 
defined in mice. Whether these factors are as strictly defining the subsets in humans too is 
currently under investigation. The 4 most studied CD4+ T cell subsets are shown in figure 1. Type 
one helper T cells (Th1) are mainly characterized by high T-bet expression and the secretion 
of pro-inflammatory IFNg and -to a lesser extent- TNFa upon activation. Type 2 cells are 
characterized by the expression of gata-3 and production of IL-5 and IL-4. Their main function 
is activation and the induction of class-switching in B cells. Th17 cells were later discovered 
and the main characteristic of these cells is their production of IL-17 upon activation. Th17 cells 
maintain barrier function at mucosal sites but are also found to play a role in several autoimmune 
diseases and can be isolated from several human cancers (reviewed by [6]). The fourth distinct 
T cell subset are the regulatory T cells (Tregs), which are either directly derived from the thymus 
(natural Tregs) or are induced in the periphery (induced or adaptive Tregs). Natural Tregs 
express high CD25 and display constitutively the transcription factor FoxP3. Adaptive Tregs may 
or may not express FoxP3. They explore a number of mechanisms to suppress other T cells or 
APC. High expression of the IL-2 receptor (CD25) enables them to consume IL-2, depleting this 
source for other T cells. Also the secretion of suppressive cytokines like IL-10 and TGFb directly 
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inhibits cells. Furthermore the expression of CD39 and CD73 generate adenosine mediated 
immune suppression and also direct killing of DC is described by granzyme A or B. Van der Burg 
et al showed that also cells that do not express FoxP3 and that produce IFNg can suppress other 
T cells, underlining the heterogeneity and plasticity of T cells [7,8].
1.2  aPc instruct t cells
T cells are instructed by APC that develop out of the myeloid lineage. CD14+ myeloid cells 
enter the tissue and develop into specialized antigen presenting cells (APC) the type of which 
depends on the local microenvironment [9]. The major myeloid populations that develop are 
Langerhans cells (LC) that reside in the epidermis of the skin, dendritic cells (DC) that reside in 
the dermis and in most tissues and are highly specialized in antigen presentation to T cells, and 
macrophages that also reside in all tissues and respond quickly to local inflammatory mediators.
DC and LC pick up antigen and environmental cues in the periphery and travel via the lymph 
towards lymph nodes (LN) where they can present the antigens and instruct T cells. Antigen 
presentation by non-activated APC results in T-cell tolerance. If APC are activated in the tissue 
by the recognition of pathogens or inflammatory cytokines they will initiate an adaptive T-cell 
response by activating T cells that recognize the presented antigen. These T cells will proliferate 
and travel to the periphery. 
All APC express MHC class I and II on the cell surface. In these molecules small parts of 





















Figure 1.  APC-T cell interaction and major CD4+ T cell subsets. APC present antigen to naïve T cells and 
provides 3 signals: 1) peptide presentation in the MHC molecule.  2) Co-stimulatory molecules interact 
with stimulating or inhibitory receptors of the T cells. Activated T cell expresses CD40-L (CD154) and 
hereby ligates CD40 which activates APC. 3) APC secretes cytokines that direct T-cell differentiation. 4 
major T-cell subsets are shown on the right with the most important cytokines secreted by the APC that 
induce these subsets. Associated transcription factors that are expressed by these subsets are depicted in 
the cells as well as the associated chemokine receptors.
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1molecules present peptides derived from inside the cells. Antigen derived from outside the cell is presented as peptides in MHC class II molecules. Interestingly APC also can take up 
antigen from outside the cell and present this in MHC class I molecules, a process referred to as 
‘crosspresentation’ [10]. In this way APC can take up antigen from infected or transformed cells 
and instruct T cells to kill these cells that express the same antigen in MHC class I.
Upon activation APC upregulate antigen presenting molecules thereby increasing the 
change that T cells recognize antigen presented by these cells. Along with this activating 
co-stimulatory molecules are expressed such as CD86, CD80, CD83, CD70 but also inhibiting 
receptors like PD-L1 and 2 or B7H4 which is referred to as ‘signal 2’. These molecules ligate 
receptors expressed by T cells and provide activation or inhibitory signals to the T cells. On 
top of this the APC produce the third signal; cytokines. The type and level of cytokines informs 
the naïve T cell in what direction to differentiate.  The concomitant 3 signals shape the T-cell 
response and therefore DC, LC and to a lesser extent macrophages are an important bridge 
between innate and adaptive immunity (Figure 1). For the induction of cytotoxic CD8+ T cells as 
well as type 1 IFNg producing CD4+ T cells interleukin 12 (IL-12) is  indispensable. The opposite 
cytokine is interleukin 10 (IL-10) which is associated with immune-shut down and suppression. 
CD8 T cells recognize antigens that are presented in MHC class I molecules on cells. MHC 
class I is expressed by all nucleated cells. When a cell is virally infected or transformed like 
in cancer, abnormal antigens will be presented in MHC-class I molecules on the cell surface 
enabling CD8 T cells to recognize and kill this cell. 
CD4+ T cells recognize antigens presented in MHC-class II molecules. MHC class II 
molecules are almost exclusively found on immune cells.
1.3 macrophages
Besides becoming DC or LC myeloid cells can develop into macrophages. These innate cells 
are less specialized in antigen presentation but are present in most tissues and are involved 
in housekeeping and inflammatory responses in health and disease. Roughly two distinct 
differentiation states are recognized; the classically activated type 1 macrophage (M1) and the 
alternative differentiated type 2 macrophages (M2). M1 phenotype develops in response to 
bacterial products and IFNg. They ingest and kill pathogen upon activation and are tumorocidal 
[11]. Furthermore, upon danger signal-mediated activation, they secrete cytokines that amplify 
the danger signal and attract more immune cells. Important features of M1 macrophages are 
the expression of iNOS, ROS and the production of the pro-inflammatory cytokine IL-12 for 
stimulation of NK and type 1 T cells. The opposite phenotype, M2 macrophages express high 
levels of scavenger receptors to take up cell debris and are associated with low production 
of pro-inflammatory cytokines and high production of IL-10, IL-1b, VEGF and matrix 
metalloproteinases (MMP). M2 macrophages play a role in chronic inflammation, parasite 
clearance and wound healing but they also polarize T cells to a Th2 phenotype and dampen 
immune responses. Notably, the terms M1 and M2 are a useful over-simplification of the type of 
macrophage that can be detected. Macrophages can adapt to a plethora of differentiation and 
activation states ranging between the M1 and M2 type.
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1.4 aPc activation by danger signals 
There are a number of pattern recognition receptors known that allow APC to sense danger, 
including the Toll-like receptors (TLR) and Nod-like receptors (NLR). In humans there are 10 
different TLR recognizing bacterial products (TLR 1,2,4,5,6) or viral products (TLR 3,7,8,9) and 
they can be expressed either on the cell surface (bacterial) or intracellular (viral) corresponding 
to where most likely a pathogen would be encountered. Not only pathogen products but also 
cell-derived products like HMGB-1 (TLR4) or heat shock proteins (HSP) can bind TLR. Ligands 
that act as agonists for these TLR and NLR are now explored as adjuvant in vaccines in order 
to induce an activated state of the APC. The choice of ligand is often based on in vitro  APC 
activation assays or effects found in mouse models. However, expression differs between mice 
and man for some TLR. Furthermore, the fact that some of the TLR and NLR are expressed by 
other cells such as non-APC immune cells like keratinocytes and endothelial cells is generally 
not taken into account [12,13]. 
1.5  immunology of tumors
In a recent update of the seminal paper of Hanahan & Weinberg on the hallmarks of cancer 
several features important for cancer progression were added including 2 immunological 
hallmarks; avoiding immune destruction and tumor promoting inflammation [14]. Tumors and 
tumor stroma can be infiltrated by high numbers of immune cells and the balance between 
these cells predicts disease outcome in several tumor types [15]. The current knowledge about 
key immunologic features in human tumors are listed below.
1.5.1 t cell infiltrate and immune escape in tumors
Mice lacking T-cell subsets are more likely to develop tumors indicating that the immune system 
operates as a significant barrier for tumor formation [16,17]. Immune deficient humans develop 
often tumors, albeit that the majority comprise virally-induced tumors. A growing number of 
studies show that in human tumors the infiltration of CD8+ T cells correlates with a certain 
level of tumor control resulting in better disease outcome for the patient [18]. For example, in 
breast carcinoma it was shown that high CD8+ T-cell infiltration or low CD4+ T-cell infiltration 
based on detection by immunohistochemistry could predict a better or worse disease outcome 
respectively [19]. In another large cohort of colorectal cancers the presence of CD3+CD8+ but 
also the number of CD8+CD4+ T cells was correlated with the absence of metastasis formation 
and better disease free survival [20]. On top of this, several studies show that the ratio between 
CD8+ and regulatory FoxP3+ cells predict outcome as for example is found for cervical cancer 
[21,22]. In contrast to the clear finding that the high infiltration of CD8 T cells contributes to 
or reflects a favorable patient outcome, the role of CD4 T cells is not as clear. This might be 
explained by the fact that not all studies dissect the type of CD4 T cell. The type of CD4+ T 
cells is of significance since  in most studies a high number of regulatory T cells is associated 
with bad prognosis, however in colon carcinoma a protective role for regulatory T cells was 
reported [23]. 
Tumor cells exploit mechanisms to avoid recognition by CD8 T cells. MHC expression is 
down regulated as a result of loss of genes or defects in the antigen loading machinery [24]. 
Also expression of tumor antigens is lost during tumor development while intrinsic resistance 
to CTL is increased, processes that are thought to be a result of immunological pressure [25]. 
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1Another way for the tumor to avoid T-cell induced apoptosis is inhibiting the T cells directly. This can be executed during cell-cell contact by the expression of inhibitory co-receptors 
like programmed-death-ligand 1 (PD-L1) or B7-H4 molecules by the tumor cells that ligate 
with activation-receptors on the T cells and results in strong suppression of functions [26,27]. 
Secondly many immune suppressive factors can be produced by tumors that directly suppress 
T cells function. These include TGFb, IDO, PGE2 and IL-10 [28,29]. Not only do these factors 
suppress local T-cell function, the APC in the microenvironment are also suppressed and 
therefore the induction of tumor-specific T-cell immunity is disturbed as well.
1.5.2  tumor-promoting inflammation
Tumors require nutrients, oxygen and the ability to discharge metabolic waste and carbon 
dioxide. These needs are addressed by tumor associated neovascularization [14]. Macrophages 
are the perfect help in this process, especially the wound-healing subset since they are 
equipped to remodel tissue and produce VEGF. How tumors attract these myeloid cells has 
been excellently reviewed by Murdoch et al [30] . 
Tumor cell and tumor-associated cell-produced CCL-2 attracts  and shapes myeloid cells 
and interferes with osteoclasts in bone metastatic disease [31,32]. Blocking CCL-2 reduced the 
number of tumor-infiltrating macrophages in pre-clinical animal studies. Hypoxia Inducible 
Factor-1 (HIF-1) and Colony Stimulating Factor-1 (CSF-1/M-CSF) produced by tumor and stromal 
cells actively attract monocytes into tumor tissue.  CSF-1 knockout mice displayed lower 
numbers of tumor-infiltrating macrophages and tumor progression was delayed [33]. Finally 
there are few reports on tumor-associated-cell produced CXCL-12 which in an autocrine loop 
fosters M2 development [34,35].
Many studies have been conducted to determine which factors induce macrophage 
differentiation upon arrival in the tumor. Cytokine levels in tumor fluids, in ascites or in 
blood have been measured but also gene expression analyses on tumor cells was performed. 
Interleukin-6 (IL-6) was often reported to be present in tumor fluids and was also found to 
be produced by tumor cell lines. IL-6 is a cytokine involved in many chronic inflammatory 
diseases such as rheumatoid arthritis [36]. A number of studies on the in vitro differentiation 
of M2 macrophages - when monocytes or immature DC are exposed to tumor cell supernatant 
derived from lung, ovarian or cervical cancer cell lines - showed that this differentiation partly 
depended on IL-6.  In nearly all cases, IL-6 was shown to act in synergy with other factors [31,37-
39]. Interestingly, IL-6 signaling results in STAT3 phosphorylation in both tumor and immune 
cells. Activation of transcription factor STAT3 suppresses the release of mediators necessary for 
immune activation [40].
CSF-1 (M-CSF) not only acts as an chemo attractant but can also differentiate monocytes into 
CD14+CD163+CD206high M2 macrophages in vitro [41].  A similar dual role has been suggested 
for VEGF which acts as an angiogenic factor when secreted by wound healing macrophages but 
which also can impair APC differentiation when secreted by tumor cells [42].
Prostaglandin E2 (PGE2), produced in chronic inflammatory environments by the COX 
enzymes, is another key-factor overexpressed in several human tumor-types [43]. Its role 
is well investigated in colorectal cancer where over expression of inflammatory induced 
COX-2 enzyme and production of PGE2 during smoldering inflammation eventually leads to 
oncogenesis. Blocking this pathway might prevent oncogenesis in the low-intestines [44]. Also 
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in 40-50 % of CxCa patients COX-2 is highly expressed and high intra-tumoral expression was 
linked to a bad prognosis [45-47]. Notably, a paracrine loop between high COX expression, 
induction of IL-6 and elevated levels of pSTAT3 has been suggested to exist in human tumor 
cell lines [48].
Human tumors are shown to harbor and shed high levels of Heat Shock Protein 27 (HSP27) 
(reviewed by [49]). High levels of HSP27 present in patient serum and breast carcinoma cells 
function as an endogenous danger signal augmenting cell activation by triggering TLR and 
scavenger receptors that directly affects APC differentiation and function in vitro [50,51].
Thus, inflammatory mediators attract myeloid cells to the tumor and actively interfere with 
APC differentiation towards tumor promoting M2 type macrophages. The type of macrophage 
that is found in tumor tissue is subject to local levels of many factors which can lead to the 
great variety in APC types present within a single tumor. Interestingly, most factors produced 
are also potently produced by macrophages themselves upon stimulation suggesting a feed 
forward loop.
1.5.3  clinical impact of tumor associated macrophages
Studies on macrophage infiltration in human tumors often did not distinguish between 
macrophage differentiation (M1 or M2) but most studies suggest that a  high number of tumor 
associated macrophages is beneficial for tumor growth and, therefore, associated with disease 
progression and poor prognoses (reviewed in [52]). However, a high number of infiltrating 
macrophages can correlate with a good prognosis. This discrepancy is found for instance in 
human papilloma virus (HPV) induced diseases. It was reported that macrophage infiltration 
correlated with disease progression of HPV-induced cervical intraepithelial neoplasia [53]. 
Yet, in cervical cancers the number of stromal macrophages positively correlated with the 
intratumoral expression of IL-12p40, which itself was associated with a favourable overall survival 
of patients [54]. In lung cancer, higher numbers of IL-10+ CD68+ macrophages correlated with 
worse survival of patients with late stage disease [55]. However, another study showed that high 
macrophage numbers may correlate with better survival. Importantly, in the latter study they 
focused on the phenotype of the macrophages revealing that improved survival was associated 
with a high M1/M2 ratio. The type of macrophage studied thus may explain the apparent 
discrepancy between the studies [56]. 
2. Human PaPilloma ViruS induced tumorS
2.1  HPV
The family of Human Papilloma Viruses (HPV) consists of over 100  DNA viruses that infect 
keratinocytes at the stratum basale of the epithelium and replicates inside the cell during the 
differentiation of these cells. Oncogenic HPV types like to infect mucosal sites at the junction 
of squamous and columnar epithelium and in the cervix are thought to enter through micro-
lesions in the epithelium.
Human papilloma virus is a circular double stranded DNA virus, which encodes for 7 proteins, 
3 regulatory proteins (E1, E2 and E5), 2 oncoproteins (E6 and E7) and 2 late proteins that form the 
viral capsid (L1, L2) [57]. All these proteins exert specific functions during the different stages 
of viral replication. Some proteins interfere with the differentiation and replication machinery 
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1of the host cell to force the cell to maintain replication to ensure high virus production. As a consequence of activation of these ‘oncoproteins’ host cells keep dividing and lose their 
natural tumor suppressor functions.  Certain viral types only cause warts (HPV 6 and 11) but HPV 
types of the alpha clade are more aggressive and may cause invasive cancer upon persistent 
viral infection. 
In the episomal replicative phase of the virus, E2 protein suppresses E6 and E7 to ensure a 
high copy number of virus particles. During integration of the viral genome into the DNA of 
the host E2 often gets lost leading to deregulated expression of E6 and E7 which is a crucial 
step in the progression to cancer [58]. The E6 and E7 oncoproteins cause aberrant proliferation 
and inhibition of apoptosis  which efficiently immortalizes cells. Importantly HPV oncogene E6 
ubiquitinates P53 tumor suppressor protein and rapidly degrades it inducing high turnover of 
this protein and deregulating the cell cycle checkpoints upon cellular DNA damage. This high 
turnover may lead to increased expression of P53 in MHC and induction of P53-specific T cells 
and antibody responses.
2.2  immunity in HPV-induced cervical cancer
HPV is the most prevalent sexual transmittable disease and almost all women and men get 
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Figure 2. HPV mediated induction of cancer. LEFT: Normal squamous epithelium at the cervix consists 
of epithelial cells that differentiate during migration towards the surface (light blue cells). RIGHT: The 
tonsils and tonsillar crypts are covered with a layer of epithelial cells. This epithelium is referred to as 
lymphoepithelium because the basement membrane is often disrupted and the co-existence of epithelial 
and immune cells. Basel cells of the epithelial layer get infected by an oncogenic type of HPV. Early genes 
are expressed from episomal DNA during cell differentiation and movement towards the skin surface (blue 
cells). Upon integration of the viral episomes into the host genome, E2 is lost and E6 and E7 are continuously 
expressed (red cells). Overexpression results in carcinogenesis: cells disrupt the basal membrane and the 
lesion progresses to a malignant carcinoma. For the location of the cervix several stages of intra-epithelial 
neoplasia -before development into malignant disease- are described. For the location of the oropharynx 
it is not clear yet whether the same processes and disease stages evolve (depicted by a question mark).
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it does not induce an overt inflammation. Microarray studies showed that HPV can actively 
suppress inflammatory responses in keratinocytes and thereby avoiding that the immune 
system gets alarmed [12]. Others showed that HPV manipulates LC residing in the epidermis 
and turns them into tolerogenic APC [59]. Although most women clear the virus, a minority is 
not able to do so and may develop viral induced neoplasia. HPV16 is the causative virus type in 
most cases followed by HPV 18, 31, 45 or sporadically other oncogenic types. 
Though many studies have been performed the question why not all women clear the 
infection is not answered yet. Genetic risk factors like IL-10 polymorphisms or differences in 
interleukin-receptors are proposed. Clearance of the virus is achieved by activation of adaptive 
immune responses. In healthy subjects that do not show active HPV infection at the cervix 
functional circulating T cells are found in the peripheral blood mononuclear cells (PBMC). In 
the majority of these women proliferating T cells were found that recognize oncoproteins 
E2,E6 and E7 and produce IFNg and IL-5 upon antigen encounter [60,61]. However failure of 
viral clearance was associated with a weak or complete lack of detectable HPV-specific T cells 
[62-64]. 
The progression of cervical intraepithelial neoplasia (CIN) is associated with the influx 
of immune cells. However in the progression towards CxCa local T cells lose their ability to 
produce IFNg. Also macrophages are attracted to the site of disease and this is associated with a 
worse disease outcome. CXCL-12 and CCL-2 are important cytokines in attracting  macrophages 
and regulatory T cells. Presumably these cells contribute to the wrong milieu by production 
of IL-10 and IDO [53,65]. Tumor cell produced PGE2 and TGFb can directly suppress infiltrating 
immune cells [46,66]. In contrast to these suppressive parameters, the presence of type 1 T cells 
preludes a good prognosis.  Infiltration of high numbers of granzyme B+ CD8+ T cells in pre-
malignant CIN lesions is related to disease regression and in line with this is the finding that once 
CxCa has developed the composition of T-cell  infiltrate is detrimental for the disease outcome 
[64]. Piersma et al showed the relation between a high CD8+/FoxP3 ratio and the absence of 
the, prognostic bad sign of LN metastasis. This finding was confirmed in another study that also 
investigated the antigen presentation machinery on tumors cells. Shut down of MHC-class I and 
the associated protein MICA further contributed to poor survival in these patients indicating 
that local T cells and their ability to recognize tumor cells is of great importance for disease 
outcome [21]. Another mechanism besides shut down of MHC-molecules on the surface of 
cancer cells is expression of receptors like Serpins to prevent the tumor cells from cytotoxic 
killing [25]. Interestingly although the inhibitory receptor PD-L1 is known to inhibit T cells, 
expression of this ligand by cervical tumors together with high numbers of Tregs  correlated 
with a better prognosis [67]. 
Aforementioned parameters were all studied in the tumor microenvironment. The most 
important site for priming the T cells that are so important for survival happens in the tumor 
draining lymph node. Interesting work of Fattorossi et al showed that  tumor draining lymph 
nodes with metastatic tumor cells contain more regulatory and Th2 type cells [68]. Tumor 
infiltrating T cells and LN derived T cells from patients with HPV16 or 18+ CxCa were shown 
to comprise HPV specific T cells in around 30% of TIL but all LN cultures [69]. However, from 
these same LN HPV specific regulatory T cells could be isolated that did not express high FoxP3, 
produced IFNg as well as IL-10 but clearly suppressed proliferation and cytokine production of 
stimulated T cells in an HPV-specific manner [7].
14
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1All these tumor specific T cells travel to the tumor via the blood. Whether the responses found in the blood are representative for what is happening in the tumor can be debated but in 
CxCa patients it is known that a detectable cellular adaptive immune response in the blood is 
often lacking in contrast to healthy women, as described previously. 
2.3  immunity in HPV-induced carcinoma of the head and neck region
In the 1970s the first reports emerged in northern Europe that HPV16 was found to be present 
in squamous cell carcinoma of the head and neck (HNSCC). The last decades steep increase 
in the incidence of HPV16+ HNSCC is reported worldwide and although the percentage 
differs per country it is reported that 30-50% of all oropharyngeal cancers harbor HPV16 (IPV 
conference 2011).  HPV16 DNA is predominantly found to be involved in tumors that arise in 
the oropharynx and the base of the tongue and not in lower regions of the pharynx or the 
nasopharynx. Interestingly HPV type 16 is involved in >90% of HPV+ HNSCC whereas in CxCa 
also other types are involved [57]. In contrast to the known etiology of HNSCC (tobacco and 
alcohol use) that is often linked to mutated and over-expressed p53, patients with HPV16+ 
HNSCC present at younger age and often lack a history of smoking and drinking. Despite the 
fact that HPV+ patients  present with more advanced stage of cancer they do much better 
in survival upon standard treatment compared to alcohol and tobacco-induced HNSCC [70]. 
Suggested reasons for this include better general health of these patients because of age, less 
morbity in general, less secondary malignancies by ‘field cancerization’ or the viral induced 
oncogenic pathway that makes the tumor more susceptible for radiotherapy. 
Carcinomas of the head and neck region use the same mechanisms to hide for and suppress 
immune cells as described earlier. In HNSCC up to 88% of the tumors showed loss of HLA class 
I expression and especially in metastatic lesions HLA-class I expression was lost [71,72]. In at 
least 40% of HNSCC high expression of COX-2 is reported, and this related to the presence of 
metastasis, VEGF levels and poor survival [73,74]. In HNSCC the infiltration of s100+ infiltrating 
DC as well as T cells including CD4+ T cells, irrespective of their subtype, correlated to a better 
prognosis [75]. The majority of HPV+ HNSCC display an adaptive inflammatory response and 
infiltration of T cells as analyzed by gene array [76]. The group of Dalianis (based in Stockholm) 
reported higher number of CD8+ but also FoxP3+ cells in HPV16+ HNSCC compared to HPV 
negative (IPV conference 2011). This suggests that HPV-induced tumors are more immunogenic 
than non-virally induced HNSCC. Except for one study that reports circulating HPV16 E7-
specific T cells and reports about the presence of circulating HPV specific antibodies, nothing 
is known HPV specific immunity in these patients.
3. tumor tHeraPy – focuS on reinforcement of 
tHe immune SyStem
3.1 treatment of cervical and oropharyngeal cancer
Surgery, with the aim to remove all the malignant cells, is still the first choice of treatment for 
most cancers including CxCa and HNSCC. In cervical and oropharyngeal cancers, the diagnosis 
is based on a tissue biopsy. The immune-stimulating effects of biopsies are not clear but cases 
of spontaneous regression of CIN lesions after a biopsy exists and there is also a correlation 
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with detectable immune responses in the blood [62]. If tumors have invaded surrounding tissue 
or have metastasized, the patients are treated with chemotherapy, radiotherapy, monoclonal 
antibodies or combinations of these. Especially advanced HPV+ HNSCC is treated with 
radiotherapy combined with platinum based chemotherapy because surgical removal would 
be too disabling. 
3.2 Platinum based chemotherapy
Worldwide, the therapy for advanced, persistent or recurrent CxCa primarily consists 
of cisplatin, carboplatin and combinations of platinum-based drugs with other types of 
chemotherapeutics [77]. In the Netherlands the current guideline is to treat patients with 
carboplatin, sometimes in combination with paclitaxel (www.oncoline.nl/cervixcarcinoom). 
Platinum-based chemotherapeutics act by binding to DNA. This results in the activation of 
various signal-transduction pathways, including those for DNA-damage recognition and repair, 
cell-cycle arrest and apoptosis. Compared to cisplatin, carboplatin forms DNA adducts more 
slowly and higher concentrations are required for similar efficacy, but the (nephro)toxicity is 
lower [78]. Unfortunately, many CxCa tumors are chemotherapy resistant and the response 
rate to cisplatin ranges from 20% to 30%, with an overall survival of 7 months [77]. Also for 
tumors of the oropharynx the first choice of chemotherapy is cisplatin.
Tumors of all origins can have or gain resistance to platinum based treatment. In search of 
predictors for response to chemotherapy a study was conducted by Ferrandina et al. in which 
they determined the expression of COX-2 enzymes - the inflammatory induced enzyme that 
produces PgE2- prior to adjuvant treatment with cisplatin based chemotherapy. The  patients 
with high COX-2 expressing tumors did significantly worse in survival [45].
If cancer patients suffer from lymphopenia before the start of treatment they are less likely 
to respond to chemotherapy suggesting that immune cells are important for the response 
to chemotherapy [79]. Although the main goal of chemotherapy (and radiotherapy) is to kill 
the tumor cells, recent articles suggested that chemotherapy partly acts through the immune 
system. Several studies in mice showed synergy between platinum treatment or radiation with 
vaccination, indicating that these therapies make tumors more prone for immune attacks 
[80,81].  In patients with CxCa the composition of immune cells in the tumor draining lymph 
nodes was distorted by the treatment with cisplatin and radiation therapy. It was shown that a 
low dose of radiotherapy in combination with chemotherapy was crucial for the induction of a 
type 1 skewed T-cell response [82]. Remarkably, the higher dose of radiation resulted in loss of 
CD4+ T cells in the tumor draining lymph node. Since T cells are not susceptible for radiotherapy, 
probably the surrounding stroma was affected hampering CD4+ T cell outgrowth [82].
Recent work form the group of Zitvogel shows immunostimulatory effects by expression 
of calreticulin (CRT) and HMGB-1 and ATP release of tumor cells treated with oxaliplatin. These 
factors supported a better uptake of apoptotic cells (CRT) and activation of tumor draining 
APC by HMGB-1 mediated triggering of TLR4, thereby contributing to a shift in the local tumor 
milieu and the boosting of tumor-specific T-cell responses. Cisplatin induced HMBG-1 release 
in several cell lines but failed to elicit a strong immune response [83]. It must be said that this 
work until now only involves mouse models with prior treated, implanted tumors and therefore 
this pro-inflammatory effects of platinum-treated dying tumor cells have to be confirmed in 
other models and human tissue. 
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1The above mentioned mechanisms can explain why the presence of immune infiltrate is a good marker to predict response to chemotherapy. However these correlations are mainly 
investigated for other classes of chemotherapeutics then platinum based chemotherapeutics 
[18,19,84,85].
3.3 monoclonal antibody therapies
Over the past decade monoclonal antibodies (MAbs) have become an important treatment 
modality for several types of tumors. As in normal B-cell produced antibody responses, these 
MAbs consist of the ‘fragment of antigen binding (Fab)’ and the ‘constant fragment (Fc)’ of 
which the latter usually resembles the IgG family in therapeutic antibodies. In contrast to the 
subclasses of IgA and IgM that predominantly bind complement, IgG is suitable to bind to 
FcgReceptors of immune cells. With antibodies targeting specific tumor expressed molecules 
for example to B-cell antigen CD20 (Rituximab), growth factor receptors and prevention of 
signaling on tumor cells (EGFR, cetuximab, Her2, trastuzumab) or soluble factors (VEGF, 
bevacizumab) there is now a broad range of functional, clinically relevant antibodies. Although 
antibodies were first designed to directly block functional pathways on tumor cells, the 
increased response in patients expressing high affinity alleles for FcgR indicated that activation 
of immune cells contributed to the clinical effects [86,87]. 
Human immune cells express 3 Fc Receptors which is not the same in mice. FcgRI (CD64) is 
the high affinity receptor for IgG1 and IgG3 antibodies expressed on neutrophils, macrophages 
and eosinophils. FcgRII (CD32) is low affinity for IgG1 and IgG3 and expressed by the same cells 
as well as by platelets. The third receptor, FcgRIIIa (CD16) is expressed on natural killer (NK) 
cells and on macrophages. Although CD16 has less affinity then FcgRI, it is capable to induce 
antibody-dependent cell-mediated cytotoxicity. Mouse models and in vitro tests with human 
cells showed that NK cells, expressing FcgRIII can recognize and kill MAb opsonized cells, the 
phenomenon referred to as Antibody-Dependent Cellular Cytotoxicity (ADCC). Based on this, 
much effort has been put into optimizing the Fc region to better bind FcgRIII [88]. Figure 3 
shows the several mechanisms of how MAbs are thought to mediate their effects. 
Figure 3. Antibody mediated anti-tumor mechanisms and immune cells. 1) MAbs bind on receptor on 
tumorcells and blocks autocrience loop of growth factor supply. MAb to soluble antigens do not interact 
with immune cells but deprive tumor cells from growth factors. 2) Tumor bound antibodies are recognized 
by FcgRIII (CD16) on NK cells and activated NK cells release granzymes and perforin to lyse tumor cells. 3) 
Antibody-opsonized tumor cells and tumor particles are engulfed by macrophages. 4) Macrophages and 






MAb-based treatment are not included in standard regimes for CxCa. In oropharyngeal 
cancer the addition of Cetuximab to target epithelial growth factor receptor (EGFR) on tumors 
in combination with radiotherapy is currently tested for efficacy compared to chemo-radiation. 
Great improvement of disease free survival with the addition of the MAb bevacizumab  which 
blocks soluble VEGF, was achieved in patients with colon cancer. Addition of Cetuximab to 
this treatment protocol did, unexpectedly, not further improve the survival of these patients 
[89,90].
outline of tHiS tHeSiS
In this thesis, several aspects and cellular players involved in the immune response to (HPV-
induced) tumors were investigated. 
 In chapter 2 a detailed analysis of HPV-specific immunity in a large group of patients 
with HPV-induced cervical cancer (CxCa) in relation to HLA-types and prognostic factors was 
performed. In 30% of the tested patients, circulating HPV specific T cells were found, most often 
in patients with deeply infiltrating tumors. In this group, patients with HPV specific proliferative 
immunity displayed better disease free survival.
It was shown earlier by Piersma et al [69] that only in 30% of TIL populations, HPV specific T 
cells were found. In chapter 3 an in depth analysis of the breadth and type of HPV specific T-cell 
populations in tumor infiltrating T cell (TIL) cultures or LN cells from HPV 16 or 18 positive CxCa 
patients was performed. We found that if patients displayed a HPV-specific T cell response, this 
was surprisingly broad. Despite recognition, a number of cells did not produce type 1 cytokines 
and therefore we tested what TLR-agonist was able to support cytokine induction by these T cells.
In chapter 4 we asked the question whether HPV-specific T cells play a role in  HPV-induced 
HNSCC. We hypothesize that HPV-induced tumors are more immunogenic and stimulate 
strong T-cell reactivity to the viral oncoproteins in contrast to HPV-negative tumors. We set up 
a pilot study to investigate whether HPV is present in HNSCC in the Dutch patient population 
and at which anatomical site. Accordingly, blood and tumor infiltrating T cells were analyzed for 
the presence of functional HPV specific T cells. 
The lack of T cell responses in CxCa patients and the ‘poised’ function of tumor-antigen 
specific T cells could be a lack of proper priming by DC. Therefore we investigated in chapter 
5A the effects of CxCa produced soluble factors on the differentiation of antigen presenting 
cells (APC). Several tumor cell lines hampered DC differentiation or even skewed monocyte 
differentiation into tolerogenic tumor promoting M2 macrophages. We identified the factors 
responsible for this and investigated the outcome of the interaction of HPV specific T-cell 
clones with these macrophages.
Since patients with advanced or recurrent disease are treated with platinum based 
chemotherapy we investigated the immune-modulating effect of this therapy on tumor 
cells,  tumor-modulated APC and subsequent interaction with T cells. This ongoing work is 
summarized in chapter 5B. 
Therapeutic vaccination is being developed for treatment of chronic infections and cancer, 
and aims to generate protective T-cell immunity. Although some clinical successes have been 
reported, particularly in the field of cancer vaccination, there is still much to be gained in terms 
of efficacy [91,92]. Especially the adjuvant used and the route of administration of vaccines 
18
Introduction
1are critical factors that determine the type and memory of the resulting T-cell response. Intradermal vaccination is an attractive method for diseases in the skin such as HPV induced 
tumors and melanomas since the induced T cells get skin-homing instructions.  In chapter 
5 we showed already that highly pure DC can become activated by the addition of several 
different TLR agonists in vitro. To assess the effect of these TLR agonists on the APC present 
in the dermis, a human skin-explant model was used to analyze the phenotype and function 
of the APC migrating out the skin upon TLR-injection. These results are described in chapter 
6. Surprisingly, only few TLR-agonists turned out to induce activation  of the migrating cells.
The current treatment of patients with advanced colorectal cancer consists of 
chemotherapy together with the MAb bevacizumab that blocks soluble VEGF. The addition 
of a second antibody that targets tumor expressed EGFR (cetuximab) to this treatment did 
not result in the expected disease free survival benefit in a large randomized phase III study 
(CAIROII). Analysis of gene polymorphisms in the FcgReceptors revealed that patients with the 
high affinity FCGR3A polymorphism did significantly worse upon addition of cetuximab to the 
standard treatment. As colon cancers are generally infiltrated with macrophages we tested the 
hypothesis that membrane bound antibodies could activate tumor promoting M2 macrophages 
and that this would happen more efficiently in patients with high affinity FCGRIIIA in chapter 7.
In chapter 8 the work of this thesis is discussed in light of recent literature.
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Chapter 2
A detailed analyses of HPV-specific immunity was performed in a large group of patients with 
HPV-induced cervical cancer (CxCa) in relation to HLA-types and prognostic factors. Patients 
were HLA-typed and HPV16/18-specific T-cell immunity was assessed by proliferation assay 
and cytometric bead array using freshly isolated PBMC and by phenotypic analysis of HPV-
specific T cells. The results were analyzed in relation to known disease-related HLA-types (DR7, 
DR13, DR15/DQ06), invasion-depth and size of tumor, lymph node (LN) status and disease free 
survival. 
In total 119 HLA-typed patients with CxCa were analyzed. Patients expressing the HLA-DR13 
haplotype were underrepresented as compared to the Dutch population (p=0.014), whereas 
HLA-DR7 was overrepresented in patients with HPV16+ CxCa (p=0.006).  In 29 of 94 patients 
(31%) from whom blood could be tested, a proliferative response to HPV16/18 was detected, 
which was associated with increased numbers of HPV-specific CD4+CD25+ (activated) T cells 
(p=0.03) and HPV-specific CD4+CD25+FoxP3-positive T cells (p=0.04). The presence of both 
FoxP3-positive and negative HPV-specific CD4+CD25+ T cells was significantly correlated 
(p=0.01). Interestingly, the detection of HPV-specific proliferation was associated with invasion 
depth (p=0.020) but not with HLA type, tumor size nor LN status. Moreover, the detection 
of HPV-specific immunity was associated with an improved disease free survival (p=0.04) in 
patients with deeply infiltrating tumors. 
In conclusion, HPV-specific proliferative T-cell response, comprising higher percentages 
of HPV-specific CD25+ and CD25+FoxP3-positive CD4+T cells, are more frequently detected in 
patients with deep infiltrating CxCa tumors and associated with an improved survival. 
abstraCt
introduction
Cervical cancer (CxCa) is the second most common cancer in women worldwide (1). It develops 
as a result of an uncontrolled, persistent infection with a high-risk type of human papillomavirus 
(HPV), in particular types HPV16 and HPV18 (2). The HPV genome encodes two oncoproteins, 
E6 and E7, which are constitutively expressed in high-grade cervical lesions and cancer since 
they are required for the onset and maintenance of the malignant cellular phenotype (3). 
As the HPV proteins are foreign to the body one would expect the immune system to 
respond against these antigens when expressed in the cervical epithelium. Indeed, HPV16-
specific Th1- and Th2-type CD4+ proliferative T-cell responses were frequently detected in 
PBMC cultures of healthy individuals (4-6) and both HPV16-specific CD4+ and CD8+ T cells 
are able to migrate upon antigenic challenge in exposed healthy individuals (7) showing that 
successful defense against HPV16 infection is commonly associated with the induction of a 
systemic effector T-cell response against these viral antigens. This notion is sustained by our 
most recent study showing that the full regression of HPV16-induced high-grade vulvar lesions 
is strongly associated with the strength of vaccine-induced HPV-specific immunity against 
these early antigens, as measured by proliferation and cytokine production (8). 
A number of relatively small in vitro studies on the presence and function of circulating 
HPV16- or HPV18-specific T cells in patients with HPV16- or HPV18-induced cervical squamous 
intraepithelial lesion or cancer have suggested that the development of CxCa is strongly associated 
with failure to mount a strong HPV-specific type 1 T-helper and cytotoxic T lymphocyte response 
and the induction of HPV-specific regulatory T cells (5;9-11). Furthermore, studies in situ suggested 
that CD8+ T cells may fail to migrate into the tumor cell nests and when tumors are infiltrated 
by CD8+ T cells it coincides with the infiltration by CD4+ T cells with a regulatory phenotype, as 
indicated by the expression of intra-nuclear FoxP3. (12) In addition, half of the tumor-infiltrating T 
cells express the programmed cell death receptor 1 as a sign of T-cell exhaustion (13). Moreover, 
the ratio between the tumor-infiltrating CD8+ T cells and co-infiltrating CD4+FoxP3-positive T 
cells is an independent prognostic factor for overall survival (14), indicating the key role of these 
different types of T cells in HPV-induced diseases such as cervical cancer. 
The limited numbers as well as the response rate of patients analyzed in most of the 
studies so far precludes the assessment of the role or impact of HPV-specific immunity in 
novelty and impact of the study: Studies on the proliferative T-cell response against 
the two oncoproteins E6 and E7 of high-risk human papillomavirus type 16 and 18 have 
shown that the presence of a strong T-cell reaction was associated with protection against 
disease progression. This notion was sustained by our recent vaccine study in which such 
a response correlated with the regression of HPV16-induced high-grade lesions. This large 
prospective study reveals that especially the patients with deep stromal infiltrating cervical 
tumors display proliferative HPV-specific T-cell responses. Moreover, patients with 
deeply infiltrating tumors displaying such a HPV-specific proliferative response less often 
show recurrence of disease, suggesting that the HPV-specific T-cells have a protective 
effect. This implies that reinforcement of the HPV E6- and E7-specific T-cell response by 
vaccination may have a positive effect on disease free survival.
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those patients with CxCa who did mount such a response. Therefore, we have performed a 
prospective study in which the HPV-specific proliferative immune response was measured 
before surgery of the primary tumor in a large group of patients with HPV16- or HPV18-
induced CxCa. The presence or absence of an HPV-specific proliferative immune response 
– for which we previously showed that it correlated with protective immunity (5;8) – was 
analyzed with respect to several prognostic factors. These include the different HLA class 
II-alleles that have been suggested to be associated with protection or risk for HPV-related 
cervical disease (15-18) as it is believed that some HLA-class II molecules may be better or less 
well equipped to present the HPV protein-derived peptides to T cells. Furthermore, T-cell 
immunity in relation to tumor-size, depth of stromal invasion by the tumor, lymph node (LN) 
status – all known tumor characteristics associated with bad outcome (19) - as well as disease 
free survival was determined. 
This prospective study reveals that a minority of the patients have circulating HPV-specific 
T cells that are able to proliferate when stimulated with cognate E6 or E7 antigen. HPV-
specific proliferation is more often detected in patients with deep stromal infiltrating tumors 
and comprises both HPV-specific helper and CD4+CD25+FoxP3-positive T cells. Patients with 




Women presenting with histologically proven CxCa at the Department of Gynaecology of 
the Leiden University Medical Center (LUMC) were enrolled in the CIRCLE study after signing 
informed consent. This CIRCLE study investigates cellular immunity against HPV in HPV-induced 
(pre)malignant lesions and was approved by the Medical Ethical Committee of the LUMC. Patient 
characteristics are described in Table 1. All patients underwent radical hysterectomy type III and 
pelvic lymph nodes (LN) were histologically evaluated for the presence of metastatic disease. 
Sixty percent of the patients received additional radiotherapy in the months after surgery. The 
subjects were tested for HPV status on DNA isolated from surgical resection specimens (20). 
Three years and 5-years follow up data were present for 86 % and 60% of the patients.
Blood samples were drawn at the day of and prior to surgery. PBMC were isolated by Ficoll 
density centrifugation. A proportion of these PBMC was tested directly ex-vivo in a proliferation 
assay and the remaining cells were cryopreserved in liquid nitrogen. DNA was isolated from 
granulocytes for the determination of  the HLA class I and II type of the patient at the national 
reference laboratory for histocompatibility testing (LUMC, The Netherlands) by PCR using 
sequence-specific oligonucleotides and the IMGT/HLA database v2.24.0 (21).
antigens and lymphocyte stimulation test (lSt)
Pools of overlapping 22-mer peptides spanning the entire HPV16 or HPV18 E6 and E7 proteins 
were used for the T-cell assays as described previously (6;22). Memory response mix (MRM), 
consisting of tetanus toxoid (0.75 limus flocculentius/mL; Netherlands Vaccine Institute), 
sonicated Mycobacterium tuberculosis (5 µg/mL; kind gift from Dr. P. Klatser, Royal Tropical 
Institute) and Candida (0.015%; HAL Allergenen Lab)  was used as positive control (6;22).
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The capacity of T cells to proliferate on 
stimulation with the antigen was determined 
by the lymphocyte stimulation test (LST) as 
described earlier (4). The average and SD of the 
8 medium-only control wells were calculated 
and the cutoff was defined as this average plus 
3 x SD. The stimulation index was calculated 
as the average of tested 8 wells divided by 
the average of the medium control 8 wells. A 
positive proliferative response was defined as 
a stimulation index of at least 3 and the counts 
of at least 6 of the 8 wells had to be above the 
cutoff value.
Phenotypical t-cell analysis by flow 
cytometry
PBMC were thawed and seeded in three wells 
of a 24-well plate (Costar) at a concentration 
of 1x106 cells/ml in IMDM supplemented with 
10% human AB serum (PAA laboratories). 
The complete set of overlapping 22-mer 
peptides of HPV16 E6 or E7 were added at final 
concentration of 5ug/ml. No peptide (medium 
only) served as negative control.
At the starting point and after 7 days 
of culture, cells were harvested, washed in 
cold PBS/5%BSA and stained for the surface 
markers CD4-APC, CD25-FITC, CD8-PerCP (BD 
Biosciences) and subjected to the intra-cellular 
staining protocol for FoxP3-PE (clone PCH101 
Ebiosciences) or the isotype control according 
to the protocol of the manufacturer.
Two well validated clones, the intranuclear 
FoxP3- expressing clone C148.31 and the FoxP3 
negative clone C271.9 (11;23) were used to discriminate between background staining of the 
cytosol (C271.9) and true high  intra-nuclear staining (C148.31) of FoxP3 because we noticed 
that the official isotype control displayed less background staining than clone PCH101. The 
samples were measured by flow cytometry (FACS-CALIBUR, BD Biosiences) and evaluated using 
Cellquest software (BD Biosciences).
cytokine analysis
The supernatants isolated on day 6 of the proliferation assay were subjected to a Th1/Th2 
inflammation cytokine bead array (CBA) kit (BD Biosciences, Erembodegem, Belgium). In this 
array the levels of IFNg, TNFa, IL-10, IL-4 and IL-2 were determined. According to manufacturer’s 
instructions the proposed detection limit was 20 pg/ml. However, for IFNg the cut-off value 











other types‡ 7 6






< 4cm 64 54
≥ 4 cm 44 37
unknown 11 9
infiltration depth
≥ 15mm 36 30
< 15 mm 76 64
unknown 7 6
*At time of intervention †At time of surgery
‡Others include HPV type 31(n=2), 33 (n=1)
39 (n=1), 45 (n=2), 69 (n=1)
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was set to 50 pg/ml. Positive antigen specific cytokine production was defined as a cytokine 
concentration above the cut-off value and at least two-fold above the concentration of the 
medium control (5). 
Statistical analyses
The HLA types of CxCa patients were compared for dedicated alleles with a cohort of healthy 
blood donors derived from the area of Leiden as published by Schipper et al (24). For each 
of the tested alleles (DRB1*07, 13 or 15) the frequency present in CxCa patients was compared 
to the frequency in the control cohort by the 2-tailed Fischer’s exact test. Note that no 
information was available about the linkage of DR and DQ alleles in this control group. The 
relationship between the presence or absence of an HPV-specific immune response and tumor 
size, LN status or infiltration depth was determined by the two-tailed Mann-Whitney test. The 
difference in the mean of CD4+CD25+ or CD4+CD25+Foxp3-expressing cells between patients 
with or without an HPV-specific proliferative response was determined by a two-tailed Mann-
Whitney test. The association between the frequencies of both CD4+CD25+FoxP3-positive and 
CD4+CD25highFoxp3-negative T cells simultaneously present in PBMC of patients was tested by 
the Wilcoxon signed rank test.  To determine the impact of the immune response on the survival 
of patients a logrank analysis using graphpad prism software version 4.02 was performed. 
Furthermore post-hoc analyses using the logrank test were performed to study the impact of 
immunity on disease free survival in subgroups of patients. Formal testing of these associations 
of tumor characteristics and the presence of HPV specific immunity was performed with Cox 
regression using SPSS version 17.0 software package for windows (SPSS inc. Chicago, USA). 
A p-value <0.05 was considered to be significant.
reSultS
Patient population
One hundred and nineteen women with cervical cancer (CxCa; Figo stage 1b to 2b) enrolled 
in the Circle study onto April 2007 were studied. Patient characteristics are shown in table 1. 
The mean age of these 119 CxCa patients was 44.9 years (range 23.4 to 76.4 years). The majority 
(>95%) of the patients were from Dutch origin. PBMC used to determine the presence of HPV-
specific T-cell immunity were isolated from blood samples drawn at the same day as but prior 
to surgery. Tumor tissue of all CxCa patients was analyzed for the presence of HPV-DNA. In 77 
cases (65%) HPV16 and in 27 patients (23%) HPV18 was detected. Other virus types were only 
found at a low frequency and in 8 cases no HPV could be detected (Table 1). As >90% of all 
recurrences occur within 3 years after surgery (25) and follow-up for this period was available 
for almost all patients (86%), we analyzed the disease-free 3-years survival after surgery which 
was 81%,  which is comparable to the percentage  found previously (25). The group of patients 
for whom 5-years follow-up was available was too small (60%) to allow for a meaningful analysis. 
the frequency of Hla alleles associated with risk or protection for cxca
Three HLA class II alleles have consistently been reported to be related with either a risk (DRB1*07; 
DRB1*15/DQB1*0602) or with protection (DRB1*13) against cervical (pre-)malignant lesions 
(15;17;26). In order to confirm these respective associations in the current cohort – as this allows 
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a more meaningful analysis of a potential relationship between HPV-specific immunity and these 
disease-associated or protective alleles – the frequency of these described ‘risk’ or ‘protective’ 
alleles was determined in our study group and subsequently compared to the previously published 
Dutch control population that consists of more than 1622 healthy individuals (24). 
Thirty of the 119 CxCa patients (25%) carried the DRB1*07 allele compared to 19.2% in the 
control group (p=0.13). When only the group of patients with an HPV16-induced tumor was 
analyzed the frequency of the DRB1*07 allele was significantly increased (p=0.006; Table 2). The 
DRB1*07 allele seems to be underrepresented in patients with HPV18-induced cancers but the 
group is too small to allow for a firm conclusion. The frequency of DRB1*15/DQB1*0602 is slightly 
but not significantly increased in our patient population (Table 2). Similar to previous observations 
DRB1*13 was found to be underrepresented in the total group of patients with CxCa as only 18% 
(21 patients) displayed this allele compared to 28.4% in the control population (p=0.014; Table 2). 
a third of the patients with HPV-induced cancer mount HPV-specific immunity
In 94 patients with HPV16- or HPV18-induced cervical cancer we determined the presence of 
circulating HPV-specific T cells by a 7-day lymphocyte stimulation test (LST) (4;6). We have 
previously shown that this assay is geared towards the detection of predominantly CD4+ T-cell 
responses (5;6). Freshly isolated PBMC were stimulated with 4 different peptide pools of the 
E6 and 2 peptide pools of the E7 oncoproteins for HPV16 and HPV18. The immune response to 
the cognate HPV type was used to determine the response rate (Figure 1a). Only 29 out of 94 
(31%) displayed a demonstrable HPV-specific proliferative T–cell response (Figure 1b; LST+). In 
16 out of 23 responding HPV16+ patients, the T cells reacted against E6 and in 14 patients against 
E7.  In 7 cases a response to the peptides of both oncoproteins was found. Six of the 18 HPV18+ 
patients responded to HPV18 peptides. Three responded only to E6 and 3 to the peptides of 
E7, including 2 patients who responded both to E6 and E7. Notably, this response rate is much 
lower as previously reported for healthy controls (5;6;22;27).
Supernatants, obtained at day 6 of these proliferation assays were analyzed for the presence 
of HPV-specific production of Th1 and Th2 cytokines by cytometric bead array.  In only 8 of 
all 29 patients that showed a HPV-specific proliferative response (28%), this proliferation was 
Table 2. Expression of specific HLA-DR frequencies in CxCa patients.
HLA§









30/89 25/52 3/24 459/1937 ** 0,0059‡
25%  32%** 11% 19%
 DR* 13
21/98 17/60  4/23 669/1686  * 0,014‡
18%* 22% 15% 28%
 DR* 15
35/84 25/52  6/21 414/1208
29% 32% 22% 26%
§The frequency of HLA-DR types previously reported to be associated with disease (DR*07, DR*15) or protection 
(DR*13) were determined. Numbers indicate the number of patients positive/negative for this specific HLA-type 
within this group.
†Controls are taken form a published Dutch cohort of healthy blood donors (Schipper et al. 1996) ‡ P-value, 
statistical analysis was performed with Fisher’s exact test, two-sided.
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accompanied by the production of detectable amounts of the Th1-effector cytokine IFNg  as 
depicted in Figure 1b and Table 3. In contrast, IFNg is detected in two-thirds of the HPV-specific 
proliferative responses of healthy subjects (4;27). Furthermore, for 3 patients the specific 
production of IL-10 and in 4 cases TNFa was detected (Table 3). IL-2 was not detected in these 
cultures which highly likely can be contributed to it’s consumption by the proliferating cells as 
this cytokine was not provided during the culture.
In each assay the positive control recall antigen mix MRM was taken along. This revealed 
that nearly all of the patients readily responded to bacterial antigens by proliferation and the 
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>50000
HPV16+ patient HPV18+ patient
figure 1 HPV-specific immunity in patients with cervical cancer. (A) PBMC  obtained at the day of 
surgery were stimulated  with HPV peptide pools representing either the HPV16 or HPV18 amino acid 
sequence of the two oncoprotein E6 and E7  (E6 pool 1-4, E7 pool 1-2) or memory response mix (MRM) and 
after 6 days the proliferation was measured using 3H-thymidine incorporation. Shown is an example of the 
response detected in an HPV16-positive (left) or HPV18-positive (right) CxCa patient. (B) The percentage 
of patients (n=65) in whom no HPV-specific proliferative response (LST-) and patients (n=29) who did show 
an HPV-specific T-cell response (LST+) is depicted. In 8 of these 29 cultures proliferation was accompanied 
by IFNg production. (C) The presence of an HPV-specific proliferative T-cell response is associated with 
deep stromal invasion by the tumor (p=0.02, two-tailed Mann-Whitney). Patients were divided into two 
groups on basis of the depth of infiltration (≤15mm or >15mm) and the percentage of patients within these 
groups displaying a systemic HPV-specific proliferative immune responses (LST+) is depicted.
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the detection of HPV-specific cd4+cd25+foxP3-positive t cells coincides 
with that of HPV-specific cd4+cd25+ t cells
Previously we showed that CD4+CD25+Foxp3+ HPV-specific regulatory T cells can be isolated 
from tumors and lymph nodes of patients with CxCa (11) as well as can be detected in their 
blood as measured by the co-expression of the intra-nuclear transcription factor FoxP3 and 
the HPV-specific activation induced upregulation of CD25 ten days after antigen-specific 
stimulation (28). Although functional assays are the golden standard for the classification 
of Treg the intra-nuclear transcription factor FoxP3 is the best marker to date(29).Using this 
approach we determined the frequency of HPV-specific CD4+CD25+FoxP3-positive T cells in 
41 patients with HPV16+ CxCa of whom enough PBMC were available. Two previously described 
HPV-specific regulatory T-cell clones (11;23) were used to set up a stringent gating strategy to 
ensure the enumeration of CD25high and FoxP3high cells only (Figure 2).
On average 3.4% of the peripheral CD4+ T cells expressed FoxP3 directly ex-vivo (Figure 2a), 
similar to observations in other types of cancer (30). Notably, non-stimulated PBMC cultured 
for 7 days comprised similar frequencies of FoxP3 expressing CD4+ T cells as PBMC stained 
ex-vivo (Figure 2a), demonstrating that our culture conditions do not induce non-specific 
FoxP3 expression.
Table 3. Overview of the responses in patients with HPV-specific cytokine production.







A 16 E6 121-158 4,7 123 28 25
B 16 E7 51-98 4,6 21
C 18 E7  1-98 6,7 121
D 16 E7 51-98 6,4 259
E 18 E6 41-92 7,6 2943
  E7  1-62 7,3 2617 64 164
  E7 51-98 8,9 3150 47 67
F 18 E7 51-98 9,2 139
G 18 E6  1-52 20 3400 56
  E6 41-92 9,5 195
H 16 E7 51-98 5,8 65
I 16 E7 51-98 6,2 50
J 16 E6 41-92 7,9 1244
The 10 patients which in addition to proliferation also produced IFNg, TNF or IL-10 upon HPV-specific stimulation 
are depicted by a letter (A-J)
†HPV type as found in the tumor by PCR
‡ indicates the antigen (E6 or E7) of the HPV type present in the tumor to which the patient responded
§ the numbers indicate the first and the last amino-acid of the 22-mer peptide pool of the corresponding antigen 
to which the PBMC responded by proliferation
*SI=Stimulation index, the fold difference in proliferation when PBMC are stimulated with the indicated peptide 
pool when compared to PBMC stimulated with medium only
** Specific cytokine production (pg/ml) by PBMC stimulated with the indicated peptide as detected in  the 
pooled supernatant of the 8 replicate test wells;
A specific response was defined as a peptide pool-induced production which was at least twice above 
background (medium control) and above the cut-off of 20 pg/ml (IL10 and TNFa) or 50 pg/ml ( IFNg) 
Only the cultures with a positive cytokine response are shown
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Figure 2 The detection of HPV-specific proliferative responses is associated with higher percentages 
of HPV-specific FoxP3-positive and-negative CD4+CD25+ T cells.  PBMC of HPV16+ CxCa patients 
isolated before surgery were cultured for 7 days in the absence or presence of the cognate HPV peptides 
E6 or E7 and stained for the expression of CD25 and the transcription factor FoxP3. (A) On average 3% of the 
circulating CD4+ T-cells express FoxP3 directly ex-vivo (left bar) and this percentage is not altered when the 
T cells are cultured for 7 days in medium (right bar). (B) Two HPV-specific T-cell clones, either expressing 
intranuclear FoxP3 (148.31) or not (271.9) were used to optimize the gating strategy in the experiments. 
(C) Dot plot example of one HPV16+ patient showing CD4+CD25+ T-cells and CD4+CD25+FoxP3-positive T 
cells without stimulation (medium) or after stimulation with HPV16 E6 (middle) or E7 (right) as measured 
by flow cytometry. (D) Increased percentages of HPV-specific CD25+ (activated) and CD25+FoxP3-
positive CD4+ T cells are found when patients display specific proliferation in the blood as compared to 
patients that do not show any T-cell response. The mean (±SEM) percentage of HPV E6- and E7-specific 
CD4+CD25+ or CD4+CD25+FoxP3-positive T cells is depicted for the group of patients lacking HPV-specific 
proliferation (LST-; n=27) or displaying HPV-specific T-cell proliferation (LST+; n=14). Means are calculated 
from stimulated cells after subtraction of PBMC in medium only. P-values were calculated using two-tailed 
Mann-Whitney. (E) In LST+ patients the detection of both types of HPV-specific CD4+ T-cells is correlated 
as analyzed by the Wilcoxon signed rank test.
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Of the 41 patients tested, 14 displayed an HPV-specific proliferative response while the 
other 27 patients displayed no detectable proliferative response. Notably, CD4+CD25+FoxP3-
positive T cells were already present in non-stimulated cell cultures (medium). The population 
of CD25highFoxP3high T cells consisted on average of 0.83% (range 0.1-3.0) of total CD4+ T cells, 
whereas CD4+ T cells with a helper phenotype (CD4+CD25highFoxP3-negative) were scarcely 
present in these control cultures (Figure 2). In the HPV peptides-stimulated cultures, however, 
both populations are present in the majority of the samples (Figure 2c). Significantly higher 
numbers of HPV-specific CD4+CD25highFoxP3-negative and CD4+CD25highFoxP3high T cells were 
detected in the HPV-stimulated PBMC cultures of the group of patients whom displayed an HPV-
specific proliferative response ( Figure 2d, p= 0.03 and p=0.04, respectively),  when compared 
to the group of patients not able to mount an HPV-specific proliferative response.  Moreover, 
the detection of HPV-specific T cells with either a CD4+CD25 highFoxP3-negative Th-phenotype 
or with a CD4+CD25 highFoxP3 high T-cell phenotype was correlated in the patient group displaying 
HPV-specific proliferative responses (p<0.001; Figure 2e). No correlation between the presence 
of LN metastasis and the numbers of CD4+ CD25 highFoxP3-negative and CD4+CD25 highFoxP3 high 
cells was found.
Notably, although recently CD8+FoxP3+ T cells were detected in the lymph nodes of early 
stage CxCa patients (31), we could not detect such a population in the PBMC of our CxCa 
patients (data not shown).
deep tumor-infiltration of the surrounding tissue is associated with detect-
able HPV-specific immune responses
In order to assess whether relationships exist between the absence or presence of HPV-specific 
proliferative responses and the known disease related or protective HLA class II alleles the 
patients were divided according to immune status and presence or absence of a particular 
HLA allele (DRB1*07, DRB1*15 or DRB1*13). However, no relationship between the absence or 
presence of HPV-specific immunity and the presence of these alleles was found. 
Known prognostic factors in cervical cancer are LN metastases (present or absent), the 
size of the tumor (< or ≥ 4cm) and the invasion depth of the tumor in the surrounding cervical 
tissue (< or ≥ 15mm) (19). These prognostic factors were entered into the Cox proportion hazard 
model, which revealed a correlation between tumor size and the presence of LN metastases 
(p=0.003) as well as with invasion depth of the tumor (p=0.002). However, depth of invasion 
was not correlated to LN metastasis in this cohort (p=0.21). 
Subsequently, the presence of an HPV-specific immune response was also analyzed in 
relation to the LN status in 93 patients, tumor size (n=82) and invasion depth (n=84). Patients 
were grouped according to the presence or absence of an HPV-specific T-cell response. No 
differences were found between these groups with respect to tumor size at time of surgery.
In 48% of the patients with nodal metastases HPV-specific T cells were detected, whereas 
only 27% of the patients without metastasizing tumors displayed an HPV-specific T-cell response 
(p= 0.06; Fisher’s exact two sided, data not shown). Interestingly, the group of patients with a 
deeply infiltrating tumor of at least 15 mm, significantly more often display a detectable T-cell 
response than patients with less invasive tumors (Figure 1c, p=0.02; Fisher’s exact two-sided). 
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Patients with deep infiltrating tumors and HPV-specific immunity display 
improved survival
The great majority of recurrences occur within 3 years after surgery (25). When the disease-
free 3-year survival curves of the CxCa patients are plotted on the basis of the aforementioned 
prognostic factors or the presence of HPV-specific immunity (Figure 3), the patients with large 
tumors (≥ 4 cm) are prone to have recurrent disease (Figure 3c, 37% vs 18%,  p=0.02). In contrast 
to patients with less deep stromal invasion relatively more patients with a deeply infiltrating 
tumor (≥ 15mm) displayed a recurrence of disease within 3 years (Figure 3d 20% vs 35%; p=0.14). 
Survival was not different when all patients were grouped according to HPV-specific immune 
status (p=0.45; Figure 3a). 
As we have found that HPV-specific immunity predominantly was detected in patients with 
deep infiltrating tumors, a subgroup analysis was performed in which the patients were divided 
according to the presence of an HPV-specific proliferative response and one of the prognostic 
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Figure 3.  Disease free 3-year survival curves. Disease free survival for the patients is plotted when patients 
are divided on basis of (A) the presence of an detectable immune response by LST (LST-: open symbols 
n=64, LST+:closed symbol n=29 (B) the presence or absence of LN metastasis (LN-: open symbols n=60, 
LN+: closed symbols n=31), (C) a prognostic-defined relevant tumor size (< 4cm: open symbols n=60, ≥ 
4cm: closed symbols n=27), or  (D) a prognostic-defined relevant depth of stromal invasion (< 15mm: open 
symbols n=58, ≥ 15mm: closed symbols n=25). (E) Patients are grouped on the presence or absence of 
an immune response and the depth of infiltration. Notably, the group of patients with deeply infiltrating 
tumors is divided into 13 patients (open triangles) displaying an HPV-specific proliferative response and 12 
patients lacking a detectable response (closed triangles). Symbols represent censored patients. P-values 
are determined by logrank analysis.
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(LST+) is beneficial in patients with deep  (≥ 15mm) infiltrating tumors as the percentage of patients 
with recurrence was much lower in this group than in those patients without a detectable HPV-
specific proliferative response  (Figure 3e 18% vs 50%; p=0.043, logrank test). Notably, all patients 
with invasion of ≥ 15 mm received radiotherapy as additional treatment. Analyses of HPV-specific 
immunity in relation to LN status or tumor size did not reveal any differences (not shown).
Multivariate analyses of these four groups by Cox proportion hazard analysis confirmed 
these observations (Table 4). While deep stromal invasion without a demonstrable immune 
response showed a highly increased disease recurrence risk (HR 4.33, 95% CI 1.45-12.96) 
as compared to having a less invasive tumor and no immune response, the presence of a 
detectable HPV-specific proliferative response was associated with a lower risk of recurrence in 
the patient group with deeply invading tumors (HR 1.18, 95% CI 0.24-5.68).
diScuSSion
This is the largest prospective study of women with HPV-16 or -18-induced cervical cancer in 
which the HPV-specific immune response was analyzed in relation to known factors predicting 
disease prognosis. The PBMC of most (69%) of the 94 tested patients failed to proliferate when 
stimulated with cognate HPV E6 or E7 peptides in vitro. Furthermore only in a limited number 
of patients HPV-specific T cell responses were associated with the production of IFNg. HPV-
specific immunity - in patients who showed an HPV-specific proliferative response - consisted 
of circulating FoxP3-negative and –positive CD4+C25+ T cells. This large study confirms previous 
findings in small groups of patients (5;32-34). Moreover, it allows a more definitive conclusion 
with respect to the response rate and the type of the T-cell response to the tumor-specific HPV 
E6 and E7 antigens in patients with CxCa as well as scrutiny of the relationship between HPV-
specific immunity and tumor characteristics or survival.
Interestingly, the presence of circulating HPV-specific proliferative T cells was associated 
with deep infiltration of the tumor in the surrounding normal tissue (p=0.02). Recently, we 
reported that surgery-mediated tissue destruction of lesions was strongly associated with the 
induction of HPV-specific immunity in patients with HPV16+ HSIL (10). Together these data 
suggest that the induction of HPV-specific immunity in patients with HPV-induced established 
cervical neoplasia is the result of local destruction of normal tissue and contact with antigen 
presenting cells therein, allowing the presentation of HPV antigen and the activation of naïve 





depth n HR 95% CI p-value
LST - < 15 mm† 44 1
LST - ≥ 15 mm 12 4,33 1,45 - 12,96 0,01
LST + < 15 mm 14 2,21 0,70 - 6,97 0,18
LST + ≥ 15 mm 13 1.178 0,24 - 5,68 0,84
HR, Hazard ratio; CI, confidence interval; † Reference category
LST- indicates no HPV-specific proliferation by lymphocyte stimulation test
LST+ indicates a HPV-specific proliferation by lymphocyte stimulation test
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or memory HPV-specific T cells. Possibly, this normally does not occur because of the tumor-
induced lack of mobility and tolerogenic phenotype of DC within cervical tumors (35;36). The 
fact that tumor size is not related to the induction of HPV-specific immunity can be explained 
because generally tumors increase in size by growing into the lumen of the cervix. 
Because the number of patients within our cohort was too low to perform an unselected 
HLA-association study, we chose to study the frequency of only three HLA class II alleles which 
have consistently been reported to be related with either a risk or with protection against 
cervical (pre-) malignant lesions. The combination of the two HLA class II alleles DRB1*13-
DQB1*0603 was found to be protective in 9 out of 19 studies reviewed by Hildesheim (17).  It is 
unclear which allele is important since DRB1*1301 and DQB1*0603 are in linkage disequilibrium. 
In our cohort DRB1*13 was also found to be underrepresented (p=0.014) when compared to a 
large group of Dutch controls (24). Furthermore, the allele DRB1*07 was found to be associated 
with an increased risk for the development of CIN lesions in Dutch patients (15). Here, we show 
that this allele is also present at a significantly higher frequency (p=0.006) in our group of 
patients with HPV16+ CxCa sustaining the observation that DRB1*07 is associated with a risk to 
develop HPV16-induced malignancies. The mechanism through which this may operate may 
relate to the absence or type of CD4+ T-cell response induced but we did not find a relationship 
between HPV-immunity and these HLA types in our cohort of cancer patients. The events 
-associated with protection or failure- possibly occur already at an early stage of the infection 
and as such, are no longer demonstrable in patients with cancer.
The size and design of our study, in which patients were followed up after surgery, allowed 
us to study the impact of HPV-specific immune responses in relation to disease-free survival at 3 
years. We did not find a direct correlation between survival and the presence of circulating tumor-
specific T cells. A similar study in patients with melanoma also failed to detect a direct correlation 
(37), albeit that there only the numbers and not the function of the tumor-specific T cells was 
studied. Here, the presence of HPV-specific T cells was determined by function (proliferation). 
Interestingly, subgroup analyses revealed that those patients with deeply infiltrating tumors – 
who in general display a low survival rate (67%, Figure 3d) – and circulating HPV-specific T cells 
able to proliferate when stimulated with E6 or E7 antigen, displayed a better 3-year disease 
free survival (82%) than patients lacking such an immune response (50%; p=0.043). Also, Cox 
proportion hazard analysis of these four subgroups showed a strong reduction of the risk of 
disease recurrence, in that the hazard ratio decreased from 4.3 to 1.2, when patients with deeply 
infiltrating tumors displayed an HPV-specific proliferative response (Table 4). Notably, both 
groups of patients comprised predominantly FIGO stage 1b tumors and all patients had received 
additional treatment with radiotherapy, excluding this as a variable. A recent study suggests 
that the presence of HPV-specific immunity reflects disease severity and is not associated with 
increased 3-year disease free survival in a small group of 32 patients (32).This is likely related to the 
stage of disease, as the group studied consisted mainly of patients with a more advanced stage of 
disease (FIGO 2b-3b), whereas we studied patients with an earlier stage (FIGO 1b-2b) of disease. 
We find an increase in proliferative responses in patients with LN metastasis when the subgroup 
analyses were performed on the basis of absence or presence of LN metastasis. It is described 
that T cells within tumor-draining metastasized LN might display a more suppressive phenotype 
suggesting that these suppressive T cells may suppress tumor-specific immunity (31). However, 
we did not observe differences in the phenotype of the PBMC of patients with LN metastatic 
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disease or without metastatic disease. Survival benefit of the presence of a HPV-specific response 
thus may be very specific for the group of patients with deeply infiltrating tumors.  
The picture that emerges from these data is that during progression of tumors, as evidenced 
by the deeper infiltration of tumors in the normal surrounding tissue, HPV antigens can be 
taken up and presented by antigen presenting cells most likely in the less suppressive context 
of the adjacent tissue. This results in activation of HPV-specific T cells, defined by their capacity 
to either proliferate or suppress HPV-specific T cells. The latter is also supported by others 
who report that HPV-specific immunity coincides with enhanced levels of regulatory T cells 
(38;39). Also in melanoma the presence of circulating antigen-specific regulatory T cells has 
been reported (40).
 A key effect of HPV-specific regulatory T cells is the suppression of proliferation and the 
production of cytokines by effector cells, including IFNg (11). The low number of HPV-specific 
responses associated with the production of IFNg suggests that such responses may have 
been suppressed. However, the detection of HPV-specific proliferation in 31% of the patients 
implies that if suppression occurs this is not always strong enough to suppress T cell function 
completely and HPV specific T cells can have a beneficial antitumor effect as the 3-year disease 
free survival of patients with deeply infiltrating tumors displaying an immune response is better 
than those without such a response. 
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Chapter 3
The diversity and extent of the local tumor-specific T-cell response in a given individual is largely 
unknown. We have performed an in-depth study of the local T-cell repertoire in a selected group 
of cervical cancer patients, by systematic analyses of the proportion, breadth and polarization 
of HPV E6/E7-specific T cells within the total population of tumor-infiltrating lymphocytes (TIL) 
and tumor-draining lymph node cells (TDLNC). Isolated T cells were stimulated with sets of 
overlapping E6 and E7 peptides and analyzed by multiparameter flow cytometry with respect to 
activation, cytokine production and T-cell receptor Vb (TCRVb) usage. HPV-specific CD4+ and 
CD8+ T-cell responses were detected in TIL and TDLNC and their relative contribution varied 
between <1% to 66% of all T cells. In general, these HPV-specific responses were surprisingly 
broad, aimed at multiple E6 and E7 epitopes and involved multiple dominant and subdominant 
TCRVb’s per single peptide-epitope. In most patients only few IFNg-producing T cells were 
found and the amount of IFNg produced was low suggesting that these are poised T cells, 
rendered functionally inactive within the tumor environment. Importantly, stimulation of the 
TIL and TDLNC with cognate antigen in the presence of commonly used Toll like receptor-
ligands, significantly enhanced the effector T-cell function. In conclusion, our study suggests 
that within a given patient with HPV-specific immunity many different tumor-specific CD4+ and 
CD8+ T cells are locally present and poised for action. This vast existing local T-cell population is 
awaiting proper stimulation and can be exploited for the immunotherapy of cancer.
abstraCt
introduction
Our current knowledge on the diversity and extent of tumor-specific T-cell immunity is largely 
based on pooled T-cell response data of many different subjects (1-4), the  T-cell response to 
a specific epitope (5;6) and/or studies of tumor-specific T-cell clones (7-9). However, little is 
known about how extensively one individual’s immune system can simultaneously respond to 
one or more tumor antigens. Cervical carcinoma offers an excellent opportunity to answer this 
question as they are caused by the high-risk human papillomavirus (HPV) which encodes two 
defined tumor-specific viral antigens E6 and E7 that are constitutively expressed in each cancer 
cell (10). Notably, cervical cancer arises more frequently in immunocompromised individuals 
(11), illustrating the role of T cells in this type of cancer.
Low levels of circulating HPV E6- and E7-specific T cells in patients with cervical cancer 
or premalignant lesions (4;12-15)  indicate that these oncoproteins activate an anti-tumor 
response. Indeed, cervical tumors are infiltrated by lymphocytes (16) and both CD8+ and 
CD4+ T cells isolated from such tumors are able to recognize the E6 and E7 tumor antigens 
(17;18). Furthermore, we showed that 43% of the isolated tumor-infiltrating lymphocyte (TIL) 
and tumor-draining lymph node cell (TDLNC) cultures from a large cohort of HPV16 or HPV18 
positive patients contained T cells specific only for the E6- and/or E7-peptides corresponding to 
the HPV type present in the tumor (3). When the tumor was negative for HPV16 or 18, the TIL did 
not react to these HPV16 or HPV18 peptides (3). While these studies clearly indicate that HPV-
specific T cells can infiltrate HPV-induced cervical cancer in a substantial number of patients, 
they do not allow a full comprehension of the contribution and role of HPV-specific TIL and 
TDLNC to the total tumor-specific immune response. The size of the HPV-specific T-cell pool 
in the TIL population, the polarization of these T cells and the breadth of this local HPV-specific 
response within a given individual with an HPV-specific response is unknown. It is important to 
gain such insights because of several therapeutic strategies under development (19-21). These 
include vaccines to enhance E6- and/or E7-specific T-cell reactivity (22-27) the results of which 
could be influenced by the presence of a preexisting HPV-specific local immune response.
Therefore, we performed a more in-depth study of the populations of TIL and TDLNC of 
patients for which we previously showed that they comprised HPV16- or HPV18-specific T cells 
(3) by comprehensive analyses of the HPV-specific CD4+ and CD8+ T-cell responses down to the 
level of the percentage, specificity, cytokine polarization and number of different responding T 
cells.. Our study revealed that many different HPV-specific T cells are present, but need proper 
stimulation to become full effector cells.
metHodS
Subjects
Women presenting with histologically proven cervical neoplasia (FIGO 1a2, 1b1/2) at the 
department of Gynecology of the Leiden University Medical Centre were enrolled in the CIRCLE 
study, which investigates cellular immunity against cervical lesions after providing informed 
consent. The study was approved by the Medical Ethical Committee. The subjects were 
tested for HPV status using HPV16 and HPV18 specific primers on DNA isolated from resection 
specimens (28). 
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antigens
A set of 22-mer peptides overlapping by 12 residues spanning both HPV16 and HPV18 E6 and 
E7 protein were synthesized and dissolved as described earlier (13;27) and used for T-cell 
stimulation assays. 
isolation and culture of t cells
Cervical tumor biopsies were obtained from patients with radical hysterectomy as described 
previously (3). Briefly, fresh cervical tissue was minced and cultured in IMDM, supplemented 
with 10% human AB serum (PAA laboratories, Pasching, Austria), 10% T Cell Growth Factor 
(TCGF, Zeptometrix, Buffalo NY, USA) and 5 ng/ml IL-15 (Peprotech, Rocky Hill NJ, USA). At day 
1, 5 ng/ml IL-7 (Peprotech) was added to cultures to drive homeostatic expansion of T cells. 
This does not alter the CD4/ CD8 T-cell composition of TIL(3),  but it allows the acquisition 
of sufficient numbers of T cells for immunological assays. After 2-3 weeks of T-cell expansion 
(mean 18x106 cells, range 4 - 40x106) the T cells were harvested and stored in liquid nitrogen. 
TDLN derived from the pelvic region contained tumor cells, indicative of metastatic cancer. 
The TDLN were cut into pieces and incubated 1 hour at 37 ºC  with collagenase (200 IU/ml, 
Sigma) and DNAse (50 mg/ml, Sigma), and put through a cell strainer (BD, Erebodemgem, 
Belgium) to obtain single cells. TDLNC were not expanded but directly stored in liquid nitrogen.
analysis of t-cell specificity by proliferation assay
T cells (25,000-50,000/well) were stimulated with autologous monocytes or irradiated 
autologous Epstein-Barr virus transformed B cell lines (B-LCL’s)  pulsed with HPV16 or 18 
E6 and E7 peptides (5 µg/ml) in triplicate wells in a 3-day proliferation assay. After 48 hours 
supernatant was harvested and stored at -20ºC for cytokine analysis. During the last 16 hours 
of culture 0.5 µCi/well [3H]thymidine was added to measure proliferation (27) The stimulation 
index (SI) was calculated as the average of test wells divided by the average of the medium 
control wells. An SI >2 was considered a positive response. Antigen-specific IFNg and IL-10 
production was measured by ELISA (29). Antigen-specific cytokine production was defined by 
a cytokine concentration above the cut-off value (IFNg 100pg/ml; IL-10 20 pg/ml) and >2x the 
concentration of the medium control (4).
analysis of t-cell specificity by multiparameter flow cytometry.
T cells were examined directly ex-vivo (TDLNC) or after homeostatic expansion (TIL) to 
quantify the number of HPV-specific T cells. B-LCL were pulsed with 5 ug/ml HPV-16 or 18 E6 
and E7 peptide pools. TIL’s or TDLNC were thawed, rested in IMDM (BioWhittaker, Verviers, 
Belgium) containing 10% Fetal Calf Serum (FCS, PAA laboratories, Pasching, Austria) for 5 hours 
and seeded into a 96-wells round bottom plate at 200,000 cells per well and 40,000 antigen-
pulsed B-LCL were added. After one hour Brefeldin A (10ug/ml) was added to the culture and 
left overnight. Cells were stained with antibodies to CD154-PECy5, CD137-APC, CD3-Pacific Blue, 
CD4-PECy7, CD8-APCcy7, IFNg-FITC and IL-2-PE (all from BD Pharmingen, the Netherlands)(30).
In addition, TDLNC and TIL were stimulated with a mix of irradiated autologous B-LCL and 
5 ug/ml HPV16 or HPV18 E6 or E7 peptide pools and irradiated allogeneic PBMC pool, in order 
to obtain enough HPV-specific T cells to measure the breadth of the response with respect to 
single peptide-antigens and for TCRVb usage analyses (8 sets of antibodies). After a 3-week 
rest period these cells were tested for their specificity by overnight incubation with each single 
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peptide. Responses were considered positive when the percentage of HPV stimulated CD154 
and/or CD137 positive cells was at least three times the medium control.
analysis of the breadth of the HPV-specific t-cell response. 
In vitro expanded T cells were stimulated with the indicated single peptides of HPV-16 or 18 
E6 and E7 (5 ug/ml). Per peptide 500.000 cells were analyzed by flow cytometry as described 
above. One day later this analysis was repeated for those peptides found positive, but then the 
antibodies to the cytokines were replaced by antibodies to different TCRVb (Beckman Coulter, 
Immunotech, France). A TCRVb was considered  dominant (>10% ), subdominant (3-10%) or 
minor (<3%) on basis of the percentage of HPV-specific cells using the same TCRVb. 
rt-Pcr 
Expanded cultures were enriched for CD8+ T cells by negative selection using CD4+ isolation 
dynal beads (Invitrogen, the Netherlands). After RNA was isolated with the RNAeasy mini 
isolation kit (Qiagen, the Netherlands), cDNA was synthesized using the iScript cDNA Synthese 
kit (Biorad). Vb PCR was performed on amplicons as previously described (31). Primers were 
kindly provided by dr M.H. Heemskerk.
in vitro stimulation with peptides and tlr ligands.
TDLNC were thawed, rested for 5 hours and stimulated with 1mg/ml pool of E6 and E7 peptides, 
TCGF 10% and IL15. Toll like receptor (TLR) 4 ligand LPS 250 ng/ml (Sigma-Aldrich, USA), TLR3 
ligand Poly(I:C) 12.5 mg/ml (InvivoGen, USA)  and TLR1-2 ligand Pam3CSK4 20 mg/ml (InvivoGen, 
USA) were added at the start of culture where indicated. To stimulate TIL, monocytes were 
pulsed with 1 ug/ml of E6 and E7 peptide pool and the indicated TLR ligands. After 5 hours 
monocytes were washed and TIL were added. Supernatant was taken every 2 days and analyzed 
by human Th1/Th2 cytometric bead array (BD Pharmingen, USA). Cells were left to rest for 2-3 
weeks before analysis of the percentage of activated and cytokine producing cells by flow 
cytometry.
reSultS
Quantification of HPV-specific  t cells in tumor and lymph nodes.
TDLNC and homeostatic cytokine-mediated expanded TIL isolated from a selected group of 
16 cervical carcinoma patients, comprising 10 patients of whom it was known that their TIL (8 
patients) or TDLNC (2 patients) contained T cells that specifically reacted to the peptides of 
the HPV type present in the tumor and 3 patients in whom we previously failed to detect HPV-
specific immunity (3), and 3 patients with unknown reactivity. 
The presence of HPV-specific T cells within these homeostatic cytokine-mediated expanded 
TIL cultures was analyzed by their capacity to proliferate upon stimulation with HPV E6 and E7 
peptides (Table 1). As expected proliferating HPV-specific T cells were found in 8/12 tumors 
tested. All HPV-specific T-cell cultures produced IFNg, yet the amount of production varied 
greatly (103 - >5000 pg/ml), irrespective of the proliferative capacity of the cells. In addition, 
4/8 positive cultures produced IL-10 (45 – 836 pg/ml). All TIL  reacted to PHA and proliferation 
was associated with large amounts of IFNg and IL-10 (not shown).
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1 16 TIL 9 16E6 2,9 103 <20 CD4 0,16 0,58 0,26
2 18 TIL 13 18E7 5,4 763 45 CD4 0,04 0,03 0,17
3 16 TIL 15 - - - - -
4 16 TIL 26 16E6 104 >5000 315 CD4 0,8 63 0,9
 CD8 0 47 0,7
5 16 TIL 79 16E6 109 >5000 836 CD4 3,1 66 2,7
6 18 TIL 25 - - - - -
7 16 TIL 12 - CD8 2,9 24 3,4
8 16 TIL 29 - - - - -
9 16 TIL 17 16E6 2,6 110 <20 CD8 0,4 4,5 0,6
10 16 TIL 27 16E6 4,8 >5000 <20 CD4 0,13 0,52 0,14
11 18 TIL 30 18E7 8,9 244 66 NT||
12 16 TIL 68 16E6 4 276 <20 NT
13 18 LN 0 NT - - - -
14 16 LN 0 NT CD4 0,12 0,63 0,16
CD8 0,23 5,92 0,11
15 16 LN 0 NT CD4 0,51 24 20
16 16 LN 0 NT       - - - -
* HPV type found in the tumor by PCR
†† Days of cytokine mediated homeostatic expansion before immune assay
** Reactivity indicates the HPVtype and protein to which the T-cell culture specifically reacted
† SI,  Stimulation Index, average proliferation of test wells divided by the average profileration of medium 
control wells. SI>2 is positive
‡ Antigen-specific cytokine production in pg/ml is indicated when test value was above cut-off level
and  at least >2 times background production (4)
§ Percentage of total CD4 or CD8 T cell population expressing CD154 and/or CD137 after stimulation 
with indicated antigen corresponding to the HPV type present in the tumor. A response equal or 
more than 3x medium control was considered positive. || NT = Not tested
To type and enumerate HPV-specific T cells within the TIL or TDLNC populations, the 
percentage of CD4+ and CD8+ T cells specifically expressing the activation markers CD137 and/
or CD154 when stimulated with E6 and E7 peptides or proteins was analyzed. CD137 is known as 
an activation marker for CD8+ T cells and CD154 for CD4+ T cells (32;33). The TIL cultures that 
were negative in the proliferation assay were taken along as control. In 7/10 TIL cultures tested 
and 2/4 TDLNC, HPV specific activated T cells were detected and comprised CD4+ or CD8+ T 
cells or both (Table 1). In two cases not enough TIL were available to perform this analysis. In 
one TIL culture – in which we previously failed to detect HPV-specific T cells by proliferation 
- an HPV-specific CD8+ T-cell response was detected. The percentage of HPV-specific T cells 
generally corresponded with the strength of proliferation. HPV-specific CD4+ T cells expressed 
both CD154 and CD137, while HPV-specific CD8+ T cells predominantly expressed CD137, yet 
sometimes co-expressed CD154 (Figure 1a; Supplemental Figure 1). The percentage of HPV-
specific T cells varied enormously between as little as 0.17% to as much as 66% (Table 1) of the 
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Figure 1. HPV-specific T cells in TIL and TDLNC. (A) An example of CD4 and CD8 HPV-specific responses 
measured by flow cytometry using the activation markers CD154 and CD137 in two TIL cultures tested 
before antigen-driven expansion in vitro (P4 and P9). (B) The breadth of the response was analyzed after 
antigen-driven expansion. TIL and TDLNC cultures were stimulated with single peptides and analyzed for 
the expression of CD154 and CD137. P9 displayed a CD8 response against four different single peptides 
(notably 41, 51, 61 and 137). P12 displayed a CD4 response against six different single peptides (notably 21, 
61, 71, 81, 91 and 101). (C) Summary of the number of different peptides recognized by each single culture 
(white bars) after antigen-driven expansion. The minimal number of epitopes recognized (black bars) was 
estimated by counting the response to two 22-mer peptides, which overlap by 12 amino acids, as one.
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Number of TCRVß found per  peptide** by FACS†
Dominant Sub-dominant Minor Total
TIL 2 CD4 E7 1 0 0 4 4
11 0 2 4 6
4 CD4 E6 41 1 0 0 1
51 1 0 0 1
CD8 E6 41 2 1 3 6
51 2 1 3 6
CD8 E7 21 3 2 0 5
7 CD8 E6 21 0‡ 3 4 7‡
9 CD8 E6 41 0 1 1 2
51 1 0 3 4
61 1 1 3 5
137 0 2 5 7
10 CD8 E6 131  2 0  0 2
137 2 0 0 2
CD4 E7 1 2 0 0 2
11 CD4 E6 21 1 2 0 3
71 2 0 1 3
81 0 1 1 2
101 1 3 0 4
12 CD8 E6 1 1 0 3 4
11 1 0 3 4
41 1 1 4 6
51 1 3 2 6
LN 14 CD4 E6 11 2 0 8 10
61 1 1 5 7
71 1 1 5 7
81 2 2 0 4
91 2 2 0 4
101 1 3 3 7
121 2 6 2 10
131 0 0 2 2
137 3 2 0 5
15 CD4 E6 21  2‡  0  0 2‡
51 1 0 0 1
81 1 2 1 4
111 1 1 0 2
121 0 2 0 2
131 1 1 3 5
* Depicted are all patients of whom enough T cells were available for TCR Vß analysis after antigen specific 
expansion by stimulation with E6 or E7 peptide pool
** The number indicates the first aminoacid of the 22-mer peptide of the antigen that the culture specifically 
responds to by the expression of the activation markers CD154 and/or CD137
† A dominant TCRVß consists of >10% of the activated T cells. A sub-dominant TCR Vß consists of between 3% and 
10% of the activated T cells. A minor TCR Vß consists of < 3% of the activated T cells 
‡ Additional TCRVb’s were found by PCR analysis for P7 and P15
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Figure 2. The T-cell response to a single HPV epitope involves multiple dominant and subdominant TCRVb 
families. (A) The TCRVb families used by T cells responding to a single peptide were analysed within the 
T-cell population with high expression of activation marker(s) after peptide stimulation. Depicted is the 
response against one peptide for four different patients (P4, P7, P9 and P12). The letters (a-h) indicate 
the eight different antibody pools, each consisting of three differently labeled antibodies (FITC (FL1), PE 
(FL2) or FITC-PE combined) specific for three different TCRVb, plotted in separate quadrants. The involved 
TCRVb and the percentage of responding cells are indicated in the plots. (B) The relative contribution of 
dominant and subdominant TCRVb families to the overall HPV-specific T-cell response is depicted. The 
grey stacked bars indicate the percentage of HPV-specific T cells comprising a dominant TCRVb(s) and the 
black stacked bars indicate the accumulated percentage of all the sub-dominant and minor TCRVb families 
(individual percentages for each family not shown) of all T cells responding to one peptide-epitope. The 
white bars indicate the percentage of HPV-specific T cells for which we could not identify the TCRVb 
CD4+ or CD8+ T cells present in TIL and from 0.63% - 24% in TDLN. This was independent of 
the total numbers of T cells isolated, indicating a great variability in the contribution of HPV-
specific T cells to the total local anti-tumor response between patients. 
the local HPV-specific response consists of a broad t-cell repertoire
To study the breadth of the HPV-specific TIL/TDLNC-repertoire the isolated cells were 
stimulated with pools of E6 or E7 peptides as otherwise there would not be enough cells to 
study the response to single peptides. This allowed the analysis of the breadth of the HPV-
specific T-cell response – based on antigen-specific expression of CD154 and/or CD137 - to 
single peptides in 12 patients (Figure 1b; Supplemental Table 1). The three TIL cultures tested 
negative before remained negative excluding priming in vitro.  In most of the patients the HPV-
specific CD4+ T-cell response was highly diverse as in 5/10 patients CD4+ T cells responded to 
�5 different peptides and in another 4 patients the CD4+ T cells recognized 2 different peptides 
(Supplemental Table 1).  HPV-specific CD8+ T-cell reactivity was detected in 6 of the 12 tested 
patients, five of whom displayed CD8+ T-cell reactivity to 2-6 different peptides (Figure 1b; 
Supplemental Table 1). 
The minimal number of T-cell epitopes recognized per patient was estimated by counting 
the response to two overlapping peptides as one because they overlapped by 12 amino 
acids. The majority of the patients (8/12) recognized ≥3 different T-cell epitopes (Figure 1c). 
The TDLNC populations reacted against 4-9 different epitopes (Figure 1c). Thus the tumor-
induced HPV-specific T-cell repertoire is directed against multiple T-cell epitopes. Based on 
the patient’s HLA-type 4 of the CD4- and 2 of the CD8-responses could involve a reaction 
against known HLA class I and II T-cell epitopes (not shown)  (3;34;35). As each individual T-cell 
epitope can be recognized by different T-cell clones, we studied the number of TCRVb families 
involved in the recognition of each epitope by using a commercially available TCRVb-specific 
antibody kit. The different T-cell clones were operationally defined as the cohort of activated 
HPV single peptide-specific CD4+ or CD8+ T cells expressing the same TCRVb-chain, within the 
population of specifically activated CD154+ and/or CD137+ T cells. Figure 2a shows examples of 
the contribution of several T-cell receptor families reactive to one single peptide. Often one 
or two dominant TCRVb’s were found (Table 2 and Figure 2b), as well as several sub-dominant 
and minor TCRVb’s. For example, the HPV-specific CD4+ T-cell response of patient P14 reacted 
to 9 different peptides and - on the basis of the different TCRVb’s present in the population of 
activated T cells - this involved the activation of at least 43 different T-cell clones (Table 2 and 
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families involved using the TCRVb kit. Patient numbers and 22-mer peptides recognized are indicated by 
the protein name and the first amino acid in the sequence of this protein. The * identifies the two cultures 
for which an additional TCRVb analysis was done by RT-PCR allowing the detection of  other TCRVb’s not 
present in the TCRVb kit. (C) RT-PCR for TCRVb in TIL of patient P7, revealing the presence of TCRVb24. The 
percentage of each TCRVb that was detected by flow cytometry is indicated on the left. (D) A fingerprint 
overview of all TCRVb’s detected upon response to a single peptide-epitope for the patients investigated. 
The black squares indicate that the TCRVb (indicated at the left) was involved in response to that particular 
peptide (indicted at bottom). A white cross means that this TCRVb was found in two independent patients 
responding to that peptide, the right column indicates in how many patients this TCRVb was found.
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Figure 2b). In a number of cases not all TCRVb could be identified as the available antibodies 
cover approximately 70-80% of the full TCRVb-repertoire (36). In one case (P7) where all 
cultured T cells responded exclusively to one peptide - but for which only 22% of the HPV-
specific T cells the TCRVb was accounted for by antibodies (Figure 2a, fourth row and Table 
2) - a semi-quantitative RT-PCR was applied revealing the presence of TCRVb24 (Figure 2c). 
In another case (P15) only 30% of the TCRVb were accounted for by antibodies. Here, three 
additional TCRVb 6C, 6D and 15 (not shown) were detected by RT-PCR. No skewing to a certain 
TCRVb within this patient group was found, nor was there any skewing of certain TCRVb families 
to individual peptides observed (Figure 2d). Thus the HPV-specific T-cell repertoire consists of 
a polyclonal T-cell population able to respond to many different CD4 and CD8 T-cell epitopes.  
HPV-specific til generally lack type 1 polyfunctional t cells.
The production of IFNg and IL-2 is essential for an effective anti-tumor response and 
instrumental to functionally characterize antigen-specific T cells (37-42). Therefore, the ex-vivo 
enumerated HPV-specific CD154+ and/or CD137+ T cells were simultaneously analyzed for their 
production of these cytokines. When specifically gated on the population of CD4 or CD8 T cells 
that expressed CD154 and/or CD137 after antigen-specific stimulation, four distinct cytokine 
profiles were found (Figure 3ab). Profile 1 was found in one patient (P7). Despite the presence 
of a high percentage of HPV E6-specific CD8+ T cells (24%), only about 4% produced either 
one of the cytokines. The second profile comprised HPV-specific T cells of which the majority 
produced both IFNg and IL-2 (e.g. P4 and P5), HPV-specific T cells in the third profile mainly 
produced IL-2 (e.g. P1, P2, P10 and P15), whereas they produced mainly IFNg in profile four (P14 
and P9). These data indicate that while most of the HPV-specific TIL can produce either one 
of the type 1 cytokines, there are only few patients (2/9) in whom the majority of their HPV-
specific TIL simultaneously produce IFNg and IL-2 (Profile 2; Figure 3ab). 
activation of HPV-specific t cells in the presence of tlr ligands increases the 
type 1 cytokine effector response.
Our results showed that in many cases the HPV-specific T-cell response is not associated with 
strong production of IFNg (Table 1 and Figure 3ab). In mouse models, the local injection of TLR2, 
TLR3 or TLR4 ligands can augment the tumor response (43-45). To mimic the local delivery of 
antigen and TLR ligand, homeostatic expanded TIL from 2 patients were stimulated with HPV 
antigen-pulsed TLR-activated autologous monocytes whereas TDLNC from 2 other patients, 
which already contained APC, were activated with their cognate HPV-antigens in the absence 
or presence of TLR-agonist directly ex-vivo. Cytokine analyses revealed a faster and higher 
production of IFNg during the first 7 days after activation in all four TIL and TDLNC cultures 
tested when PAM3CSK4 (TLR2) was added and in 3 out of 4 of the cultures with poly(I:C) (TLR3) 
(Figure 3c). The use of the TLR4 agonist LPS boosted the IFNg-response in one patient (P14), 
but with somewhat slower kinetics.  Notably, PAM3CSK4 (TLR2) also increased the production 
of the Th2 cytokine IL-5 in 3 of 4 cultures (not shown). 
Analysis of the constitution of the responding cell population after 14 days, allowing the 
activated T cells to come to rest needed to decrease background staining for the activation 
markers and cytokines, revealed no overt differences in the number of activated cells or 
the percentage of IFNg, IL-2 or double- producing T cells within the CD154- and/or CD137-
expressing HPV-specific T-cell population after this period (not shown). 
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Figure 3.  Functionality of HPV-specific TIL and TDLNC . (A) The specific activity to HPV16 or 18 E6 and E7 
peptide pools by simultaneous analysis of CD154, CD137, IFNg and IL-2 in homeostatic cytokine-mediated 
expanded TIL as well as directly ex-vivo in TDLNC. Four different cytokine profiles could be distinguished 
within the population of HPV antigen-induced CD154- and/or CD137-expressing T cells. Profile I: HPV-
specific T-cells with few T-cells producing cytokines (P7). Prolife II: Predominant production of IFNg and 
IL-2 (P4). Profile III: predominant production of IL-2 (P15). Profile IV: mainly IFNg producing HPV-specific 
T cells (P9). (B) Overview of the cytokine production. The percentage of activated HPV-specific T-cells 
is indicated on top of the bars. The stacked bars indicate the percentage and type of cytokines (black: 
IFNg, grey: IL-2, hatched: IFNg+IL-2 and white: no IFNg or IL-2 (none)) produced within the activated HPV-
specific T-cell population. (C) The homeostatic expanded TIL of patients 7 & 9 as well as the TDLNC of 
patients 13& 14 were stimulated with HPV16/18 E6 or E7 peptide pools and TLR-agonist when indicated 
(medium control indicates peptide stimulation without addition of TLR-agonist). After 2, 4 and 7 days 
supernatant was harvested and analyzed for cytokine production by cytokine bead array.
diScuSSion
We have comprehensively analyzed the spontaneous tumor-specific immune response in 
patients with cervical cancer by dissecting local HPV E6- and E7-specific CD4+ and CD8+ T-cell 
responses down to the level of the percentage, specificity, cytokine polarization and number of 
different responding T-cells. The expression of the two known tumor antigens E6 and E7 in all 
cervical cancer cells and the use of overlapping peptide arrays in combination with the activation 
markers CD154 and CD137, offered the advantage to study the complete cervical cancer-specific 
local T-cell repertoire - independently of the knowledge of defined T-cell epitopes and not 
restricted to particular HLA-types – in a quantitative manner.  We used a selected panel of 
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HPV16- and HPV18-typed cervical cancer patients for whom we previously showed that their 
TIL comprised HPV type-specific T cells, indicating that the current set of data applies to about 
40-50% of all patients with an HPV16- or HPV18-positive cervical carcinoma (3). Our data show 
that while HPV-specific T-cell responses can be detected within the tumors and tumor draining 
lymph nodes of this group of patients with cervical cancer their relative contribution to the 
overall local anti-tumor response varied enormously, ranging from <1% to 66%  (Table 1). While 
we can’t exclude that the quantification of HPV-specific T cells within the total population of TIL 
is accurate as it likely to be biased due to the isolation procedure, the results obtained in the 
ex-vivo measurement of HPV-specific T cells among TDLNC still sustains this notion.   Strikingly 
the HPV-specific response of most patients tested was broad as it targeted multiple peptide-
epitopes within the E6 and E7 tumor-specific antigens and the T-cell response to each and every 
peptide-epitope involved multiple dominant and/or subdominant TCRVb families, or T-cell 
responses to multiple different epitopes within a single peptide (Table 2, Figure 2). One could 
argue that our analysis concerning the breadth of the response is biased through the expansion 
of TIL by either homeostatic cytokines or peptide stimulation, as these rounds of expansion may 
not equally amplify all possible responding cells and less well proliferating HPV-specific T-cell 
clones may even become extinct. Yet in view of the broad responses observed already this would 
only mean that in reality the response is even broader and even now is still underestimated. 
The broad and hierarchical responses closely resemble the published pattern of CD4+ and 
CD8+ T-cell responses to genetically stable viruses, such as CMV (36). This brings forward the 
question whether the HPV-specific T-cell responses observed in these cancer patients reflect a 
characteristic antiviral response or an anti-tumor response. As shown previously, patients with 
HPV-induced pre-malignant disease either fail to mount HPV-specific immunity (4;12) or induce 
a non-beneficial HPV-specific T-cell response during progression of disease (4;12). Therefore, 
we deem it more likely that the T-cell responses studied here reflect a typical tumor-specific 
T-cell response. Indeed, a similar hierarchy of the spontaneous T-cell response was observed in 
a study of two patients responding to NY-ESO-1 (46), and in the HLA-A*0201-restricted Melan-A/
MART-1
26-35
-specific CD8 T-cell response (6).  The presence of single peptide-specific dominant 
and subdominant (based on TCRVb-chain expression) T cells within the tumor tissue implies that 
subdominant TIL participate in the immune surveillance of tumors and not simply act as a reservoir. 
The different dominant and subdominant HPV-specific T cells may have different functions. This 
is illustrated by the isolation of both HPV-specific T-helper and T-regulatory cells from the same 
tumor in a group of cervical patients studied previously (47). Overall, the local HPV-specific 
immune response consists of a polyclonal T-cell population able to respond to many different CD4 
and CD8 T-cell epitopes. We deem it unlikely that this breadth is overestimated due to potential 
cross-reactivity of the T cells with non-related peptide-MHC complexes as even between the 
highly homologous sequences of HPV16 and HPV18 this has never been observed (3;13).
CD4+ and CD8+ T cells as well as the cytokines IFNg and IL-2 play a key role in the protection 
against cancer (4;37-40) as well as in the control of chronic viral infections (41;42). In most of 
the ex-vivo tested TIL and TDLNC the population of IFNg and IL-2 producing T cells or IFNg-
producing T cells among the total population of HPV-specific T cells as well as the amount of 
IFNg produced was low (Table 1 & Figure 3b), suggesting that most of the HPV-specific TIL and 
TDLNC with respect to the production of these cytokines are rendered functionally tolerant 
within the tumor environment and implying that the local tumor-specific immune response in 
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cervical cancer patients does not differ from others, such as melanoma (48). In vitro stimulation 
of these HPV-specific T cells with their cognate antigen resulted in an increase in the number 
of HPV-specific T cells (e.g. P9, compare Figure 1a and Figure 1b) as well as in an increased IFNg 
production (data not shown). We recently reported that the majority of patients vaccinated 
with a HPV16 long peptide vaccine, displayed a broad vaccine-induced HPV-specific immune 
response as detected by IFNg-ELISPOT (23;24). Most likely this vaccine taps the broad available 
T-cell repertoire we identified in this study and either primes (in patients without HPV-specific 
reactivity) or boosts their number. Interestingly, when TIL and lymph node derived T cells are 
ex-vivo stimulated with cognate antigen in the presence of TLR ligands, such as PAM3CSK4 or 
poly (I:C), a pronounced increase of effector function is observed (Figure 3c). This suggests 
that local delivery of these innate immune-derived stimulating factors can stimulate a stronger 
anti-tumor response in human cancers similar to murine tumor models (43-45). Moreover, they 
may assist therapeutic vaccines in driving T-cell responses with increased function as shown for 
a melanoma peptide vaccine in combination with CpG (49). Such type of responses is highly 
required as they correlate with clinical efficacy in murine models (43) and in human trials (50). 
Interestingly, the widely used TLR4 ligand LPS did not overtly increase IFNg production of TIL 
and TDLNC in our study. 
In conclusion, TIL or TDNLC isolated from 40-50% of patients with an HPV16 or HPV18-
induced cervical tumor contain HPV type-specific T cells (3). Our study of the local T-cell 
repertoire within this group of patients suggests that within the tumor environment or tumor-
draining lymph node of a given patient many different tumor-specific CD4+ and CD8+ T cells 
are poised for action but are awaiting proper stimulation. 
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Supplemental figure 1. (A) Activated cells (CD154+ and/or CD137+) within CD3+ T cell population and 
within the CD3+ T-cell gated population expressing either CD4 or CD8. In these plots the homeostatic 
expanded TIL from two patients (P9 and P4) after stimulation with medium only, E6 or E7 peptide pools and 
E6 or E7 protein is shown. The peptide or proteinactivated CD154+ and/or CD137+ T cells as shown in Figure 
1 where back-gated and indicated by a red color (activated CD8 T cells) or a blue color (activated CD4 T 
cells). Down regulation of CD8 is seen in the CD8+ T-cell population stimulated with the peptide pool and 
to a lesser extent in CD8 T cells stimulated with protein and this is not observed for CD4 on activated CD4 
T cells. (B) An overview of all the single peptides used for analysis of the breadth of response after antigen-
driven expansion for P9 and P12 (as partly shown in figure 1). Shown here are all the positive and negative 
responses as measured by the expression of CD154 and CD137. P9 displayed a CD8 response against four 
different single peptides (notably 41, 51, 61 and 137). P12 displayed a CD4 response against six different 
single peptides (notably 21, 61, 71, 81, 91 and 101).
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Chapter 4
Squamous cell carcinomas of the head and neck (HNSCC), in particular those of the oropharynx, 
can be caused by human papilloma virus type 16 (HPV16).  Whereas these HPV-induced 
oropharyngeal carcinomas may express the HPV16 E6 and E7 oncoproteins and are associated 
with better survival, the non-virally induced HNSCC are associated with over-expression of 
p53. In this study we assessed the presence of systemic and local T cells reactive against these 
oncoproteins in HNSCC. 
An exploratory study on the presence, type and function of HPV16- and/or p53-specific T 
cells in the blood, tumor and/or metastatic lymph node as measured by several immune assays 
was performed in an unselected group of 50 patients with HNSCC. Tumor tissue was tested for 
HPV DNA and the overexpression of p53 protein.
Almost all HPV16+ tumors were located in the oropharynx. Circulating HPV16- and p53-
specific T cells were found in 17/47 and 7/45 tested patients. T cells were isolated from tumor 
cultures and/or lymph nodes of 20 patients. HPV16-specific T cells were detected in 6 of 8 HPV+ 
tumors, but in none of the 12 HPV- tumors. Tumor-infiltrating p53-specific T cells were not 
detected. In depth analysis of the HPV16-specific T-cell response revealed that this response 
comprised a broad repertoire of CD4+ T-helper type 1 and 2  cells, CD4+ regulatory T cells and 
CD8+ T cells reactive to HPV16.
The local presence of HPV16-specific T-cell immunity in HPV16-induced HNSCC implicates 
a role in the antitumor response and support the development of immunotherapy for HNSCC. 
abstraCt
introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer  (1) and 
comprises cancers from the oral cavity, hypopharynx and oropharynx. Human papilloma virus 
type 16 (HPV16) induces HNSCC squamous cell carcinoma almost exclusively at the oropharynx, 
the incidence of which is rising worldwide  (2). Patients with HPV-induced HNCSCC often 
present with advanced disease but their prognosis is better than HNCSCC  associated with 
smoking and drinking  (3-5). Notably, the majority but not all patients with an HPV+ tumor 
display a strong gene signature for adaptive immune response in their tumor  (6) as well as 
strong tumor infiltration by T cells  (4) suggesting that the presence of HPV may be related to 
an enhanced local tumor-specific T-cell response.  
HPV16-induced cancer cells express two virally-derived oncoproteins E6 and E7 and 
because these oncoproteins are foreign to the body, they are expected to evoke an immune 
response. So far, there are only few reports on HPV16-specific T-cell immunity in HNCSCC. 
They describe elevated levels of circulating HPV16 E7-specific CD8+ T cells  (7) as well as the 
presence of HPV16-specific IFNg-producing T cells in in vitro cultures of PBMC from patients 
with HPV16+ HNSCC  (8). In addition, circulating antibodies to HPV16 have been detected in 
HNCSCC patients with high viral load and it is suggested that the HPV-specific antibody status 
is related to clinical outcome  (9, 10).
In non-viral induced, smoking and drinking-associated HNCSCC, p53 over-expression is 
one of the most common abnormalities identified. Mutation of p53 is correlated with poor 
prognosis. Mutations in p53 protein or in the p53 regulating pathway can cause overexpression 
of the protein. The expression of the HPV16 E6 oncoprotein, however, induces increased 
degradation of p53. Both mechanisms may result in an enhanced presentation of p53-derived 
peptides to T cells, the latter mechanism predominantly to CD8 T cells. P53-specific IgG 
antibodies have been found in patients with HNSCC and this was suggested to be linked with 
bad prognosis  (11, 12).  These p53-specific IgG responses indicate that p53- specific CD4+ T 
cells are also present in these patients. Indeed, the presence of both circulating and tumor-
infiltrating p53-specific T cells has been reported  (13, 14).
In HNSCC a number of cytokine-, antibody- and vaccine-based immunotherapeutic 
approaches have been tested or are currently underway  (15-17). Recently, clinical success 
was achieved in the field of the immunotherapy of HPV16-induced (pre-)malignancies of the 
anogenital region, in particular with therapeutic vaccines  (18-20). Similar vaccine approaches 
are tested for the treatment of p53-overexpressing cancers  (21-23). There is a strong notion that 
the presence and type of pre-existing circulating and local tumor-specific immunity influences 
the clinical outcome as well as that of immunotherapeutic approaches  (6, 18). Thus, in order to 
optimize immune resistance to HNSCC, a better understanding of the character and specificity 
of tumor-infiltrating-lymphocytes (TIL) in HNSCC is needed. Therefore, an explorative study 
was performed in which the blood of 50 patients and 20 successfully obtained T-cell cultures 
from their tumors and/or lymph nodes were studied for the presence, type and function of 
HPV- or p53-specific T cells. In addition the tumors were studied for the presence of HPV and 
p53-overexpression.
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Patients presenting with an epithelial lesion of the head and neck region were included after 
informed consent.  After inclusion 50ml of blood and 2 (research and diagnostic) biopsies 
were taken in parallel with physical examination under sedation however for several patients 
a diagnostic biopsy had been taken 2-3 weeks earlier before the patients were referred to our 
hospital. None of the patients received treatment prior to study inclusion. Diagnosis was based 
on histopathological analysis of biopsies. PBMC were isolated by Ficoll-density centrifugation 
and obtained cells were directly tested in a lymphocyte stimulation test (LST). Remaining 
PBMC were  preserved in liquid nitrogen until further use. In a number of cases, PBMC were 
transformed with EBV to obtain B-LCL lines.
immunohistochemistry
Immunohistochemical analysis was performed on 3 µm paraffin sections, mounted on 





 in methanol for 20 min to block endogenous peroxidase activity. Antigen 
retrieval was performed (0.01 M citrate, pH 6.0) and sections were blocked with 1 % BSA. 
Subsequently, sections were stained for p53 (overnight, room temperature) using a 1:2000 
dilution of anti-human p53 (Clone DO-7, Neomarkers, Fremont, CA) in PBS containing 1% 
BSA. Next the slides were incubated with Powervision-Poly/HRP (Immunogenic, Duiven, the 
Netherlands) and immune complexes were visualized with diaminobenzidine. Slides were 
evaluated by light-microscopy and scored for the presence, intensity and percentage of tumor 
cells expressing P53.
HPV typing 
DNA was isolated from formalin-fixed, paraffin-embedded biopsy samples as previously 
described  (24). The aqueous solution obtained from the DNA analysis was diluted 1:10 and 1:50. 
The presence of HPV in the diluted samples was determined by genotyping the samples that 
demonstrated 65 basepair PCR amplimers on a 3% agarose gel using an INNO-LiPA Genotyping 
Extra test (Innogenetics, Ghent, Belgium), according to the manufacturer’s instruction. This 
assay allows the detection of the following HPV types: HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 43, 
44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 69/71, 73, and 74. Hybridisation patterns were visually 
inspected and interpreted using a grid. 
antigens and lymphocyte stimulation test
Pools of overlapping 22-mer peptides spanning the entire HPV16 E6 and E7 proteins were 
used and pools of overlapping 30-mer peptides spanning the whole p53 protein as described 
previously  (25, 26). The first and last amino acid within the sequence of the indicated antigen 
that is represented by the pooled peptides is indicated (e.g. E6 1-92). Memory response mix 
(MRM)was used as positive control  (26, 27). The capacity of T cells to proliferate on recognition 
of the antigen was determined by LST as described earlier  (27). The average of 8 tested wells 
divided by the average of the medium control plus 3 SD was calculated and is referred to as the 
stimulation index (SI).  
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Day 6 supernatant was analyzed for the presence of IFNg and IL-10 by ELISA (Sanquin, the 
Netherlands). Cut-off value (IFNg 50pg/ml; IL-10 20 pg/ml) and >2x the concentration of the 
medium control.
isolation and culture of til
All T-cell cultures and tests were performed in IMDM supplemented with 10% human AB serum 
(Greiner Bio-one, Germany). Biopsies were incubated in IMDM+10% AB serum supplemented 
with Fungizone 25ug/ml, 1000 units pen/strep and 20ug/ml gentamycin (all Invitrogen) for 
1 hour to decrease the bacterial load in the tissue. Subsequently, the biopsies were minced 
in to pieces of ~ 1mm3 and cultured in medium with 10% T-cell Growth Factor (Zeptometrix, 
Buffalo NY, USA) and 5 ng/ml IL-15 (Peprotech, Rocky Hill, NJ). During the first day 5 ng/ml IL-7 
(Peprotech) was added.    TIL were expanded for 2-3 weeks with only addition of medium and 
cytokines and analyzed for phenotype and function.
In 2 patients whit large lymph node metastases, a needle aspirate was taken and frozen in 
liquid nitrogen until further use.
analysis of til specificity
Autologous PBMC were cultured for 2-3 days with GM-CSF and the obtained differentiated 
monocytes were loaded with  peptide pools (5 ug/ml). When more then 1.5 x106 T cells grew out 
also peptide pools of p53 were tested as well as separate smaller pools of HPV-peptides were 
used. Monocytes were washed and TIL were added (20.000-50.000) in fresh IMDM+10% AB 
serum. All tests were performed in triplicate and proliferation was determined by incorporation 
of 0.5 Ci/well [3H]thymidine for the last 16 hr. Phytohaemagglutinin (PHA) (Remel, Germany) 
was taken along as a positive control for T-cell activation. 48 hr-supernatant was pooled and 
analyzed by Th1/Th2 cytometric bead array (CBA, BDbiosciences). Responses were considered 
positive when 3 times medium control and above cut-off value of 20 pg/ml. One TIL and LN 
culture were stimulated with E6 peptide pool in order to obtain enough HPV-specific T cells 
to measure the breadth of the response with respect to single peptide-antigens as described 
earlier  (28). Data was recorded on a FacsCalibur or LSR-II (BD biosciences) and analyzed using 
Flowjo software (Treestar inc, USA).
isolation of t-cell clones
T-cell clones from the TIL of patient 27 were isolated using limited dilution as described 
earlier  (29). T-cell clones were tested for phenotype and TCRVb usage by flow cytometry and 
specificity was tested by 48 hr proliferation assay on peptide or protein loaded B-LCL. Cytokine 
production was analyzed by ELISA and CBA.
Suppression assays
The capacity to suppress the proliferation of stimulated naive CD4+CD25+ cells by the T-cell 
clones of patient 27 was tested as previously described  (30). 
64
HPV-specific T cells in HNSCC
4
reSultS
circulating HPV16- and p53-specific t cells are present in patients with head 
and neck cancer
A total of 50 patients with HNSCC in a variety of regions were included in this study (Table 1). In 
41 and 43 cases we were able to test the tumors tissue of the biopsy for the presence of HPV and 
the over-expression of p53 protein, respectively. The patients presenting with an HPV16+ tumor 
were slightly younger (average 60.4 years) compared to HPV16- and unknown oropharyngeal 
tumors (average 63.3 years) or all HPV- patients (average 65.8 years).
Of the 41 tested tumors, 12 contained DNA of HPV 16.  It is known that HPV infection is often 
present in the oropharynx. Indeed, when we divided our cohort according to region 11 of the 12 
HPV16+ tumors were located in the oropharynx region (52% of all  oropharyngeal tumors) and 
one was present in the oral cavity (8% of oral cavity tumors). No HPV was detected in 10 tested 
tumors of the hypopharynx (Table 1). In 12 out of 43 tumors p53 was over-expressed, more often 
(6/10) in the tumors of the hypopharynx (Table 1). 
PBMC were isolated and directly tested for the presence of specific T cells to peptides of the 
HPV 16 oncoproteins or p53 by LST (4 examples are shown in Fig. 1). In 17 of 47 tested patients 
a proliferative response to HPV16 was detected. Interestingly most responses to HPV were 
found in patients with an HPV+ tumor. There is a trend that the detection rate is higher in this 
group 7 out of 11 patients displayed a detectable response to HPV16 than in patients with a HPV- 
tumor (7 out of 28 patients; p= 0.061 Fisher’s exact). Only in a minority of patients (5/17) this 
proliferative response was accompanied by detectable IFNg production (patient 8, 9, 22, 28 and 
52; range 77-440 pg/ml). The response of patient 8 was also accompanied by detectable IL-10 
(28 pg/ml). Notably, in 4 of these 5 cases the patient’s tumor was HPV16 negative.
Proliferative T cell responses to p53 were found in the blood of 7 out of 45 tested patients. 
In only one patient this response was associated with IFNg-production (patient 7, 61 pg/ml). No 
correlation existed between p53 over-expression or the presence of HPV in the tumor and the 
detected p53-specific immune response in the blood. Only one of the patients with a p53 over-
expressing tumor displayed p53-specific immunity (Table 1).
Thus, within an unselected group of patients treated with head and neck cancer 52% 
of patients with an oropharyngeal tumor presented with tumor-integrated HPV16 DNA. 
Furthermore, circulating HPV16-specific T cells  are more often detected in this group.   
the percentage of circulating and tumor-associated cd4+cd25+foxp3+ t cells
For 12 patients of whom enough PBMC were available the number of regulatory T cells was 
determined. The mean percentage of CD25+Foxp3+ cells within the CD4+ T cell population in 
the blood was 2.7% (range 0.68-6.29, n=12) and no difference was found between patient groups 
or HPV status (data not shown). Interestingly a substantial number of CD4+ T cells present in the 
tumor cultures displayed Foxp3+, the transcription factor associated with regulatory function 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































HPV-specific t cells can be isolated from oropharyngeal tumors and draining 
lymph nodes
We were able to culture T cells from the tumor biopsies of 19 patients. In all cultures, both 
CD8+  and  CD4+ T cells grew out (CD4/CD8 ratio median 2.45, average 5.1 and range 0.1-19) 
. The composition of T cells was not clearly influenced by the culture conditions (Fig. 2a). 
After a 3-week homeostatic expansion period (no exogenous antigen was added) the T cells 
were tested for their reactivity against autologous monocytes loaded with indicated pools of 
HPV16 E6 or E7 peptides (n=19) and when enough cells were available to monocytes pulsed 
with pools of p53 peptides (n=10). Non-specific stimulation with PHA revealed that the TIL from 
most tumors comprised a heterogeneous population of T cells that displayed a high capacity to 
proliferate and to produce the type 1 cytokines IFNg and TNFa as well as the type 2 cytokines 
IL-5 and IL-4 (Fig. 2b and not shown).
While none of the TIL isolated from HPV negative tumors displayed a proliferative response 
to HPV (data not shown), we were able to detect HPV16-specific T-cell proliferation in 5 out 
of 7 patients with an HPV16+ tumor (Fig. 2b). TIL from patient 27 reacted against HPV16E6 by 
both proliferation and the production of IFNg. TIL from patient 28 reacted with strikingly high 
proliferation and high production of IFNg, TNFa and IL-5 against both HPV16 E6 and E7. The TIL 
from a third HPV16+ patient displayed a modest proliferative response to E6 but without the 
concomitant production of IFNg (patient 35; Fig. 2b). In all these patients we had also detected 
an HPV16-specific response in the blood. The TIL of patient 46 displayed an IFNg-associated 
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Figure 1. HPV-  and p53-specific T cells  circulate in the blood. Lymphocyte stimulation test of freshly 
isolated PBMC. Proliferation of T cells stimulated with pools of peptides indicated at the x-axis after 7 days 
of culture. The positive control  is the memory response mix (MRM). Shown are the counts of 8 separate 
wells and the mean.  Top: patient 9; positive response to peptide pools covering E6 aa81-158 and p53 aa241-
393. Patient 35 responding to E6  aa81-158 and E7. Bottom: patient 26; weak response to E6 aa81-158. lower 
right: patient 25 no response.
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Figure 2. HPV-specific T cells are present in HPV+ tumors. A, Phenotypic analysis of freshly isolated T cells 
derived from tumor tissue of patient 53 (top panel) or after 3 weeks of culture (bottom panel) by flow 
cytometry. An increase in the percentage of CD4+ and CD8+ T cells (while their ratio remains relatively 
unchanged) during the 3 week culture period is observed. Within the CD4+ T cell population CD25+Foxp3+ 
regulatory cells are found. B, Proliferation assay of TIL of 5 different patients. Monocytes were loaded 
overnight with medium only (med), peptide pool of overlapping 22 mer peptides of the HPV16 E6 and 
E7 oncoproteins. As positive control for T-cell reactivity  PHA stimulation was used  (PHA).  The number 
of conditions that could be tested depended on the number of TIL obtained. T cells were added and 
proliferation was measured at 48 hr by the incorporation of [3H]-thymidine (top row). Mean of triplicate + 
SEM is shown. Supernatants isolated at  48 hrs of culture were analyzed by CBA (bottom row). All tumors 
were HPV16+.
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and TNFa-associated HPV16 E6-specific T-cell response. In the latter two cases no response 
was detected in the blood suggesting that measurements of HPV16-specific immunity in PBMC 
may underestimate the total number of patients that have mounted an immune response. Of 
the 10 different TIL that could be tested for the presence of p53-specific T cells, none displayed 
p53-specific reactivity despite that 2 patients had tumors that over-expressed p53 (Patient 22 
and 31; not shown). 
In 2 patients large lymph node metastasis were palpable in the neck and a needle aspirate 
was taken (patient 6 and 35, both HPV16+). For patient 6, the cells were stimulated ones with 
pools of E6 or E7 peptides to obtain enough cells to test. These bulk cultures were tested by 
overnight activation and intracellular cytokine staining  (28). As indicated by the up regulation 
of  the activation markers CD137 and CD154,  the lymph node cells comprised HPV16-specific T 
cells reactive to peptide pools of E6 and E7 and which were able to produce both IFNg and IL-2 
(Fig. 3b). The T cells were able to recognize their cognate antigen when naturally processed and 
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Figure 3. Specificity as well as IFNg and IL-2 production of TIL by multiparameter flow cytometry. 
A, Analyses of the specificity and cytokine production of TIL of patient 46. T cells were stimulated with 
single peptides and analyzed for expression of activation markers CD137 and CD154 and the production of 
the cytokines IL-2 and IFNg. Cells were gated on CD3+CD4+ expressing  cells, the numbers represent the 
percentage of gated cells. Bottom  row; IL-2 and IFNg expression of CD154+,CD137+ cells gated in the plots 
of the top row. Numbers indicate percentage  cells in that quadrant. * peptide 21-32 is representative for all 
other peptides covering E7 since no response was found in this group. B, Analysis of HPV-specific reactivity 
in LN cells of patient 6. T cells were cultured with B-LCL loaded with medium only (med) or peptide 
pools of E6 or E7,  HPV16 E6 or E7 protein and  HIV-RT protein (ctrl prot) measured by multi parameter 
flowcytometry as described in A. Shown is the percentage of CD4+ T cells expressing activation marker 
CD137 and CD154 in response to the indicated stimulus as well as the percentage of cells that produced the 
depicted cytokines within the activated cell population.
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presented as E7 protein-pulsed APC were clearly recognized but not APC pulsed with control 
protein. Unfortunately in  the LN of patient 35 we did not detect HPV-specific T cells although 
both the TIL and blood of this patient displayed HPV16-specific T-cell reactivity.  
Thus in 6 out of 8 of patients with HPV-induced  tumors of the oropharynx, we detected 
functionally active HPV-specific T cells in the tumor or lymph nodes. 
the breadth of  the  HPV16-specific cd4+ and cd8+ t–cell response  in til
To assess the type and specificity of the HPV16-specific T cells in the TIL, the tumor-derived T 
cells of patient 46 were stimulated overnight with autologous B-LCL pulsed either with a pool 
or each individual single 22-mer peptide of HPV16 E7 and analyzed by multiparameter flow 
cytometry. The CD4+ T cells within this TIL population responded to a sequence located in the 
first part of the HPV16 E7 protein by the expression of both CD154 and CD137 and the production 
of IL-2, IFNg and IL-2, or IFNg only (Fig. 3a). Not only B-LCL pulsed with the E7 22-mer peptides 
were recognized but also B-LCL loaded with whole protein confirming that these T cells 
recognized the naturally processed antigen. The population of CD4+ T cells predominantly 
produced IL-2 and IFNg although some T cells only produced IL-2, IFNg or neither cytokine 
upon antigen-specific stimulation. 
As the number of TIL isolated from patient 27 was to low to do a direct analysis we decided 
to isolate T-cell clones from this TIL culture. This resulted in the isolation and expansion of 18 
HPV16-E6 specific T-cell clones, 14 of these where CD4+ T cells and 4 CD8+ T-cell clones. Upon 
antigenic stimulation all T-cell clones proliferated and most T-cell clones produced high amounts 
of IFNg. A limited number of clones produced IL-10 (Fig. 4a). Interestingly, in 2 clones IFNg 
production was accompanied by high levels of IL-5 upon peptide or processed protein recognition 
(Fig. 4c and not shown). All CD4+ T cell clones tested responded to epitopes within the sequence 
covered by amino acids 41-72 of HPV16E6 and recognized naturally processed E6 protein. At least 
3 distinct epitopes were recognized (examples see Fig. 4bc). Unfortunately, the exact CD8+ T-cell 
epitope recognized could not be determined since the in vitro life span of these cells was limited. 
Phenotypical analysis of surface markers and intra-cellular FoxP3 by flow cytometry on 2-3 weeks 
rested T-cell clones revealed that some CD4+ T cells expressed low levels of the transcription 
factor Foxp3 (Fig 5a, clone 4 and 245). Interestingly, 2 of the 3 HPV16-specific CD8 T-cell clones 
expressed high levels of CD25 and Foxp3 as well (Fig. 5a). The analysis of the T-cell receptorVb 
(TCRVb) usage of the T-cell clones revealed the presence of at least 5 different TCRVb families. 
Since the T-cell clones expressing TCRVb17 recognized different epitopes (Clones 4 and 142; E6 
aa51-72 and Clone 245; E6 aa41-62) (Figures 4+5) and also the 2 T-cell clones expressing TCRVb2 
recognized different epitopes (Clone 49; E6 aa51-72 and Clone 251 E6 aa41-62 and 51-72) , we 
conclude that at least 6 distinct HPV16E6-specific CD4+ T cell populations were present in the 
tumor. It was reported for  CD4+ T cells isolated from oropharyngeal tumors that they exert 
suppressive function via ectonucleotidases CD39 and CD73  (31). Interestingly, all isolated CD4+ 
T cells tested expressed the ectonucleotidases CD39 and CD73 on the surface whereas this is not 
the case for peripheral CD4+ T cells isolated from a healthy control (Fig 5b). 
Based on the expression of Foxp3 by the isolated CD4+ T-cell clones, as well as on our 
experience with HPV16-specific T cells in cervical tumor, we tested the HPV16-specific CD4+ 
T cells for their capacity to suppress the proliferation and cytokine production of allogeneic 
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Figure 4. TIL isolated from patient 27 contains functional CD4+ and CD8+ HPV-specific T cells. Clones 
were isolated by limited dilution and tested for the recognition of HPV16E6 peptides loaded on autologous 
B-LCL (black) or B-LCL only (white). A, T cell function was tested by proliferation (top row), IFNg production 
(middle) and IL-10 production (bottom) after 48 hrs. Clone number is depicted at the X-axis, 14 CD4+ and 4 
CD8+ clones were isolated. B, all clones recognized a sequence between aa41 and aa82 of the E6 protein as 
shown by the IFNg production upon stimulation with peptide loaded B-LCL. Shown are 4 typical examples 
of the recognition of aa41-62, aa51-72 or the overlapping peptides aa41-62 and aa51-72. C, Not only 
stimulation with  peptide but also with naturally processed protein results in T-cell proliferation (left) and 
production of cytokines (right). Clone 25 produces IFNg, TNFa as wells as high amounts of IL-5 whereas 
clone 251 mostly produced IFNg . Two representative clones out of 6 are shown.
also helper T cells (clone 251) were present. Taken together we conclude that the local HPV-
specific T-cell response comprises a mixed population of Th1, Th2 and regulatory T cells, as well 
as IFNg producing CD8+ T cells. 
diScuSSion
In this explorative study of the tumor-specific immune response in 50 patients with HNSCC we 
found HPV16 DNA to be present in almost half of the patients presenting with a malignancy in 
the oropharynx but not in other regions. Circulating T cells reacting against HPV16 E6 or E7 
peptides were detected in the blood, often in patients with an HPV16+ tumor, largely extending 
previous data on HLA-A2 restricted T cells in a small group of patients  (7) Similar to what was 
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observed in patients with cervical carcinoma the HPV16-specific T-cell proliferative responses 
in HNSCC were not/hardly ever accompanied by the production of IFNg  (26, 32). Although 
these responses in the blood clearly show that adaptive immune responses are induced upon 
exposure to the HPV viral oncoproteins, this reaction does not necessarily reflect an ongoing 
immune response against the tumor. This is exemplified by the detection of circulating HPV16-
specific T cells in the blood of some patients with HPV-negative tumors, which in a number of 
cases displayed a similar cytokine profile as described for HPV16-specific reactivity in healthy 
females (27).
Here, we showed that HPV16-specific T cells are present in 5 out of 7 TIL populations and 
in 1 out of 2 tested tumor-draining lymph nodes from patients with HPV16+ tumors. Notably 2 
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Figure 5.   HPV specific helper and regulatory cells are present within the tumor. A, Flowcytometric analysis 
of resting clones by surface markers CD4 and CD8 (top row) and  intracellular staining for the Treg markers 
CD25 and FoxP3 (second row). Gates are adjusted to unstained control. Bottom row shows the TCRVb 
usage of the clones as determined with sets of antibodies. Shown is the antibody set that stained positive 
as depicted in the graphs and the concommitant TCRVb is indicated. B. Ectonucleotidase expression was 
analyzed by flowcytometry for 5 clones and PBMC. All clones express high CD39 and CD73 receptor (grey 
fill is background fluorescence). C, The capacity of the T-cell clones to suppress the response of naive T 
cells was tested by the activation of CD4+CD25- T cells with  a pool of mixed B-LCL anti-CD3 antibodies. 
Proliferation and IFNg production is measured at 48 hr. The T-cell clones were added in increasing numbers 
(100/10, 100/50, 100/100). Example of suppressive clone 4 (left) and helper clone 251 (right). Proliferation 
test was performed in triplicate, mean with SEM.
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detectable response in the blood. This indicates that the peripheral T-cell compartment not 
always reflects the local anti-tumor response. Importantly our data indicate that HPV16-
specific T cells are locally present in the majority of patients with HPV16-positive oropharyngeal 
tumors, this in sharp contrast to the only 32% of the patients with HPV16+ cervical cancers (29). 
We speculate that the location of the disease is likely to contribute to this as the oropharynx 
consists of lymphoid tissue and our studies on cervical tumor-draining lymph nodes suggest 
that they generally contain HPV-specific T cells  (28, 29).  In addition, the high load of bacterial 
and fungal co-infections present in the oropharynx of these patients may also act as stimulus 
for the local immune system.
So far, the data on TIL in HNSCC  was limited to the quantification and phenotyping of 
tumor infiltrating immune cells by immunohistochemical studies and microarray  (6, 33, 34). We 
now show that such infiltrating immune cells comprise functionally different T-cell subsets and 
importantly that they are reactive to the HPV16 oncoproteins. In TIL we find different subsets 
of HPV16-specific T cells (Th1, Th2, CTL and Tregs) with different cytokine profiles (IL-2, IFNg, 
IL-5) comparable to what is found in anogenital HPV16 induced lesions  (29, 35, 36). Together 
this advocates that local adaptive immune cells might play a role in the response to therapy and 
the altered survival of this patient group.
P53 specific CD8+ T cells have also been detected in HNSCC by means of tetramer staining, 
albeit that these cells were present at low frequencies  (14). In this study 28 % of the tumors 
over-expressed p53 protein but we did not find evidence for p53-specific T cells in the 10 TIL 
tested. We have previously shown that it is possible to isolate p53-specific CD4+ T cells from 
the TIL of patients with ovarian cancer  (23). Furthermore both p53-specific CD4+ and CD8+ 
T cells can be isolated from the vaccine site in our studies on p53 vaccination  (22). Although 
the existence of HPV16-specific regulatory T cells is reported, there is no evidence for the 
existence of p53-specific regulatory T cells  (22, 37). However other types of regulatory T cells 
may have suppressed the outgrowth of p53-specific T cells. We can not exclude that the high 
numbers of CD4+Foxp3+ T cells detected in the tumors may have played a role. In some patients 
circulating p53-specific T cells were detected but there was no obvious relation with either p53-
overexpression or the potential HPV-mediated increased degradation of p53 as some tumors 
did not overexpress p53 and were HPV negative. Previously it has been argued that such p53-
negative tumors may represent immune escape variants  (13, 14), alternatively the tumors may 
harbour p53-mutations that do not result in overexpression.
We report that HNSCC are infiltrated by high numbers of CD4+CD25+Foxp3+ T cells and that 
the frequency of these cells exceeded the frequency in the blood. Furthermore, we isolated 
both HPV16-specific CD4+ and CD8+ T-cell clones that expressed high levels of Foxp3 under 
resting conditions. In HNSCC the ratio between CD8+ and regulatory T cells is associated with 
disease  (5, 33). Similarly, in HPV16 induced genital malignancies the presence of FoxP3 positive 
as well as FoxP3 negative HPV16 specific regulatory T cells in tumor and LN is described  (36, 
38, 39) and a low CD8/Treg T-cell ratio is associated with worse outcome  (40).  While the 
regulatory function of the CD4+CD25+Foxp3+ T cells present in TILs needs to be confirmed, at 
least one of our isolated clones clearly exerted regulatory function. The expression of CD39 and 
CD73 has been found on  CD4+ T cells as well as on the great majority of regulatory T cells in 
HNSCC, and has been implicated as a mechanism for T cell suppression  (31). Analyses of these 
markers on the isolated T cell clones revealed that all CD4+ T-cell clones highly expressed CD39 
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and CD73 at the cell surface in resting state, but these included CD4 helper T cells that were not 
suppressive in a classical suppression assay. Notably, also influenza virus-specific CD4+ helper 
T cells and regulatory T cells that were isolated from PBMC cultures  (41) express similar high 
levels of CD39 and CD73 (unpublished observations).  Although the transcription factor Foxp3 
is mainly reported in CD4+ regulatory T cells we found CD8+CD25+FoxP3high T cells in TIL and 
in CD8+ T-cell clones derived from the tonsil region. Siegmund and colleagues describe this 
phenotype to be uniquely present in human tonsil tissue  (42), however their presence was also 
demonstrated in human prostate cancer  (43). Whether these T cells with tolerogenic phenotype 
are a reflection of suppressed local immunity or part of an ongoing adaptive immune response 
can not be concluded from this data. 
Stimulation of local immunity might change the balance from a pro-tumor microenvironment 
to a hostile tumoricidal environment. Recently,  different forms of immunotherapy – 
vaccination to enhance the HPV16-specific T cells response, imiquimod to enhance the local 
innate immune response, and combination hereof - have been successful in the treatment of 
HPV16-induced lesions of the vulva  (19, 20, 44). Similar to HPV-induced lesions of the vulva, 
the HPV-induced HNSCC are relatively accessible and one could envisage that these strategies 
might be applicable to tumors of the oropharynx.
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Chapter 5.1
Monocytes attracted by tumor-induced chronic inflammation differentiate to antigen-
presenting cells (APC), the type of which depends on cues in the local tumor milieu. Here, we 
studied the influence of human cervical cancer cells on monocyte differentiation and showed 
that the majority of cancer cells either hampered monocyte to DC differentiation or skewed their 
differentiation towards M2-like macrophages. Blocking studies revealed that M2-differentiation 
was caused by tumor-produced PgE2 and IL-6. TGFb, IL-10, VEGF or M-CSF did not play a role. 
Notably, these CD14+CD163+ M2-macrophages were also detected in situ. Activation of cancer 
cell-induced M2-like macrophages by several TLR-agonists revealed that when compared 
to DC these M2-macrophages displayed a tolerogenic phenotype reflected by a lower 
expression of co-stimulatory molecules, an altered balance in IL-12p70 and IL-10 production 
and a poor capacity to stimulate T-cell proliferation and IFNg production. Interestingly, upon 
cognate interaction with Th1 cells these tumor-induced M2-macrophages could be switched 
to activated M1-like macrophages that expressed high levels of co-stimulatory molecules, 
produced high amounts of IL-12 and low amounts of IL-10, as well as acquired the lymphoid 
homing marker CCR7. The effects of the interaction between M2-macrophages and Th1 cells 
could partially be mimicked by activation of these APC via CD40 in the presence of IFNg. Our 
data on the presence, induction and plasticity of tumor-induced tolerogenic APC in cervical 
cancer suggest that tumor-infiltrated Th1 cells can stimulate a tumor-rejecting environment by 
switching M2-macrophages to classical pro-inflammatory M1 macrophages.
abstraCt
introduction
Cervical cancer (CxCa) is induced by human papilloma virus (HPV) (1). In many cases, the 
development of CxCa is associated with a weak systemic and local immune response to HPV, 
reflected by low numbers of tumor-infiltrating T cells that comprise functionally impaired 
T-helper cells and regulatory T cells (2-7).  When the tumor-specific immune response is 
stronger and more in favor of a Th1/CTL response, this is associated with an improved prognosis 
(4,8-10). 
Tumors foster a tolerant microenvironment by the activation of a plethora of 
immunosuppressive mechanisms, including the modulation of antigen presenting cells (APC) 
that otherwise may stimulate adaptive immunity against cancer (11). Monocytes are attracted by 
the chronic inflammation caused by tumors and differentiate into a variety of tumor-associated 
macrophage (M2) and dendritic cell (DC) subtypes depending on local mediators (12-14). 
Factors secreted by tumor cells that have been implicated in the  prevention or modulation of 
DC differentiation and/or function are vascular endothelial growth factor (VEGF), macrophage 
colony stimulating factor (M-CSF),  transforming growth factor (TGFb1), IL-10, IL-6 and 
prostanoids(e.g. PgE2) (12). Cervical cancers are known also to secrete immunomodulatory 
compounds but their effect on APC is yet unknown (15-19).
 Therefore, we studied the effect of cervical cancer cells on monocyte differentiation 
and function. We found that DC differentiation was hampered or even skewed towards the 
tolerogenic M2 macrophages by tumor-derived PgE2 and IL-6. Subsequently, we assessed 
the effects of APC activation by several different Toll like receptor (TLR)-agonists, which are 
currently used or tested for the treatment of cancer in human beings (20), CD40 stimulation or 
cognate interactions with Th1 cells. Notably, the interaction with Th1 cells resulted in a switch 
to activated M1-like macrophages expressing high levels of co-stimulatory molecules and 
producing high amounts of IL-12p70. Our data suggests that a highly immune-stimulatory local 
microenvironment might be achieved by utilizing COX-inhibitors and IL-6 blocking antibodies 
to prevent M2-differentiation and vaccine-mediated stimulation of  Th1 cells to switch M2 
macrophages to tumor-rejecting M1 macrophages. 
material and metHodS
immunofluorescent staining of tumor tissue
Ten patients with cervical cancer with FIGO stage I and II underwent radical hysterectomy (type 
III) in our hospital. Patients had not received radiotherapy or chemotherapy before surgery. 
Tumors were HPV typed by PCR and sequencing, as described previously (21). The use of clinical 
material was approved by the institutional review board according to the guidelines of the 
Dutch Federation of Medical Research Associations.
Staining was performed on 4 mm tissue-sections of formalin-treated and paraffin embedded 
tumor material. Immunostaining was performed with a monoclonal antibody mix of anti-CD14 
(clone 7, Abcam USA) and anti-CD163 (clone 10D6, Novocastra United Kingdom) and after 
incubation overnight stained with fluorescent antibody conjugates (IgG2a-Alexa Fluor 488 and 
IgG1- alexa Fluor 647, Invitrogen USA )(22). Control staining with only secondary antibodies 
were included to ensure specificity. Images were captured at 25 X magnification with a confocal 
laser scanning microscope (Zeiss LSM 510, Germany) in a multitrack setting. 
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media and reagents
APC and tumor cell-lines were grown in RPMI (Invitrogen) supplemented with 10% Fetal Calf 
Serum (Greiner bio-one Germany), penicillin/streptomycin (Invitrogen) and L-glutamine 
(Cambrex USA). Adherent cell-lines were treated with trypsin/EDTA 1x (PAA, Austria). T cell 
clones were grown in IMDM (Lonza Switserland) supplemented with 10% FCS (PAA), P/S and 
L-glutamine. The following factors and final concentrations were used to generate APC: 500 
U/ml IL-4, 800 u/ml GM-CSF (Gibco, USA), ,10-100 ng/ml M-CSF (R&D systems USA), 50-1000 
pg/ml TGFb1 (BD biosciences USA), 1-50 ng/ml prostaglandin E2 (Sigma-Aldrich Germany). TLR 
ligands used for activation: 25 mg/ml Poly(I:C), 10 mg/ml R848/CL097 (all from Invivogen, USA) 
and 0.25 mg/ml LPS (Sigma-Aldrich). Optimal concentrations were used based on maximal 
cytokine release in mo-DC. To mimic T-cell interaction APCs were stimulated with irradiated 
CD40-L expressing mouse fibroblasts (23). 
Blockade of TGFb signaling was achieved with 1µM SB431542 hydrate (Sigma-Aldrich) after 
optimization of the dose. IL-6 was blocked by adding 2.5 ug/ml antibody to IL-6 receptor (clone 
B-R6) and 2.5 ug/ml antibody to IL-6 (B-E8) (Abcam, USA) to the culture. 
Supernatant of cervical cancer cell-lines
To confirm the origin of the  established lines HeLa and CaSKi, lines were tested for the 
presence of integraded HPV 16 or 18 DNA using the INNO-LiPa HPV Genotyping procedure 
(Innogenetics). CSCC-1, CSCC-7, CC-8 , CC-10B and CC-11- were typed and cultured as described 
earlier (24). Stock ampoules were thawed and cultured for 10 passages and tested for the 
presence of mycoplasm monthly.
Cell-lines were grown in flasks at 80-90% confluence, harvested with trypsin/EDTA. 100.000 
cells were plated in 2 ml/well of 6-well culture plate and cultured for 5 days. Supernatant was 
stored at -20 degrees. In case cultures were treated with COX-inhibitors,  250.000 cells in 2 ml 
were plated in 6-well plates in the presence of 25mM Indomethacin  or 5 mM NS-398 (Cayman 
Chemical, USA) dissolved in DMSO or as a control only with the corresponding concentration 
of DMSO. Medium was replaced after 24 hr and then harvested after 24 hours of culture. 
dc culture
PBMC were obtained from buffy coats of healthy donors. CD14+ monocytes (>95% purity) were 
isolated using the MACS cell separation (Miltenyi Biotec Germany) and stored in liquid nitrogen 
until further use. Monocytes were thawed and cultured in 48- or 24-well plates in a density 
of 0.25 or 0.5 million cells/well respectively in the presence of IL-4 and GM-CSF (mo-DC). 
After 2 days fresh medium with cytokines was added. At day 5-6 the cells were analyzed for 
differentiation by flow cytometry and activated in the culture medium or harvested, washed 
and activated in fresh medium. Tumor supernatant (TSN)-APC are cultured as described above 
but 20% supernatant of tumor cell-lines or medium was added. Titrations showed that 20% 
supernatant gave the best reproducible results between donors. DC were activated at day 6 
and after 48 hr the supernatant was harvested and stored at -200 C for cytokine analysis and 
cells were stained for flow cytometric analysis. 
mixed lymphocyte reaction
Naïve CD4 cells were isolated from PBMC by CD25+ cell depletion using MACS and subsequently 
isolation of CD4+ cells with the DynalBead system (Invitrogen) to a purity of > 99%. These 
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CD4+CD25- cells were plated in a 96-well plate at 50.000 cells per well. Matured DCs were 
added at different doses up to 10.000 cells/well in triplicate. T-cell proliferation was measured 
after 5 days by [3H]thymidine incorporation (0.5 uCi/well). Supernatant was taken at several 
time points and stored at -200C for cytokine analysis.
cd4+ t cell helper clones
HPV specific CD4+ T cell clones were obtained by limited dilution of LN cells of a patient with 
a HPV16+ cervical tumor. Clones were stimulated every 2 weeks with B-LCL loaded with the 
cognate HPV peptide, feeder-cells, TCGF and IL-15. Clones were used for DC activation after 2.5 
weeks resting period.
Clone 214 recognized HPV16E6 aa61-82, clone 238 recognized HPV16 aa61-82 and clone 
16 recognized HPV16E6 aa 11-32 and all clones produced IFNg and IL-2 but only clone 238 
produced IL-10 upon antigen-specific activation. HLA-class II matched APC were loaded with 
an irrelevant or the cognate peptide for CD4+ Th1 clones and co-cultured at different DC:T-cell 
ratio’s in medium containing 20% TSN. After 48 hours supernatant was analyzed and APC were 
phenotyped.
flow cytometry.
Mouse monoclonal antibodies to human CD80, CD86, HLA-DR, CD206, CD1c(FITC) and CD83, 
CD86, CD14, CD16, CD163 (PE) and CD14, HLA-DR (PERCP) or CD11c, CD1a, CD4 (APC) (all from 
BD-biosciences) and CD163 (R&D systems) and PD-L1 (Ebioscience) were used. Cells were 
recorded (20.000/live gate) using a BD-FACS calibur with Cellquest software (BD-biosciences) 
and analyzed by Flowjo software (Tree star, inc. USA). 
cytokine analysis
IL-12p40 and IL-12p70 were analyzed using ELISA kits from BD-biosciences or by inflammatory 
CBA (BD-biosciences). Il-10 and IFNg was measured with ELISA (Sanquin, the Netherland). To 
evaluate the cytokines present in supernatant of tumor cells IL-6, IL-8 and IL-10 were determined 
by CBA, M-CSF by Bioplex (BioRad). PgE2 was measured with the prostaglandin E2 parameter 
assay kit (R&D systems), TGFb-1 with the human TGFb1 ELISA from Ebioscience. Samples were 
tested with and without acidic treatment to determine active and latent TGFb1 in the cultures.
reSultS
dc differentiation is altered by cervical carcinoma cells.
To explore the effects of soluble factors secreted by CxCa on the differentiation of monocytes, 
in vitro cultures were set up to analyze the direct effect of tumor supernatant (TSN) derived 
from five early passage CxCa cell lines (Table 1) (17,24) and the two well known cell lines 
CaSKi and HeLa. GM-CSF and IL-4 differentiated monocyte-derived DC (mo-DC) are defined 
as antigen presenting cells that lack the expression of CD14 but display the lineage marker 
CD11c, HLA-class I and II and CD1a. Healthy donor-derived monocytes were differentiated 
in the presence of 20% TSN of the 7 tumor cell cultures. The presence of TSN had a striking 
effect on their differentiation as shown by evaluation of surface marker expression typical for 
monocytes, DC, MDSC and macrophages. Mo-DC cultures typically contain >80% CD1a+ cells 
but when monocytes were differentiated in the presence of TSN from CC11-, CSCC1 or CaSKi 
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this percentage dropped, reflecting poor DC-differentiation (Fig. 1a). TSN of the cell lines 
CCSC-7, CC-8 and HeLa did not only hamper CD1a expression but skewed the differentiation 
of monocytes towards the macrophage lineage as reflected by the high expression of CD14. 
Further evaluation of these CD14+ cells revealed that they expressed CD163 and CD206 as well. 
Notably these TSN induced cells expressed all human Fcg-receptors (CD16, CD32 and CD64) as 
well as PD-L1  and HLA-class II, while CD1b and CD1c were absent (Fig.1b and not shown). This 
profile is highly similar to that of in vitro M-CSF-induced M2-macrophages and distinct from 
monocyte derived DC (Supplemental Fig. 1) (13,25). TSN of cell line CC-10B did not overtly alter 
the differentiation of monocytes to DC, indicating that CxCa supernatant does not per se result 
in phenotypical changes. Analysis of CD33, CD11b and CD124 expression revealed no evidence 
for skewing of monocytes to MDSC (data not shown). 
To verify that these different cell types reside in the tumors of patients, paraffin embedded 
tissue sections of 10 patients with FIGO stage I or II  CxCa were stained for macrophages (CD14+) 
and M2-macrophages (CD14+CD163+) (26,27). Figure 1c shows the presence of CD14 single 
positive cells (macrophages), CD163 single positive cells but also CD14+CD163+ M2-polarized 
macrophages. 
functional impairment of aPc by tSn.
Next we assessed the capacity of these tumor-modulated APC to respond to 5 different TLR 
agonists or CD40-L expressing fibroblast cells (CD40-L) to mimic T-cell interaction. Since the 
supernatant of CSCC-7, CC-8 and HeLa induced strikingly induced these M2-macrophages 
(TSN-M2), which are known to foster immune tolerance, we focused on these cell lines for further 
evaluation and compared the results to those obtained with normal differentiated mo-DC. 
Stimulation of mo-DC  with LPS or R848 for 48 hours resulted in a strong increase in the 
expression of CD86, CD80, CD83, HLA-DR and PD-L1 (Fig. 2a and not shown). PolyI:C was the 
least potent TLR-agonist. TSN-M2 expressed higher basal levels of CD86, HLA-DR and PD-L1 
but stimulation with R848 or PolyI:C did not raise their expression level to that of mo-DC (Fig. 
2a and not shown). 
Table I. Immuno-suppressive factors produced by CxCa cell-lines.
Cell-line Passage‡ HPV§
cytokine production (pg/ml)*
IL-8 TGFb-1** PgE2 IL-6
CC-10B P80 45 14000 0 0 10
CSCC-1 P22 16 1500 221 0 20
CC11 - P32 67 425 398 403 3438
CaSKi x 16 324 410 298 2335
CSCC-7 P9 16 9306 313 2781 263
CC-8 P41 45 1222 250 3662 2228
HeLa x 18 4500 548 5389 12000
(‡)number of passages since origin - HeLa and CaSKi not known
(§)integraded DNA found to be present in the tumor (24)
(*)100.000 cells/2ml cultured for 5 days in RPMI/10%FCS
(**)latent form of TGF-b1 measured by ELISA after acidic treatment
x, HeLa and CaSKi not known
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For the induction and polarization of cytotoxic T cells and Th1 cells the secretion of IL-12p70 
by APC is essential (28,29). Mo-DC produced the biologically active IL-12p70 upon stimulation 
with LPS, R848, or CD40-L cells. The amounts varied per donor of whom the mo-DC were 
prepared (Fig. 2b, Supplemental Fig. 2). Relatively to stimulated mo-DC, the TSN-M2 almost 
completely lacked the ability to produce IL-12p70 when stimulated with TLR agonists. The 
strong activation signal induced by CD40-L cells allowed TSN-M2 to produce IL-12p70, albeit at 
significantly lower concentrations than CD40-stimulated mo-DC. In contrast, the production 
of the cytokine IL-10 – which varied greatly between donors -was at least 2-fold increased when 
TSN-M2 were stimulated with TLR agonist or with CD40-L cells  in 2 out of 3 experiments (Fig. 2b, 
Supplemental Fig. 2). The alterations in APC function were imprinted during the differentiation 
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Figure 1 CxCa-secreted factors skew monocyte differentiation towards M2 macrophages. Monocytes 
were cultured for 6 days with GM-CSF and IL4 in culture medium with 20% tumor supernatant (TSN) of 
indicated CxCa cell lines or 20% control medium (mo-DC) and (A) analyzed for expression of CD14 and 
CD1a. TSN reduced CD1a expression and in 3 cases induced CD14+ expression. (B) The cultures of monocytes 
differentiated with CD14+ cell-inducing TSN were analyzed for the expression of typical M2-macrophage 
markers. Numbers in quadrants represent percentage of cells within live gate. One representative of 5. 
(C) In situ immunofluorescence stainings of cervical tumor tissue of 3 out of 10 different patients for CD14 
(green) and CD163 (blue) and measured by confocal microscopy (25 x magnification). CD14+CD163+ display 
as turquoise, white arrows indicate M2 macrophages.
84
REVERSAL OF CERVICAL CANCER-SKEWED APC
5.1
of the monocytes since activation of TSN-M2 cells in fresh medium without additives gave 
similar results (data not shown). 
Subsequently, the capacity of TSN-M2 to induce proliferation and cytokine production of 
T cells was compared to mo-DC. Graded doses of APC were co-cultured with a fixed number 
of allogeneic CD4+CD25- T cells. Clearly, the activated TSN-M2 displayed a lower capacity 
to induce T-cell proliferation and/or concomitant IFNg release (Fig. 2c). The percentage of 
CD25+Foxp3+ T cells, which can be increased upon stimulation with immature APC (30), was not 
clearly altered  after 10 days of culture with TSN-M2 (data not shown). These results indicated 
that TSN-skewed APC were both phenotypically and functionally shifted towards that of M2 
macrophages and that TLR mediated activation of TSN-M2 reinforced their tolerogenic profile. 
mediators of altered aPc differentiation
Numerous mediators may cause the altered differentiation of monocytes to DC, including 
TGFb, PgE2, IL-6, IL-8, IL-10 and M-CSF (12). TSN of CxCa cell cultures were analyzed for these 
compounds. Latent TGFb was produced by almost all cell lines, except for CC-10B. Three cell-
lines produced high amounts of PgE2, and significant amounts of IL-6 were produced by 5 cell 
lines. IL-8 was present in all TSN, of which CC-10B produced the highest levels (Table 1). Since 
the tumor supernatant of CC10B did not affect monocyte to DC differentiation, IL-8 was not 
further evaluated. IL-10 and M-CSF were not detected in the tumor supernatants. 
The three likely candidates, TGFb, PgE2 and IL-6 were further evaluated. The addition of 
TGFb during differentiation of monocytes to DC did not induce the expression of CD14 but 
resulted in higher expression of CD1a. Likewise, blocking of the TGFb pathway in TSN-APC 
cultures did not restore the phenotype to that of mo-DC, indicating that TGFb was not 
responsible for the observed effects of TSN (Supplemental Fig. 3).
Skewing of APC to a macrophage phenotype can occur at concentration of > 2 pg/ml 
PgE2 (31). In fact, mo-DC differentiated in the presence of 1-50 ng/ml PgE2 resulted in CD14+ 
macrophages that are polarized to CD163+ M2-like macrophages (Fig 3b). To test if PgE2 was 
the M2-inducing factor in the TSN, the tumor cells were treated with specific COX-enzyme 
inhibitors. After treatment, the tumor cells were washed and incubated with fresh medium to 
obtain COX-blocked tumor supernatant. This procedure was chosen to avoid interaction of the 
inhibitor with COX in APC. Indeed, PgE2 production was totally abrogated by inhibition of COX 
1 and 2 using Indomethacin or COX-2 by NS-398 (Fig. 3a). 
Depletion of PgE2 in TSN by preventing its production revealed a striking effect on the 
DC-differentiation of monocytes. The expression of CD14 and CD163 was completely reversed 
(Fig. 3c) but the phenotypic differentiation towards DC was only partly restored as indicated 
by the percentage of CD14-CD1a+ APCs that was still lower than observed in mo-DC cultures 
(Fig. 3d). Furthermore, the capacity to produce IL-12p70 upon activation was restored while 
that of IL-10 was lowered (Fig. 4ab). The most pronounced effect of COX-inhibition was shown 
for CSCC-7 as the resulting APC from this COX-blocked tumor supernatant were completely 
comparable to mo-DC. The effects of COX-inhibition in lines CC-8 and HeLa on the function of 
TSN-altered APC was predominantly shown in CD40-activated APC.  The functional restoration 
was reflected also by partial up regulation of their T-cell stimulatory capacity (Fig. 4c). As a 
control, TSN of Indomethacin treated CaSKi cells - which hardly produce PgE2 - was tested and 
neither clear differences in the hampered differentiation of the APC nor in LPS-induced IL-12 
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Figure 2 TSN-differentiated monocytes are phenotypically and functionally different from mo-DC. 
(A) Monocytes were differentiated in the presence of the indicated TSN and activated with single TLR-
ligands or CD40-L cells for 48 hr. TSN-M2 cells express higher basal levels of CD86 and PDL-1. R848 or 
Poly-IC can not induce equal expression of CD80 and CD86 in all APC types. (B) Supernatants of the cultures 
described in (A) were tested for the presence of IL-12p70 and IL-10 revealing that TSN-M2 produce more 
IL-10 and less IL12 than mo-DC. (C) CD4+CD25- allogenic responder T cells were cultured with activated 
mo-DC or TSN-M2 (obtained with TSN from HeLa cells) at indicated ratio’s (DC:T cell). Top row shows 
the higher proliferation of T cells when stimulated with upon activated mo-DC at day 5 as measured by 
[3H]-thymidine uptake. Test performed in triplicate, shown is mean with SEM. Means were compared 
by unpaired  t-test, *p < 0.05, **p<0.005. Bottom row shows the IFNg production within these cultures 
measured in the supernatant isolated at day 4 by ELISA. One representative of 3 experiments (A-C). 
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Figure 3 Cox-inhibition blocks PgE2 production and prevents M2-macrophage differentation. (A) 
Tumor cell lines were treated for 24 hr with DMSO (control) or Cox-inhibitor (NS398 or Indomethacin) 
followed by culturing in fresh medium without additives for 24 hrs. PgE2 levels were measured by ELISA. 
Inhibition of COX totally abrogates PgE2 production. P<0.005 for all comparisons of PgE2 production by 
cells treated or not with indicated COX-inhibitor in 2 separate experiments (B) Culturing mo-DC (black fill) 
in the presence of 10 ng/ml PgE2 (dotted line) induce CD14+CD163+ expressing APC. (C) Flowcytometric 
analysis of CD14 and CD163-associated M2-macrophage marker expression on monocytes differentiated 
in the presence of TSN of  Indomethacin-treated (black) tumor cells or TSN from non-treated tumor 
cells (white). (D) Comparison of CD1a and CD14 expressing populations following the differentiation 
of monocytes in the presence of TSN of  Indomethacin-treated or non-treated tumor cells shows that 
TSN of COX-inhibitor treated cell lines induce less CD14+ cells and more CD1a+ DCs. Representative of 3 
experiments (B-D).
87
Since restoration of the phenotype and function of APC induced by PgE2 producing cell 
lines treated with Indomethacin was not complete and the cell lines CC-8 and HeLa produced 
significant amounts of IL-6, we explored the possibility that IL-6 mediated also an effect. 
Mo-DC were cultured with or without 20% TSN of the non-treated or the COX-inhibitor treated 
HeLa cell line in the presence of monoclonal antibodies to IL-6 and IL-6-receptor (32,33). The 
differentiation of mo-DC, nor the production of cytokines was altered by the presence of these 
antibodies (Fig. 5).  However, blocking of IL-6 showed a profound effect on the phenotype of 
TSN-M2 in that the cultures contained a higher percentage of CD14-CD1a+ APC. IL-6 blocking 
acted synergistically with the inhibition of COX since the combined treatment resulted in a 
complete phenotypical restoration of TSN-M2 to mo-DC (Fig. 5a). Blocking of IL-6 during 
the culture resulted in TNS-altered APC that after CD40-activation produced more IL-12p70 
although this was not significant (p=0.079, n=3 experiments). There were no significant 
alteration in cytokine production (p>0.05, n=3 experiments) when the APC were activated by 
the TLR agonists (fig 5b). No major synergistic effect of IL-6 blocking on IL-12p70 and IL-10 
production was found when COX-inhibited TSN was used. Since the supernatant of CaSKi cells, 
which hampered DC differentiation and function (Supplemental Fig. 4), also contained high 
levels of IL-6 we blocked this cytokine during the differentiation of monocytes to DC with 
TSNcaski. Blocking of IL-6 restored both CD1a expression and the balance between IL-12p70 
and IL-10 to what is found for mo-DC (Supplemental Fig. 4c). Together, these data showed 
that PgE2 predominantly influenced the expression of the macrophage markers, whereas IL-6 
altered CD1a expression. While both pGE2 and IL-6 affect the balance between IL-12p70 and 
IL-10, PgE2 had a more dominant negative effect. Blocking of these two mediators prevents 
M2-skewing and restores normal monocyte to DC differentiation.
cd4+ th1 t cells can switch tumor-induced m2 to activated m1 macrophages.
Initially, we had used CD40-L cells to mimic the interaction between T cells and TSN-M2.  Since 
CD40-activation was the best stimulus to induce IL-12p70 production by  APC we investigated 
the phenotypical and functional changes in TSN-M2 following cognate interactions with CD4+ 
T cells. Co-cultures of TSN-M2 and Th1 cells were performed in the same TSN-containing 
culture medium since tumor secreted factors may  directly suppress T-cell function (34). Three 
different CD4+ Th1 clones were clearly able to fully activate mo-DC and TSN-M2 in an antigen 
dependent manner (Fig. 6). Notably, Th1-mediated activation of TSN-M2 resulted in a number 
of changes that suggested a shift from M2-like to M1-like macrophages. The levels of the co-
stimulatory molecules readily increased to the same level as mo-DC (Fig. 6a). In addition, 
the expression levels of PD-L1 increased. The strong activation was also reflected by the high 
amounts of IL-12p70 produced reaching IL-12 levels similar to that of mo-DC, as there is no 
significant difference (p>0.05, n=3 T-cell clones)  between mo-DC or TSN-M2 (Fig. 6b and not 
shown) and much higher than previously observed after TLR- or CD40-activation (compare 
Fig. 2b and 6b). Strikingly, the production of IL-10 remained low and around the same level as 
the corresponding mo-DC cultures (p>0.05 for TSNcscc7 and TSNcc8, p=0.03 for TSNhela; n=3 
T-cell clones). After the interaction with Th1 cells,  the typical M2-like macrophage markers 
CD206 and CD163 were lost. This was also observed when TSN-M2 were stimulated with LPS, 
R848 and CD40-L cells indicating that this is a reflection of APC activation (Supplemental Fig. 
1bc).  Furthermore, high amounts of T-cell produced IFNg, TNFa and IL-2 were detected in the 
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Figure 4   Restored cytokine production 
when PgE2 production by tumor cells is 
blocked. (A) The production of IL-12 and 
IL-10 by APC differentiated in the presence 
of TSN of  Indomethacin-treated (black) 
tumor cells or TSN from non-treated 
tumor cells (white) upon 48 hr activation 
with LPS, R848 or CD40-L as measured 
by ELISA. Top row shows the cytokine 
production of untreated mo-DC. One 
representative experiment of 3. The block 
of PgE2 production by tumor cells alters 
the balance in IL-12 and IL-10 towards that 
observed in the corresponding mo-DC. (B) 
Comparison of the cytokine production 
by APC differentiated in the presence of 
TSN from non-treated tumor cells (white) 
to Indomethacin-treated (black) tumor 
cells that where activated for 48 hours 
(combined data of LPS, R848 and CD40-L 
stimulated cells; n=3 experiments).  IL-12, all 
p<0.003. IL-10, TSNcscc7 p=0.015; TSNcc8 
p=ns; TSNhela p=0.026. (C) Mo-DC or 
TSN-M2 obtained with TSN of untreated 
(+DMSO) or Indomethacin-treated HeLa 
cells (+Indomethacin) were activated 
with LPS or R848 for 48 hours and used to 
stimulate allogeneic responder cells. APC 
differentiated in TSN of Indomethacin-
treated cells induce better T-cell 
proliferation at day 5 of culture as measured 
by [3H]-thymidine incorporation. Test 
performed in triplicate, shown is mean 
with SEM. Means were compared by 
unpaired  t-test. Comparison of non versus 
indomethacin treated HeLa cells (1:5 ; 1:10) 
for LPS p=0.009; p =0.024, and for R848 
p=0.0003;  p =ns. Comparison of mo-DC 
versus indomethacin treated HeLa cells (1:5 
; 1:10) for LPS p=0.004; p =ns, and for R848 




















































































Figure 5 Blocking IL-6 and PgE2-induced 
altered differentiation restores 
monocyte to DC differentiation 
completely. (A) Monocytes were 
differentiated in the presence of 
control(+DMSO) or COX-inhibited HeLa 
cells(+Indomethacin) without or with 
blocking antibodies against IL-6 and IL-6 
receptor. A combination of tumor cells 
treated with Indomethacin and blocking 
IL-6 during differentiation results in full DC 
differentiation reflected by high expression 
of CD1a and lack of CD14. (B) Blocking IL-6 
during differentiation did not affect the 
production of IL-12 (ng/ml) and IL-10 (pg/
ml) of mo-DC upon activation by indicated 
agonists. CD40-activated TSN-M2 cells of 
which the IL-6 in TSN was blocked during 
differentiation, produced more IL-12. One 
representative experiment out of 3.
supernatant of the co-cultures reflecting the activation of the T cells upon recognition of their 
cognate peptide (Fig. 6b and not shown). Apart from IL-12p70 and IFNg for which it is clear that 
they are only produced by the APC or T cells, respectively, IL-10 may be produced by both cell 
types and this can not be distinguished by ELISA. It is likely that the IL-10 detected in co-culture 
with clone 238 is produced by the T cell clone as mo-DC stimulated with the other 2 clones 
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Figure 6 CD4+ T cells switch TSN-M2  to M1-like macrophages and activate them to produce IL-12p70. 
(A) Mo-DC or TSN-M2 were pulsed with the cognate Th1-peptide and co-cultured with HPV-specific CD4+ 
T-cell clones (2 DC:1 T cell) or CD40-L cells. T-cell interaction results in high expression of co-stimulatory 
molecules and PDL-1. One representative experiment out of 3. (B) Top row: Cognate interaction of Th1 
cells with TSN-M2 results in high IL-12 production. Stimulation with CD40-L cells in combination with 500 
pg/ml IFNg induces IL-12p70 production in TSN-M2 cultures to the level of mo-DC. Middle row: Cognate 
interaction with Th1 cells induced the production of IL-10 in TSN-M2 cultures at similar low levels detected 
for mo-DC. The addition of IFNg to CD40-stimulation results in similar production of IL-10 as after CD40-L 
cell stimulation. Bottom row: The Th1 clones produce IFNg when stimulated with peptide-pulsed mo-DC 
and TSN-M2. Shown are the results of the experiment in which all conditions and 3 clones were combined. 
Similar results were obtained in experiments where individual clones and TSN-M2 combinations were 
tested (C) APC cultured in the presence of M2-inducing TSN or PgE2 were activated with CD4+ T-cell clone 
16, CD40-L expressing fibroblasts or IFNg and analyzed for the expression of CCR7 at 48 hr after activation. 
Cognate Th1 cell interaction  induces high CCR-7 on TSN-M2 and this can be mimicked by activating DC 
with IFNg. The level of CCR7 is enhanced when PgE2 is present during the differentiation of monocytes. 
One representative experiment out of 3.
do not produce IL-10. Our previous experiments indicated that ligation of CD40 could not 
switch M2 to M1 macrophages, therefore, we analyzed if one of the T-cell produced cytokines 
synergized with CD40-L cell-mediated activation to switch M2 to M1-like macrophages. 
TSN-M2 were activated with CD40-L and IFNg or TNFa. This revealed that the combination 
of CD40-L cells with IFNg but not CD40-L cells or IFNg alone resulted in high levels of IL-12 not 
only in mo-DC but also in TSN-M2 cultures (Fig. 6b right and not shown). This capacity of Th1 
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cells or CD40-L cells + IFNg to switch M2-like macrophages to M1-like macrophages could be 
reproduced in co-cultures with M-CSF-induced M2 macrophages (not shown).
TSN-M2 expressed higher levels of CCR7 than mo-DC following their cognate interaction 
with CD4+ Th1 cells (Fig. 6c). As we had already found that IFNg synergized with CD40-activation 
to switch M2- to M1-like macrophages we tested the hypothesis that IFNg or TNFa secreted by 
the T-cell clone either alone or in combination with PgE2 present in TSN was responsible for 
the high levels of CCR7. Indeed, incubation with IFNg but not TNFa induced the expression of 
CCR7 on mo-DC and a very high expression on TSN–M2. Furthermore, pretreatment of mo-DC 
with PgE2 during the differentiation phase resulted in similar high expression of CCR7 as found 
on TSN-M2 (Fig. 6c). 
Thus, cognate interaction with IFNg-producing T cells can switch the tumor-promoting 
M2-like polarized macrophages to activated classical M1-like macrophages that express high 
levels of co-stimulatory molecules, produce high amounts of IL-12 and gain the expression of 
the lymphoid homing receptor CCR-7.
diScuSSion
Our analysis on the effect of tumor-secreted factors from 7 different cervical cancer cell lines 
on the differentiation of monocytes to dendritic cells and their functional capacity revealed 
that these cancer cells can be sorted into two major categories; -1- cancer cells that hamper 
DC differentiation and function and -2- cancer cells that induce M2-like macrophages. These 
two categories comprised similar HPV types ruling out that the effects seen were HPV type 
specific. Tumor secreted PgE2 and /or IL-6 were clearly responsible for these effects while no 
role was found for TGFb, IL-8, IL-10 or M-CSF.  In vivo, such APC are present at different levels 
of differentiation in stroma and epithelial compartments of HPV-induced cervical cancer and 
these include next to immature DC, mature DC, macrophages and type II macrophages (Fig. 1)
(10,35). 
Category 2 cancer cells stimulated the differentiation of CD14+, CD16+, CD206+, CD163+ 
M2-like macrophages. Consequently, these TSN-M2 displayed an altered cytokine profile 
and a poor capacity to stimulate T cells when compared to mo-DC. Careful evaluation of the 
expression of co-stimulatory molecules, cytokine production and T-cell stimulatory capacity 
of these TSN-M2 showed that stimulation with a number of clinical applicable TLR-agonists 
or CD40-L cells could not provoke the same phenotypical and functional activity as found 
for mo-DC. Interestingly, unstimulated TSN-M2 cells expressed PD-L1 at higher levels than 
mo-DC. While stimulation of mo-DC and TSN-M2 resulted in an increased expression of PD-L1, 
the expression on TSN-M2 remained higher on TSN-M2, suggesting that TSN-M2 display an 
altered co-stimulatory/inhibitory molecule ratio on the cell surface as compared to mo-DC. 
High levels of PDL-1 expression on monocytes have been shown to effectively suppress tumor-
specific T cell immunity and to contribute to the growth of human hepatocellular carcinoma 
cells in vivo(36). Furthermore, knockdown of PD-L1 in activated DC has been shown to increase 
the IFNg and IL-2 production of reacting T cells (37). We are currently investigating the role 
of PD-L1 expression level with respect to the lack of responsiveness of naive T cells in our 
experiments. Notably, comparison of the two different agonists R848 and LPS to stimulate 
TSN-M2 revealed clear differences in their effects on co-stimulatory molecule expression and 
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cytokine production, indicating that previous results reported with the TLR4 agonist LPS – most 
often used to stimulate tumor-induced DC in vitro (16,38)– can not be translated to other TLR 
agonists. Earlier studies identified macrophages (CD68+) within the CxCa microenvironment 
and showed that an increase in macrophages is inversely correlated with survival (39). The 
presence of macrophages correlated with a high production of IL-6 by tumor cells, the latter 
of which was associated with poor survival (19). IL-6 was shown in vitro to hamper the DC 
differentiation and allogeneic T-cell stimulatory capacity and could even switch monocyte 
differentiation from DC to macrophages (32,33,40-42). Others showed that the over-expression 
of COX-enzymes in HPV-induced lesions is associated with a loss in CD1a+ cells and PgE2 was 
suggested to mediate this effect (16). Under our experimental conditions IL-6 alone was able 
to hinder DC-differentiation and function but PgE2 was responsible for the conversion of 
monocytes to M2 macrophages.  Differentiation of monocytes to M2 macrophages could be 
prevented by inhibition of the production of PgE2 in tumor cells and blocking IL-6 during the 
differentiation period of the monocyte.
Importantly, when fully polarized M2 macrophages present antigen to Th1 cells within the 
context of a M2-polarizing milieu – as represented by the M2-inducing tumor supernatant – this 
interaction not only results in re-polarization of M2- to M1-macrophages but it also activated 
these M1 macrophages to express high levels of co-stimulatory molecules, to produce IL-12 
and to express the lymph node homing marker CCR7. The switch from M2- to M1-macrophages 
is in concordance with the plasticity of macrophages to change their functional phenotype 
from classically activated macrophages to wound-healing or regulatory macrophages and 
vice verse (43,44). This switch could be reproduced by stimulating TSN-M2 with CD40-L cells 
and IFNg. While activation via CD40 was enough to induce changes in the typical M2 markers, 
IFNg provided the necessary signals for the macrophages to produce IL-12 without additional 
IL-10 production. Mouse models have elegantly demonstrated the importance role of the Th1-
macrophage axis in anti-tumor immunity. Tumor-resident macrophages were shown to process 
and present tumor antigen to Th1 cells which in return activated these macrophages – through 
the local release of IFNg - to become tumoricidal and to induce a CD4+ T-cell dependent tumor 
protection (45,46). Our data suggest that alteration of the suppressive tumor microenvironment 
by tumor-infiltrating Th1 cells - which change the tolerogenic M2-macrophage phenotype to 
that of activated M1-macrophages- could be one of the underlying mechanisms of this tumor 
protection system. 
The local presence of IFNg-producing T cells responding to antigen presented by these 
altered APC may restore proper tumor-rejecting immune function, but such T cells are often 
absent in tumors. (47,48). COX-inhibiting drugs are widely used in the clinic for treatment of 
auto-immune diseases and trials are now ongoing, with the aim to determine the effect of low 
dose NSAID on tumor prevention by disrupting the COX-2 meditated oncogenic pathways 
(49). Furthermore, monoclonal antibodies to IL-6 receptor are already in clinical use for the 
treatment of autoimmune diseases (50). It can be envisaged  that a combination therapy 
consisting of COX-inhibition,  IL-6 blocking and the induction of a strong Th1 T cell response by 
currently available vaccines may form the next generation of immunotherapy for the treatment 
of cervical cancer(51,52). 
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Supplementary fig 1. Phenotype of in vitro differentiated DC 
and M2 macrophages. (A) Monocytes were cultured for 6 days 
with GM-CSF+IL-4 to obtain imm DC or M-CSF to obtain M2 
macrophages and analyzed by flowcytometry for the expression 
of phenotypical markers. M2-differentiated macrophages typically 
display high expression of  the scavenger receptor CD163 and the 
mannose receptor CD206. In contrast to monocyte derived DC 
M2-macrophages express all FcgReceptors (CD32, CD64 and CD16). 
(B+C) Stimulation of TSN-M2 for 48 hr with (B) indicated TLR-ligands 
and (C) Th1 cells or CD40-L cells results in a lowered expression of 
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Supplementary fig 2  Function of DC is hampered by 
TSN. Compared to mo-DC, TSN-M2 cultures produce 
less IL-12 and more IL-10 upon depicted stimulus. We 
observed  large variation in  the amounts of cytokines 
produced by each donor to the different TLR-ligands. To 
compare 3 different donors with respect to the amounts 
of cytokine produced; the relative production of cytokines 
of each condition within one experiment was calculated. 
The amount of cytokines produced by monocytes to the 
indicated stimulus was set to 100%.  Three experiments 
combined, mean with SEM. For each stimulus means were 
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Supplementary fig 3  Blocking of the TGFb pathway in TSN differentiated APC. (A) Mo-DC were 
cultured  with increasing concentration of TGFb and activated for 48 hrs with LPS.  Flowcytometric 
analysis show that high levels of TGFb make APC unresponsive to LPS as reflected by a failure to upregulate 
the expression of co-stimulatory molecules. One representative experiment of 3. (B) Mo-DC or APC 
differentiated in the presence of 500 pg/ml TGFb-1 (TGFb) or 20% TSN (obtained from HeLa or CaSKi) were 
treated without (white) or with the ALK-inhibiting compound SB431542 (black) during culture and activated 
with LPS for 48 hr. Although the effect of TGFb on the unresponsiveness to LPS is completely abrogated 
by compound SB431541, no effect of this compound is found on the expression of CD1a, CD86 and CD83 
by APC in TSN cultures. (C) The production of IL12p70 upon 48 h LPS stimulation of control (white) or 
compound SB431542 treated (black) cultures. The compound restores the IL12p70-production by TGFb-
treated cells to the same level as mo-DC, but does not restore IL-12 production by TSN-differentiated APC.
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Supplementary fig 4 Blocking IL-6 in the TSN of CaSKi cells abrogates the suppressive effect on DC 
differentiation and function. (A) A lower percentage of monocytes differentiated in the presence of 
20% supernatant of caski cells expresses CD1a after 6 days of culture, reflecting poor DC differentiation. 
Addition of IL-6 and IL-6Receptor blocking antibodies to the culture does not influence normal 
monocyte to DC differentiation but increases the percentage of CD1a expressing cells in cultures with 
TSNcaski. Depicted is the percentage of all ells in live gate  One epresentative of 3 experiments. (B) APC 
differentiated in the presence of TSNcaski produce more IL 10 and less IL-12 upon activation by TLR-ligands 
or CD40-L when compared to fully differentiated mo-DC. Blocking of IL-6 in the supernatant during 
differentiation of monocytes restores the capacity of the resulting cells to produce IL-12 while reducing 
the production of IL 10. To compa e different donors   the amount of cytokine produces is depicted as a 
percentage of the cytok ne when produced by mo DC a tivated by the same stimulus without blocking 
of IL-6. Three experiments combined. Means were compared by the two-tailed unpaired t test using 
Graphpad software. * indicates p<0.05, ** indicates p<0.005.
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Modulation of tumor associated macrophages
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Ongoing work
Chapter 5.2
CxCa patients with recurrent disease are treated with cisplatin or carboplatin. These 
chemotherapeutics may not only affect tumor cells but also the local immune cells. Previously 
we showed that CxCa can skew monocyte differentiation toward type 2 macrophages (M2) by 
secretion of PGE2 and IL-6. Therefore we studied the effects of these drugs on soluble factor 
mediated effects of tumor cells lines on APC differentiation.
Tumor induced M2 can be skewed towards pro-inflammatory M1 by interaction with IFNg+ 
CD4+ T cells. In CxCa-patients however, a considerable proportion of tumor antigen specific T 
cells display an non-Th1 phenotype. To study the activation of tumor supernatant skewed M2 by 
Th2 or Th17 cells we activated APC with CD40-L and several T-cell derived cytokines.
We show that only CD40-L+IFNg can skew M2 cells into activated M1 cells. Furthermore 
while CD40-L stimulated M2 macrophages induced strong T cell proliferation, only when 
stimulation was in the presence of IFNg, the responding T cells were polarized into Th1. 
Treatment tumorcells with cisplatin, and to a lesser extent carboplatin, resulted in increased 
production of PGE2 and IL-6, resulting in induction of more M2 cells. This is an unwanted 
immunological effect and could be prevented by treating the tumor cells with COX-inhibitors.
abstraCt
introduction
Currently the therapy for advanced, persistent or recurrent cervical cancer (CxCa) consists of 
cisplatin or carboplatin treatment although many tumors are resistant and the response rate 
does not exceed 30% (1,2). One described predictor of poor response to treatment is high 
expression of COX-2 protein in the tumor (3). COX-2 , which is the inflammation induced rate 
limiting enzyme for the conversion of arachnoid acid into prostaglandin E2 (PGE2) is found in 
several human solid tumors and we recently showed that PGE2 skews local antigen presenting 
cells (APC)  into type 2 macrophages (M2) (4). The presence of M2 macrophages in tumors is 
correlated to poor prognosis in several human cancers (5-7). 
Platinum based therapeutics act by binding to DNA. This activates various signal 
transduction pathways including those for DNA repair, cell cycle arrest and apoptosis. As a 
result it may have immune-modulating side effects (8). In a mouse tumor model oxaliplatin 
caused immunogenic cell death, thereby activating local APC and enhancing anti-tumor T-cell 
responses. Cisplatin triggered the release of the TLR-4 stimulating protein HMGB-1 (9,10). In 
addition, several platinum based drugs down regulated surface molecules in tumor and human 
APC via regulation of STAT6 (11).
In contrast to TLR-agonists or CD40-L help, a signal of CD40-L+IFNg supplied through 
interaction with Th1 CD4+ T cells can switch tumor cell-induced M2 macrophages (TSN-
skewed APC) into activated M1 macrophages (4). Studies on murine macrophages confirmed 
macrophage plasticity by showing that exposure  to a type 1 cytokine environment before 
activation directs the macrophages towards M1 macrophages, whereas exposure to IL-10 
directed them to M2 (12,13). In line with this Dulluc et al. comprehensively showed that IFNg 
can prevent and reverse M2 differentiation of human monocytes by ascites of ovarian cancer 
in vitro (14). Together this indicates that IFNg is a strong polarizing cytokine for macrophages. 
However in several human tumors not only Th1 (IFNg/TNFa) CD4+ T cells but also Th2 (IL-5/
IL-4), Th17 (IL-17) and regulatory T cells (TGFb, IL-10) play a role. Especially in cervical cancer 
draining lymph nodes considerable numbers of tumor-antigen specific T cells are found that do 
not express a clear type 1 cytokine profile.
Subsequently we questioned the impact of platinum based chemotherapy on the micro 
milieu of cervical tumors. We focused on APC differentiation influenced by chemotherapy 
treated tumor cell lines as well as the impact of cognate interaction with several types of T 
cells in our in vitro system geared to result in M2 macrophages. To study the potential role 
of such differently polarized CD4+ T-cell subsets in the activation of locally present APC we 
cultured mo-DC without or with supernatant of CxCa cell lines (TSN-skewed APC) with CD40-L 
expressing cells in the presence of several Th-cytokines to mimic interaction with the separate 
T cell subsets.  
material and metHodS
media and reagents
APCs and CxCa cell lines were cultured in RPMI 1640 medium (Invitrogen, USA) supplemented with 
10% FCS (Greiner Bio-one, Germany), 2 mM L-glutamine (Cambrex, USA), 100 U/mL penicillin, 100 
µg/mL streptomycin and 50 µM b-mercaptoethanol (all Invitrogen), also referred to as complete 
or control medium. Adherent cell lines were harvested using trypsin/EDTA (Invitrogen).
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The following factors were used to culture APCs: 500 U/mL IL-4 (Invitrogen), 800 U/mL 
GM-CSF (Immunotools, Germany), 5 ng/mL PGE2 (Sigma-Aldrich, Germany), 5 ng/ml IL-6 
(immunotools) or 25 ng/ml M-CSF. The following was used to activate APCs. CD40-L expressing 
J558 mouse plasmacytoma cells ratio J558:APC 1:5 (The J558 cells were a kind gift of dr. E. de 
Jong, Amsterdam and dr. P. Lane, Birmingham); 10 µg/mL R848(CL097) 500 U/mL IFNg (Bender 
Medsystems, Austria, this is approximately 1000 pg/ml), 2 ng/ml TNFa, 5 ng/ml IL-5, 2 ng/ml 
IL-17 (all immunotools). These concentrations were based on levels found in DC:T cell clone 
co-cultures or TIL cultures like described in chapter 6.
chemotherapeutics and coX inhibitors
Cells were treated with 0.2-50 µg/mL cisplatin or 2-100 µg/mL carboplatin (Pharmachemie, NL) 
or the corresponding volume of PBS as well as with 25 µM indomethacin   or the corresponding 
volume of DMSO. 
tumor cell line culture
The CxCa cell lines HeLa, CaSki, CSCC-1, CSCC-7, and CC-8 were typed and cultured as described 
earlier (4,15). Cell lines were cultured in 6- or 12- well plates (Corning, USA) for 24h, and treated 
with chemotherapeutics and/or COX inhibitors, as indicated. After 16h of treatment, cells were 
washed carefully and medium was refreshed. Supernatants were harvested after 24h and stored 
at -20ºC.
Only for RNA isolation cells were treated with chemotherapeutics for 18 hr, carefully washed 
and RNA was extracted. cDNA was prepared and gene expression was analyzed using pre-designed 
taqman probes of Applied Biosystems for GAPDH, IL-6, COX-1 (PTGS-1) and COX-2 (PTGS-2).
transwell assay
Monocytes were cultured in a 24 well plate in complete medium containing IL-4 and GM-CSF 
and 0.5 or 2 µg/mL cisplatin, or PBS control. CC-8 cells (50,000 cells in 100 µL complete 
medium) were cultured in the upper compartment of a transwell 0.4 µm pore insert (Corning). 
To control wells, without transwell inserts, 100 µL control medium or tumor supernatant from 
untreated CC-8 or HeLa cells was added. After 3 days, complete medium with cytokines but 
without cisplatin was added. At day 6, cells were analyzed by flow cytometry.
cell survival
To determine tumor cell line survival upon chemotherapeutics treatment, a MTT assay (Trevigen, 
USA) was performed according to the manufacturer’s instructions. Cells were cultured as 
described above, in a 96 well flat bottom culture plate (Corning), but instead of harvesting the 
supernatant, MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was 
added. Absorbance was determined at 570nm and corrected for absorbance at 655 nm. Cell 
survival was calculated as follows: (OD
570-655nm
 for treated / OD
570-655nm
 for untreated) x 100%.
To determine APC survival upon chemotherapeutics treatment, cells were analyzed by flow 
cytometry (see below). Cell survival was calculated as follows: (% of cells in live gate for treated 
/ % of cells in live gate for untreated) x 100%.
flow cytometry
APC were phenotypically analized as described earlier (4).




ELISA was used to quantify cytokine levels of IFNg, IL-10 (Sanquin, NL) IL-12p70 (BD Biosciences) 
and chemokines CXCL-10 and CCL-22 (RndD systems), according to the manufacturer’s 
instructions. Further analysis of inflammatory and T cell cytokines was performed by 
cytometric bead array (BD Biosicences). PGE2 levels were measured using the competitive PGE
2
 
immunoassay kit (R&D systems).
reSultS
ifng is the only cytokine that skews m2 to activated m1
We found that in LN of CxCa patients tumor-antigen specific T cells produce IFNg, TNFa, IL-5 
or IL-17. Therefore we assessed whether these type of T cells also could activate TSN-skewed 
APC. Monocytes were cultured with IL-4 and GM-CSF in the presence of supernatant of HELA 
or CSCC-7 cells (TSN-skewed APC). Routinely this resulted in 30-40% cells expressing typical 
M2 markers (4). Addition of the cytokines IFNg, TNFga, IL-5 or IL-17 at quantities produced 
by patient derived T cell clones in antigen specific tests did not result in the production of 
IL-12, IL-10 or IL-23 by mo-DC or TSN-skewed APC. Only IFNg induced  the upregulation of 
costimulatory molecules CD86, CD80, CD83 and PD-L1 on APC(not shown).
To mimic T-cell help but to ensure no other receptors were involved we made use of the 
J558 cell line transfected with CD40-L (CD40-L). Upon stimulation with CD40-L the mo-DC 
and TSN-skewed APC expressed high co-stimulatory molecules and lost CD163 expression (not 
shown). Addition of cytokines did not induce any change in co-stimulatory molecule expression 
compared to CD40-L stimulation only. Upon CD40 stimulation, TSN-skewed APC produced 
lower levels of IL-12 but high IL-10 compared to mo-DC upon CD40-L stimulation. Only addition 
of the cytokine IFNg to CD40-L stimulation resulted  in increased IL-12 production indicating 
a switch from M2 into M1-like cultures (Figure 1a). No phenotypic or functional effects were 
observed upon TNFa, IL-5 or IL-17 addition to CD40-L. Also several combinations of cytokines 
were tested but no additive effect to IFNg was seen (not shown). 
APC secrete chemokines to attract other inflammatory cells. CXCL-10 is the ligand for CXCR-3+ 
type 1 effector T cells whereas CCL-22 attracts CCR-4 expressing Th2 and regulatory T cells. CCL-22 
was shown to be induced in human APC when activated in the presence of PGE2 (16). Unstimulated 
mo-DC or TSN-skewed APC did not produce any detectable CXCL-10 but did produce high levels 
of CCL-22 (mo-DC cultures 40 ng/ml or more). Interestingly, HELA-supernatant APC produced 
only half the quantities CCL-22 of mo-DC (p< 0.043 paired t-test). When APC were stimulated with 
IFNg CXCL-10 production was increased almost 10-fold and this was the same for all APC cultures 
(fig 2b). No chemokine induction upon stimulation with TNFa, IL5 or IL-17 was seen.
CD40 mediated activation did not induce significant CXCL-10 release but induced even 
more production of CCL-22 in mo-DC as well as TSN-skewed APC. These results show that  IFNg 
is the only T-cell produced cytokine that can activate TSN-skewed APC and reverse the cells to 
pro-inflammatory cytokine production and attraction of type 1 T cells.
activation of aPc by th1 signals determines type of t-cell induction
Previously, we showed that CD40ligation of mo-DC resulted in the production of high levels 
of IL-12, a known strong type 1 directing stimulus (4). To assess whether the type of T cell 
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providing the activation signal may program the APC to subsequently instruct naïve T cells to 
adapt to a particular phenotype, we used a mixed lymphocyte reaction assay (MLR). Mo-DC 
or TSN-induced APC were activated for 48 hr with irradiated J558-CD40-L in the presence of 
recombinant cytokines. APC were extensively washed and cultured with allogeneic CD4+CD25- 
cells for 5 and 10 days. All APC types and activation signals induced comparable proliferation of 
the responder cells (fig 2. top left). However type 1 T-cell induction as reflected by the amounts 
of IFNg and TNFa produced, was determined by the type of T cell providing the activation to 
the APC. Mo-DC activated with Th1 signals (CD40-L+IFNg) clearly induced 4 fold higher type 
1 cytokine production in the responder T cells. High IFNg levels were also induced by TSN-
induced M2 cultures stimulated with Th1 signals (figure 2, middle panels). Interestingly some 
type 2 cytokines were also detected in the cultures of T cells stimulated with CD40-L+IFNg 
activated APC, but the production of these cytokines was more prominent in the T-cell cultures 
stimulated with TSN-skewed APC. Nine days after start of culture, the T cells were analyzed 
for expression of transcription factors. Figure 2 clearly shows that T cells display the highest 
T-bet expression following stimulation with mo-DC. Activation of APC in the presence of IFNg 
resulted in higher T-bet expression in the responder T cells (figure 2 bottom left).
different cytokines result in different macrophages in vitro
In vitro, macrophages can be obtained by culturing monocytes with only GM-CSF, M-CSF 
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Figure 1. IFNg activates tumor supernatant induced APC. Compared to mo-DC, supernatant induced 
cultures produce less IL-12 and more IL-10 upon CD40-L stimulation and only IFNg can revert this balance. 
A) mo-DC or TSN-M2 (supernatant of HELA left, supernatant of CSCC-7 right) were activated with J558-
CD40-L cells (ratio 5 DC:1 CD40-L cell) and recombinant cytokines (depicted at the x-axis ). Supernatant 
was analyzed by ELISA after 48 hr. Mean cytokine production of CD40-L stimulated mo-DC: 24 ng/ml IL-12, 
14 ng/ml IL-23 and 275 pg IL-10. Calculation: (activate TSN-M2 / Value mo-DC stimulated with CD40-L 
only)*100. Mean of 3 experiments + SEM. B) Chemokine production by cells described in A. Here also 
unstimulated and IFNg only is shown. (In unactivated cultures no CXCL-10 was detected but CCL-22 was 
produced in all cultures.CCL-22 in mo-DC cultures >40 ng/ml) Mean of 3 experiments + SEM.
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macrophages even in the presence of the DC-skewing cytokines GM-CSF and IL-4. All cultures 
expressed macrophage marker CD14 and CD163 at day 6 with the latter being most prominently 
expressed by M-CSF induced M2 (data not shown). Since all these in vitro cultured macrophages 
display a similar phenotype, we tested whether they responded equally to T-cell interaction. 
Only the cytokine IFNg upregulated co-stimulatory molecules on macrophages. CD40-L is a 
strong activator for mo-DC, less strong for GM-CSF or PgE2+IL-6-differentiated APC but hardly 
activated M-CSF-induced macrophages (Fig.3a). Compared to mo-DC, all macrophage subsets 
produced no to low levels of IL-12 upon activation with the indicated stimuli. In contrast IL-10 
was produced by all cultures but PgE2+IL-6 derived macrophages produced extreme levels of 
IL-10 following activation via CD40 (fig 3b). Also here IFNg was the only cytokine that clearly 
worked in synergy with CD40-L for activation of macrophages and the production of IL-12. 
Platinum based chemotherapy of tumor lines increase m2 induction
Patients with recurrent or advanced disease are treated with cisplatin or carboplatin. It is 
reported that expression of the PgE2 converting enzyme COX-2 in tumors favors a poor 
response to this treatment (3,17). In view of recent literature indicating that chemotherapy may 
also influence the response of immune cells we assessed the impact of chemotherapeutics on 
tumor cells and the effect on APC differentiation. First monocytes that differentiate to DC as 
well as several tumor cell lines were treated with creasing doses of cisplatin or carboplatin. 
Figure 4a shows that all cell lines survive up to concentrations of 2 mg/ml for cisplatin and 20 mg/
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Figure 2.  Th1  derived activation of APC instructs for type 1 T cell induction. Activation of APC in the presence 
of IFNg results in higher T-bet expression and more type 1 cytokines. Allogeneic responder cells were cultured 
with mo-DC or TSN-skewed APC that were prior to co-culture activated with irradiated CD40-L only or in 
combination with cytokines (IFNg, IL-5 or IL-17) as depicted at the x-axis. Top panel left; proliferation of T cell 
cultures at day 5 (initial ratio APC:T cell 1:5, triplo mean+SEM). Lower left panel: expression of the intra-cellular 
transcription factor T-bet at day 9 of T cell culture determined by intra-cellular staining and flowcytometry. 
Middle and right panels; cytokine levels in T-cell cultures at day 5 of co-culture. One experiment of 2 
performed with IFNg and IL-4 derived from MLR 17, IL-4 and TNFa from MLR 16.
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doses ( 2 mg/ml cisplatin, 20 mg/ml carboplatin) with less than 10% dead cells but cell death was 
rapidly increasing at higher doses. No effect was seen on APC phenotype if chemotherapeutics 
were directly added during mo-DC or TSN-skewed APC differentiation. 
Tumorcells were cultured and treated for 16 hr with cisplatin or carboplatin, carefully 
washed and cultured for another 24 hr. This supernatant was harvested and used in monocyte 
cultures. As shown earlier, TSN of line CC-8 and HELA skewed DC differentiation towards 
M2 macrophages. Strikingly, TSN from tumor cells treated with cisplatin induced a higher 
percentage of M2 macrophages. Carboplatin had the same effect on CC-8 cells but not on 
HELA cells (fig 4b). Remarkably, TSN of line CSCC-7 treated with cisplatin or carboplatin did not 
induce a higher percentage of M2 macrophages. The TSN of treated control lines CASKI and 
CSCC-1 did not show this effect (fig. 1c). 
In vivo tumor cells and immune cells are in the same microenvironment when treated 
with platinum. To better resemble the natural situation, monocytes and tumor cells were 
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Figure 3.  Different responses by cytokine induced macrophages. Macrophages were cultured with 
GM-CSF only, M-CSF only or to mimic tumorsupernatant IL-4/GM-CSF and 5 ng/ml IL-6+ 5 ng/ml PgE2 and 
compared to mo-DC. Cells were activated and analyzed after 48 hr for activation markers and cytokine 
production. A) CD86 expression unactivated or after activation, IFNg only or CD40-L only. All other 
conditions as depicted in B did not induce CD86 expression. B) Depicted is the percentage of cytokine 
production compared to mo-DC in the same experiment stimulated with CD40-L only. Calculation: (Value 
TSN-M2 / Value mo-DC stimulated with CD40-L only)*100. Mean of 3 experiments + SEM.
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Figure 4. Platinum based chemotherapy treatment of CxCa Lines enhances M2 induction. Cxca cell lines 
that are treated with a  dose of cisplatin or carboplatin that does not induce major cell death produce 
soluble factors that induce more type 2 macrophages. A) Survival of CxCa cell lines upon increasing doses 
of cisplatin (left) or carboplatin (right) measured in a MTT assay. Shown the mean of 3 experiments with 
SEM. Lines that induce M2 are shown in black.  B) Monocytes were differentiated with IL-4 and GM-CSF in 
the presence of 20% tumor supernatant from CC-8 (left) or HELA(right) that were treated with 2 µg/mL 
cisplatin or 20 µg/mL carboplatin, or control medium (untreated). Differentiation was analyzed at day 5 by 
flow cytometry for expression of DC and M2 markers. Numbers in quadrants represent the percentage of 
cells within the live gate.  Representatives of 5 independent experiments. C) CD1a+, CD1a-CD14- and CD14+ 
subpopulations of  cells within the live gate of APCs described in B. Mean of 3 (CC-8, HELA, CSCC7, CSCC1) 
or 2 (CASKI) experiments.
0 of culture. Again treatment with cisplatin resulted in an increased percentage of M2 cells 
when monocytes were cultured in the presence of cell line CC8 and cisplatin (fig.5a). However, 
chemotherapeutic treatment also resulted in a functional suppression of APC (fig. 5b). TSN 
induced APC produced less IL-12 and more IL-10 upon activation compared to mo-DC, but the 
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Figure 5. Platinum enhances macrophage induction and induce poor cytokine production. A) Monocytes 
were cultured with IL-4 and GM-CSF. In the upper chamber of a transwell tumor cells were added and in the 
lower chamber control (untreated) or cisplatin was added only at day 0 of culture. At day 3 fresh medium 
was added with IL-4 and GM-CSF. Cells were analyzed for phenotype at day 6. Numbers are percentages 
of cells in live-gate (livegate was similar for each condition). B) APC were cultured in the presence of 
supernatant of control or platinum treated tumor cells and stimulated with R848 for 48 hr. Cytokine 
production was measured by ELISA. All tumor lines were tested separately and this is one experiment of 
2 of each.
chemotherapeutics. Line CSCC-7 did not induce more M2 macrophages after treatment and 
also the cytokine production upon activation by these APC was not affected (fig 5b, one of 2 
experiments).
chemotherapeutics enhance Pge2 and il-6 production in tumor cells
M2 macrophage induction by CxCa cell lines depends on the levels of PGE2 and IL-6 (ref). 
Therefore we measured the amount of PGE2 and IL-6 produced by the cell lines upon platinum 
treatment. Cisplatin treatment increased the production of PGE2 2-7 fold by line CC-8 and HELA 
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but not by line CSCC-7. Carboplatin had no effect on PGE2 levels (fig 6a). Furthermore cisplatin 
and carboplatin increased the IL-6 production by CC-8 and HELA. Also IL-6 was induced in 
line CSCC-7, albeit at much lower levels compared to the other lines. The CASKI line, known 
to produce already high levels of IL-6 also responded to treatment with cisplatin by increasing 
the production of IL-6. Still this did not skew APC differentiation into M2 macrophages (fig 
4c) (4). This indicates that both PGE2 and IL-6 in sufficient levels are needed to induce M2 
differentiation.
As expected by the increase in cytokine levels, gene expression analysis revealed that 
IL-6 as well as COX-2 were induced upon platin treatment in both CC8 and CSCC7 cell lines 
with highest induction in CC8 cells.  Furthermore levels of COX-1 mRNA were not increased 
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Figure 6. Induction of PgE2 and IL-6 by platinum based chemotherapy. Upon cisplatin production the 
levels of the M2-inducing factors PgE2 and IL-6 are increased in CxCa cell lines. A) Tumor cell lines were 
treated with cisplatin (2 ug/ml) or carboplatin (20 ug/ml) for 24 hours, carefully washed and cultured for 
another 24 hrs. This medium was analyzed for the production of IL-6 and PgE2 by ELISA. B) Tumor lines 
were treated as described in A, but after 18 hr  total RNA was isolated and TaqMan gene expression assay 
was perfomed. Ct-values were corrected to GAPDH expression and depicted are relative mRNA levels 
compared to untreated CC-8 cells. Example of 1 cell culture, measured in triplo. C) Tumor Lines were 
treated with indomethacin (25 mM) and cis- or carboplatin for 24 hrs, washed and supernatant was used 
in APC cultures. APC cultured with supernatant were analyzed at day 5 and CD1a+, CD1a-CD14- and CD14+ 
subpopulations of  cells within the live gate are shown. M2 induction is abolished if cells are treated with 
COX enzyme inhibitor. Mean of 3 (CC-8) or one single experiment (CSCC7)
110
enhances the expression of COX-2 and IL-6 but not COX-1 and the production of PgE2 and IL-6 
thereby inducing more M2 macrophages.
PgE2 is a critical factor in the in vitro skewing of monocytes to macrophages. If COX-enzymes 
are blocked with indomethacin in the tumorlines during chemo treatment, M2 induction is 
abolished (fig 6c). For line CC8 and HELA specific inhibition of COX-2 by NS398 resulted in 
abolished M2 induction, indicating that induced PGE2 levels upon platinum treatment are 
COX-2 mediated. For line CSCC-7 specific COX-2 inhibition was not yet tested.
diScuSSion
Activation of mo-DC or TSN-skewed macrophages by CD40-L stimulation in the presence 
of helper T-cell produced cytokines all resulted in activation but no synergism of IL-5, 
IL-17 or TNFa with CD40-L was found for the induction of pro-inflammatory cytokines or 
chemokines.  We showed that the presence of IFNg clearly activates the TSN-skewed APC 
cultures to stimulate a type 1 inflammatory response reflected by the pre-dominant Th1 profile 
in subsequent stimulated T-cell cultures. In this model, we mimicked T-cell interaction with 
the use of CD40-L expressing cells that have a (artificially) high expression of this molecule. 
However when APC and T-cell crosstalk, more co-stimulatory molecules will be involved and 
therefore the activation is likely to be altered. T-cell receptor-peptide-MHC interaction results 
in the formation of immunological synapses –with locally high levels of cytokines- that is not 
mimicked in this system (18). The concentrations of cytokines used in our system were based 
on the amounts detected in patient derived HPV specific T-cell cultures. We did not find any 
response to IL-5, TNFa or IL-17 on mo-DC or TSN-skewed APC by upregulation of co-stimulatory 
molecules or IL12, IL23 or IL-10 production. Lack of IL-5 receptor may form one explanation as 
so far it was not reported to be present on unactivated myeloid cells (19,20). In contrast TNFa 
has been described in human monocytic cultures and mice DC to induce moderate activation 
(16,21) and high doses of IL-17 could activate human macrophages in vitro as well (22). Doses 
used in these studies outreached the amounts we detected in our in vitro T cell assays and used 
in our system. 
PGE2 was described to induce CCL-22 production in human APC cultures if added during 
activation (16). Indeed in our cultures unactivated and activated APC produced high levels of 
CCL-22 but this was the same for mo-DC as well as TSN-skewed APC.  Both HELA and CSCC7 
supernatant contain PGE2 but addition of this supernatant induced CCL-22 production in the 
unactivated APC as high or lower then mo-DC cultured without PGE2.  
Interestingly, IFNg was the only stimulus that instructed mo-DC and TSN-skewed APC 
to produce the type 1 attracting chemokine CXCL-10. Thus, based on this limited study,  the 
interaction of APC with antigen specific T cells may result in attraction of  Th2/Treg cells which 
would contribute to shut down of the immune response. However when IFNg is present, high 
levels of CXCL-10 are secreted which may attract more type 1 T cells.
In concordance with the IL-12/IL-10 cytokine balance produced by APC upon activation by 
CD40-L+IFNg, induced naïve T cells become activated IFNg-producing T cells even when APC 
were skewed into M2 by TSN. 
Treatment of 2 out of 3 tumor cell lines that produce high PGE2 and IL-6 with a non-lethal 
dose of cisplatin resulted in an increased production of these inflammatory mediators and 
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subsequent M2 skewing in differentiating monocytes. Maximum doses in patients as measured 
in the blood for cisplatin or carboplatin are 5-6 ug/ml and 40-80 ug/ml respectively and 
assuming that levels in (poorly vascularized) tumor tissue is several times lower the used in 
vitro doses may be representative for the in vivo situation (23-25). Here we show that myeloid 
cells can survive the chemotherapeutic treatment but are affected by tumor released factors. 
The mRNA levels of COX-1 were higher expressed in line CSCC7 compared to line CC8 but were 
not influenced by treatment with cisplatin or carboplatin. In line CC8 the COX-2 and IL-6 mRNA 
levels clearly increased upon cisplatin treatment. This increase corresponds with the induction 
of M2 macrophages. The fact that supernatant of cisplatin treated CSCC7 did not result in more 
M2 induction correlates with the limited elevation of PGE2 and IL-6 upon treatment of this line. 
A possible explanation lies in the chemoresistence of this tumor cell line.
High COX-2 expression in CxCa identified the patients with a poor response to cisplatin 
and unfavorable prognosis (3). This effect was explained by enhanced apoptosis resistance of 
the tumor cells, but this was not reflected by our tested tumor cell lines. CCSC7 and CASKI cell 
lines were the most resistant to chemotherapy but did not express the highest levels of COX-2 
and PGE2. Our data suggests an immunological explanation for the correlation of high COX-2 
expression with poor response to treatment. Cisplatin increases the inflammatory mediators 
IL-6 and PGE2 in lines with high COX-2 expression, thereby promoting M2 macrophages and 
supporting tumor survival and growth. Interestingly these effects of cisplatin were only seen 
in the cell lines CC8 and HELA. Wang et al. showed that the chaperone protein PRDX-1 can join 
and stabilize the NF-kB complex at NF-kB promotor site of the COX-2 promotor region. This 
complex was shown to be selectively crosslinked to the DNA by cisplatin and therefore COX-2 
gene expression is promoted (26). 
Importantly, the effects of the supernatant on monocytes be reversed by inhibiting COX-
enzymes in the tumor cells. The effects of IL-6 blocking is not yet addressed in this work.
Thus these results indicate that activation of tumor-skewed M2 by T cells without IFNg 
results in IL-10 production and the induction of non-type 1 polarized T cells. Only CD40-L+IFNg 
reverts TSN-skewed APC into Th1 inducing activated APC.  Since spontaneous evoked T-cell 
responses often lack Th1 cytokines in patients with CxCa, therapeutic vaccination that can 
induce a strong type 1 T cell response is needed (4). This vaccine should not only aim for the 
induction of specific CTL but also strong IFNg producing Th1 CD4+ T cells to activate the local 
macrophages and change the inflammatory balance in the tumor.
Concomitant treatment with cisplatin may have a devastating impact on local myeloid cells 
in tumors with high PGE2 and IL-6 production. Treatment of patients with COX-2 inhibiting 
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Chapter 6
TLR agonists are attractive candidate adjuvants for therapeutic cancer vaccines as they can induce 
a balanced humoral and T-cell mediated immune response. With a dense network of dendritic 
cells (DCs) and draining lymphatics, the skin provides an ideal portal for vaccine delivery. 
Beside direct DC activation, TLR agonists may also induce DC activation through triggering the 
release of inflammatory mediators by accessory cells in the skin microenvironment. Therefore, 
a human skin explant model was used to explore the in vivo potential of intradermally delivered 
TLR agonists to stimulate Langerhans Cells (LCs) and dermal DCs (DDCs) in their natural 
complex tissue environment. The skin-emigrated DCs were phenotyped and analyzed for T-cell 
stimulatory capacity. We report that, of six tested TLR-agonists, the TLR-2 and -3 agonists PGN 
and Poly I:C were uniquely able to enhance the T-cell priming ability of skin-emigrated DCs, 
which in the case of PGN was accompanied by Th1/Th17 polarization. The enhanced priming 
capacity of Poly I:C stimulated DC was associated with a  strong upregulation of appropriate 
costimulatory molecules, including CD70, while that of PGN-stimulated DC  was associated 
with the release of a broad array of proinflammatory cytokines. Transcriptional profiling further 
supported the notion that the PGN- and Poly I:C-induced effects were mediated through 
binding to TLR2/NOD2 and TLR3/MDA5 respectively. These data warrant further exploration 




Vaccines aimed at the induction of neutralizing antibodies are widely used with great success 
to prevent microbial infections. Therapeutic vaccination is being developed for treatment of 
chronic infections and cancer, and aims to generate protective T-cell immunity. Although some 
clinical successes have been reported, particularly in the field of cancer vaccination, much is 
yet to be gained in terms of efficacy (1,2). 
In vivo studies have shown that the vaccine delivery route determines the instruction of T 
cells by locoregional antigen-presenting cells (APCs), thereby affecting the homing capacity 
of primed T cells (reviewed by Kupper and Fuhlbrigge (3)). Langerhans cells (LCs) and dermal 
dendritic cells (DDCs) reside in the epidermis and dermis, respectively. Both subsets are well 
equipped to sense pathogenic threats in their microenvironment, to take up antigen and 
to migrate to the draining lymph nodes (LN) where they prime and program T cells. Hence, 
neoplastic diseases that present within the skin (e.g. melanoma and human papilloma virus 
(HPV)-induced tumors) may benefit most from intradermal vaccination, as in the LN the 
migrated LCs or DDCs will imprint the T cells to express a pattern of homing and chemokine 
receptors that facilitates migration to the skin. Immunization with poxviruses is a clear example 
of a remarkably successful induction of strong and long-lasting antibody and T-cell responses 
by vaccination via the skin (4). Also, intradermal vaccination with synthetic long peptides (SLPs) 
derived from HPV type 16 oncoproteins resulted in the induction of both CD4+ and CD8+ T cells 
specific for HPV that were able to migrate to the skin (5). 
The choice of adjuvant will influence the type of immune response induced by therapeutic 
vaccines. More and more, it is realized that for effective anti-tumor immunity a balanced 
humoral and cell-mediated response with long-term T-cell memory is obligatory. Based 
on pre-clinical mouse models, human in vitro experiments and early clinical experience, 
compounds  targeting toll like receptors (TLRs) are promising adjuvant candidates in this regard 
(6,7). TLRs are trans-membrane pattern recognition receptors (PRRs) that bind pathogen-
associated molecular patterns (PAMPs). TLRs can be expressed at the cell membrane, to bind 
bacterial structural molecules such as peptidoglycans (PGN) and lipopolysaccharides (LPS) 
(TLR1,2,4,5,6), or intracellular in endosomal compartments, to bind viral or bacterial RNA or 
DNA (TLR 3,7,8,9). Subsequent signaling through MyD88 or TRIF leads to activation of the NF-κB 
and MAPK pathways resulting in APC activation and pro-inflammatory cytokine and chemokine 
release. Human epidermal LCs have been reported to express only virus-recognizing TLRs, 
to keep them from inadvertently being activated by commensal bacteria. In contrast DDCs 
express TLRs recognizing both bacteria and viruses  (8). So far, the ability of TLR agonists to 
stimulate cutaneous DCs has mostly been tested in vitro (9). However, other skin-resident cells 
such as keratinocytes, melanocytes, endothelial cells and fibroblasts also express TLRs and can 
release cytokines that contribute to DC maturation and the induction and skewing of T cells 
(10,11). Moreover, alternative intracellular microbial PRRs, such as NOD-like receptors (NLR, 
NOD1 and NOD2) or RIG-I-like Helicases (RLH, MDA5 and RIG-I), can  be expressed by DCs and 
accessory cells, and share ligands with TLRs (7). Therefore, a human skin explant model was 
used to explore the in vivo potential of TLR agonists to stimulate LCs and DDCs in their natural 
complex tissue environment (12). By intradermal delivery of TLR-ligands (TLR-Ls), intradermal 
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active constituent monophosphoryl lipid A (MPLA, TLR4-L), Polyribosinic:polyribocytidic acid 
(Poly I:C, TLR3-L), and R848 (Resiquimod, TLR7/8-L), all of which are either used or considered 
as vaccine adjuvants (7). So-called crawl-out DCs, migrating from the skin explants, were 
analyzed for their expression of maturation and co-stimulatory molecules and their capacity 
to prime allogeneic T cells and induce Th1/2/17 responses. We report that Poly I:C and PGN 
are uniquely able to enhance the T-cell priming ability of skin-emigrated DCs. While for Poly 
I:C this appeared to be due to up-regulation of co-stimulatory molecules, PGN was a powerful 
inducer of pro-inflammatory cytokine release, thereby promoting Th1 induction. From these 
observations, we conclude that TLR2/NOD2 and TLR3 ligands are attractive candidate adjuvants 
for intradermally delivered therapeutic vaccines. 
material and metHodS
Preparation and culture of skin explants. Healthy human skin was obtained after informed 
consent from patients undergoing corrective breast or abdominal plastic surgery at the VU 
University medical center (Amsterdam, The Netherlands) or the Tergooi hospital (Hilversum, 
The Netherlands), following hospital guidelines, within 24h of surgery. Cytokines or TLR-Ls 
(endotoxin contaminations not exceeding 1 EU/mg, excepting MPLA and LPS) were dissolved 
in serum-free medium (IMDM) and injected intradermally into skin: GM-CSF (100 ng/biopsy, 
Berlex Laboratories Inc. Montville, NJ), IL-4 (10 ng/biopsy, R&D), PGN (10 mg/biopsy, InvivoGen), 
Poly I:C (20 mg/biopsy, InvivoGen), R848 (10 mg/biopsy, InvivoGen), LPS (250 ng/biopsy, Sigma 
Aldrich), MPLA (250 ng/biopsy, InvivoGen), PAM3CSK4 (10 mg/biopsy, InvivoGen). These 
amounts were based either on optimal maturational effects or on maximal sub-toxic doses 
found upon titration and were all found active on monocyte-derived DCs in vitro (see SFig.1). Of 
note, the TLR5 agonist flagellin was found to be too toxic in active concentration ranges (based 
on findings for monocyte-derived DCs) and was therefore not further included in these studies. 
Using a 500 ml microfine syringe (Becton Dickinson), 20 µl was injected into skin so that an 
urtica formed. A biopsy was immediately taken of the injection site with a 6 mm biopsy punch 
(Microtec) and floated in 1 well of a 48 well plate, which contained 1 ml IMDM supplemented 
with 5% Human Pooled Serum (HPS, Sanquin Blood Supply, Amsterdam, The Netherlands), 100 
IU/ml sodium penicillin (Yamanouchi Pharma), 100 µg/ml streptomycin sulfate (Radiumfarma-
Fisiopharma), and 2 mM L-glutamine (Invitrogen Life Technologies). Per experimental 
condition, 10-30 biopsies were taken. Biopsies and medium were placed in an incubator (370C, 
5% CO
2
) for 2 days, after which biopsies were discarded and migrated cells and conditioned 
media were harvested. Conditioned media from 48h-cultured full-thickness skin explants were 
analyzed for cytokine content with the inflammatory cytokine bead array (CBA) kit from BD 
Biosciences (San Jose, CA), and 1:2 diluted for CCL5 content with a DuoSet development system 
(R&D sytems, Minneapolis, MN), both according to the manufacturers’ instructions.
Phenotypical analysis. Phenotypical analyses were performed by flow cytometry. Cells were 
washed in PBS supplemented with 1 % BSA and 0.02% NaN
3
 and incubated for 30 min. at room 
temperature in the presence of appropriate dilutions of FITC or PE fluorochrome-conjugated 
specific mAbs to CD14, CD1a, B7-H1 (PD- L1), CD80, CD86, CD70, HLA-DR (BD, San Jose, CA), or 
CD83 (Beckman Coulter Immunotech), or corresponding isotype-matched control mAbs (BD, 
San Jose, CA). The cells were subsequently analyzed, using a FACSCalibur and Cellquest-Pro 
TLR-mediated activation of dermal DC
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FACS analysis software (Becton Dickinson, San Jose, CA). As described, DC were gated by their 
high Forward and Side Scatter properties (12).
Mixed Leukocyte Reaction (MLR). Migrated DCs were resuspended at 1x105/ml in IMDM with 
10% HPS, penicillin, streptomycin, and glutamine and 100 ml was plated in triplicate in a 96-well 
round bottom sterile culture plate. Peripheral blood lymphocytes (PBLs) were isolated from 
allogeneic healthy donors after plastic adherence to deplete monocytes and labelled with 3 
µM CFSE (Invitrogen) for 10 minutes at 37°C. After washing, the labelled PBL were resuspended 
at 1x106 /ml in IMDM with 10% HPS, penicillin, streptomycin, and glutamine and 100 µl was 
added to wells containing migrated DCs, and to 3 wells containing only medium. Control wells 
of unlabelled PBLs were also included. On days 3, 6, 8 and 10 cell culture samples were taken 
and analysed for proliferation by flow cytometry. On day 6, supernatants were collected and 
subsequently analyzed for cytokines secreted by the T cells using a Th1/Th2/Th17 CBA kit (BD 
Biosciences, San Jose, CA) according to the manufacturer’s instructions.
Microarray analysis of TLR transcriptional profiles. Epidermal and dermal fractions were 
prepared from dermatome-sliced human skin (3mm) as described previously(13). After CD1a-
guided MACS (Miltenyi, Bergisch Gladbach, Germany), RNA, isolated from LCs and DDCs from 
three different donors, was dissolved in TRIzol reagent (Invitrogen Life Technologies) and stored 
at –20°C. After chloroform extraction, total RNA was precipitated in isopropanol, rinsed with 
70% ethanol, lyophilized, and dissolved in 10 µl distilled water. Fragmentation, hybridization, 
and scanning of the Human Genome U133 Plus 2.0 arrays were performed according to the 
manufacturer’s protocol (Affymetrix, Santa Clara, CA, USA) and as described (13). The arrays 
were scanned with a GeneArray scanner (Affymetrix). Data analysis was performed with 
GeneSpring 7.1 software (Agilent Technologies). Gene expression levels of TLR, NOD2, RIG-I, 
or MDA5, present on the Human Genome U133 Plus 2.0 Arrays, are presented as mean signal 
values of triplicate DDC or LC samples (signal intensity range from 0- 22,000). Samples with 
an absent detection call in one to three of the replicate samples were set at 0 (i.e. no reliably 
detected expression). 
Real-time quantitative RT-PCR. Cells were lysed and mRNA was specifically isolated by capture 
of poly(A)-RNA in streptavidin-coated tubes using an mRNA capture kit (Roche, USA). cDNA 
was synthesized using a reverse transcription system kit (Promega, USA) following the 
manufacturer’s guidelines. cDNA was diluted 1:2 in nuclease-free water upon synthesis and 
stored at -20°C until analysis. Specific primers for human TLR1–10 were designed as described 
(14). Real-time PCR was performed using the SYBR Green method in an ABI 7900HT sequence 
detection system (Applied Biosystems, USA) as previously described (15). Briefly, 4 µl of the 
Power SYBR Green master mix (Applied Biosystems) were mixed with 2 µl of a solution containing 
5 nmol/µl of both oligonucleotides and 2 µl of a cDNA solution (1/100 of the cDNA synthesis 
product). The cycle threshold (Ct) value is defined as the number of PCR cycles where the 
fluorescence signal exceeds the detection threshold value (fixed at 0.045 relative fluorescence 
units). GAPDH was selected as the endogenous reference gene from a set of 10 functionally 
unrelated housekeeping genes according to Garcia-Vallejo et al. (15). For each sample, the 
relative abundance of target mRNA was calculated from the obtained Ct values for both target 
and endogenous reference gene GAPDH by applying the following formula: relative mRNA 
expression =2[Ct(GAPDH) -Ct(target)].
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Statistical analyses. DC subset frequencies, marker expression levels, cytokine release levels, 
and proliferated T cell fractions were compared between conditions using the 2-sided repeated 
measures one-way ANOVA test with post-hoc Tukey multiple comparison analysis. Prism 4.0 
statistical software (GraphPad Software Inc., La Jolla, CA) was used. Differences were considered 
significant when P<0.05.
reSultS
Effects of TLR-L on subset distribution among the skin-emigrated DC. We previously identified 
several DC subsets  among DCs that had migrated from human skin explants, based on 
multicolor flow cytometry ((12) and Lindenberg, submitted). An overview of the phenotype 
of the four major discernable subsets is presented in Table I. Of note, LC and CD1a+ DDC are 
mature subsets with a high T-cell stimulatory potential, whereas the CD1a+CD14+ and CD14+ 
DDC subsets are immature cells with macrophage-like features and a poor capacity for T-cell 
stimulation (Table I, (12)). We previously reported that intradermal injection of GM-CSF and IL-4 
prior to skin explant culture, led to predominant migration of the mature CD1a+ subsets, while 
inhibiting migration of the CD14+ immature subsets (12). Here we confirm these observations 
(Fig.1) and in all subsequent experiments GM-CSF+IL-4 was included as a positive control. 
TLR agonists were intradermally injected at subtoxic active doses (see Material and Methods) 
that induced phenotypic and functional activation in vitro of highly pure monocyte-derived 
DC (SFig.1). None of the intradermally delivered TLR-Ls significantly increased (or decreased) 
the absolute number of migrated DCs per explant at 48h after start of culture (range of mean 
absolute numbers: 1800-4000; data not shown). LPS injection into the dermis prior to explant 
culture significantly increased the frequency of migrating LC, while injection of either Poly 
I:C or LPS increased the proportion of migrated CD1a+ DDC over that observed for medium 
controls (Fig.1). Of note, unlike GM-CSF+IL-4, none of the tested TLR-Ls was able to significantly 
down-regulate the frequencies of migrated immature CD14+ DDC.
TLR-L effects on DC maturation, inflammatory cytokine release and T cell induction. Whereas 
intradermal delivery of most of the tested TLR-Ls had no effect on phenotypic maturation of 
the migrated cells, Poly I:C consistently upregulated  the expression of CD80, CD83, CD86, and 
HLA-DR, as well as of the coinhibitory molecule PD-L1 (B7-H1) (Fig.2A). Similarly, LPS induced 
 Table I. DC subsets and their phenotype.
DC subset Marker profile*
LC CD1ahi, Langerin+, E-Cadherin+, CD11cint, CD1c+, CD83+, CD80+, PD-L1+
CD1a+ DDC DC-SIGN-†, CD11chi, CD1c+, CD83+, CD80+, PD-L1+
CD14+ DDC DC-SIGN+(30%)†, CD11chi, CD1c+, CD163+(15%)‡, CD83-, CD80-, PD-L1+(20%)‡
CD1a+CD14+ DDC DC-SIGN+(20%)†, CD11chi, CD1c+, CD163+(35%)‡, CD83-, CD80+(50%), PD-L1+(30%)‡
* Based on multicolor FACS analyses as described by de Gruijl et al. (12) and Lindenberg et al., submitted, 
marker expression was considered negative (-) when percentage positive cells did not exceed 10%; hi=high 
fluorescence intensity levels, int=intermediate fluorescence intensity levels.
†Up-regulated by intradermal GM-CSF and IL-4 injection prior to explant culture
‡Up-regulated by intradermal IL-10 injection prior to explant culture
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a significant upregulation of the percentages of DCs expressing CD83 and PD-L1, but the 
expression of CD80 and CD70 was enhanced  by Poly I:C only (Fig.2B).
To assess the influence of the TLR-L on the local cytokine balance, explant-conditioned 
media were collected 48h after the start of culture, and tested for their inflammatory cytokine 
and chemokine content. As demonstrated in Fig.3, PGN by far proved to be a superior inducer 
of inflammatory cytokine release with high levels of IL-6, IL-8, and IL-1b, but also of the 
suppressive cytokine IL-10. IL-10 was produced upon administration of most TLR-Ls, with the 
notable exception of Poly I:C (Fig. 3). IL-12p70 was undetectable in the explant-conditioned 
media (not shown), while low but detectable levels of TNFa were induced by Poly I:C (Fig.3). 
In addition, variable but consistently elevated levels of the pro-inflammatory chemokine CCL5 
were observed after intradermal delivery of Poly I:C (Fig.3). 
Poly I:C and PGN were the only tested TLR-Ls that significantly enhanced the capacity of 
the skin-emigrated DC to induce the proliferation of allogeneic T cells (Fig.4A). Interestingly, 
DC migrated from GM-CSF+IL-4-injected skin explants, induced low but selective IL-4 release 
by the allogeneic T cells (Fig.4B, top panel) but this was not observed when DC were activated 
through their TLR. Whereas multiple TLR-Ls induced the release of IL-6, only PGN was able to 
induce the release of high levels of the Th1 cytokines IFNg and TNFa (Fig.4B). In addition, PGN 
was uniquely able to induce the release of variable but consistently elevated levels of IL-17A by 
the primed T cells (Fig.4B, bottom panel).
PRR transcriptional profiles in LC, DDC and keratinocytes are conform the responsiveness 
to TLR-L. To assess PRR expression in the skin environment, transcriptional analysis of TLRs 
was performed in isolated LCs, CD1a+ DDCs and keratinocytes from healthy human skin. As 













































































Figure 1. Subset distribution among skin emigrated DCs. Based on CD14 and C1a expression, four major 
subsets were discerned among skin-emigrated DCs (gated by high forward and side scatter properties) 
and their frequency determined for each of the test conditions. Means ± s.e.m. are shown based on 6 














































































Figure 2. Expression of activation markers on skin-emigrated DCs. A) Expression of activation 
markers on the total population of skin-emigrated DCs at 48 hr after injection (and start of explant culture) 
of medium, GM-CSF+IL-4, or the denoted TLR agonists. Flowcytometric histograms of the expression of 
the indicated activation markers on all the cells within the live gate of one representative experiment. 
Fluorescence intensities are listed. Open histograms: IgG isotype controls; closed histograms: activation 
marker expression. B) Percentages of DCs that express the indicated activation markers as described in 
(A). Means ± s.e.m. of 3-6 experiments are shown. Asterisks denote significant differences vs. medium 
controls.


















































































































Figure 3. Inflammatory cytokine release from skin explants upon TLR-L injection. 48 hr after injection 
of TLR-Ls or controls and start of culture, skin explants were discarded and the medium was analyzed for 
the levels of the listed inflammatory cytokines by CBA or of CCL5 by ELISA. Means ± s.e.m. of 5 experiments 
are shown. Asterisks denote significant differences vs. medium controls.
TLR transcripts as compared to C-type Lectin Receptor (CLR) transcripts selectively expressed 
by LCs (Langerin, CD207) or by DDCs (Macrophage Mannose Receptor [MMR], CD206). Only 
TLR2 mRNA levels in DDC were relatively high. As PGN can also bind to NOD2 and Poly I:C to 
RIG-I/MDA5, expression of these receptors was also analysed. Relatively high expression levels 
were observed for both NOD2 and MDA5 in LCs as well as DDCs (Fig.5A). Epidermis-derived 
keratinocytes were tested by qRT-PCR for the expression of TLR transcripts. As shown in Fig.5B, 
resting keratinocytes expressed mostly TLR2, -3, and -5. Stimulation of keratinocytes with 
the TLR3-L Poly I:C led to up-regulation of TLR1-3, and -5 transcription, confirming functional 
expression of TLR3 on keratinocytes (Fig.5C). Thus, the observed DC activation by PGN and 
Poly I:C in the human explant cultures was in line with the detected expression of TLR2/NOD2 
transcripts in DDCs and of MDA5 and TLR3 transcripts in LCs/DDCs and keratinocytes.
DISCuSSION 
Immunization through the skin leads to the induction of T-cell mediated and humoral immunity 
(16). TLR agonists have been proposed as prime adjuvant candidates for therapeutic vaccines 
but most of our knowledge on TLR agonists and their effects on skin-mediated immunization 
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stems either from murine in vivo studies or from in vitro studies with isolated human primary 
LCs or DDCs, and more often from their monocyte-derived counterparts. However, vaccines 
and adjuvant deposited in the skin can interact with a complex mix of cells, amongst others DCs 
and keratinocytes. Therefore, we sought to assess the overall effect of these interactions in the 
context of intact human skin and intradermally 
injected a panel of TLR-Ls into human skin 
explants to study their effects on DC migration, 
activation, and subsequent T-cell priming in an 
organotypic culture model. Our studies point out 
Poly I:C and PGN as prime candidate adjuvants for 
clinical translation to skin-based cancer vaccines.
Of a panel of six tested TLR agonists, only the 
TLR3-L Poly I:C consistently induced phenotypic 
activation of the skin-emigrated DC population. 
This general lack of skin-derived DC activation 
upon TLR-L treatment is in striking contrast to 
our own observation for Monocyte-derived DCs 
(SFig.1). Strong activation by TLR-Ls was also 
reported for isolated monocyte-derived LCs 
(8,17). Of note, also overall migration rates of 
the skin APCs were not affected by intradermal 
injection of any of the tested TLR agonists. This 
general lack of reactivity in primary LCs and DDCs 
in the context of their tissue microenvironment 
may in part be explained by their low TLR 
transcript levels (Fig.5A), but may also be caused 
by specific local suppression. For instance, 
Jurkin et al. recently reported that selective 
overexpression of miR-146a in LCs interfered 
with TLR2-mediated signaling and caused their 
non-responsiveness to PGN (18). Alternatively, 
TLR triggering in DCs or skin-resident cells such 
as keratinocytes, melanocytes or fibroblasts, may 



























































































































Figure 4. Allogeneic T cell priming and differentiation 
induction by skin-emigrated DCs. Emigrated DCs 
were washed and cultured with allogeneic CFSE-
labeled PBLs for 6 days. The cells were analyzed by flow 
cytometry for proliferation by dilution of CFSE intensity 
(in % proliferated cells within the live lymphocyte gate). 
Means from 4 experiments are shown. B) Supernatants 
were collected from the mixed leukocyte cultures at day 
6 and analyzed for Th cytokines by CBA. Means ± s.e.m. 
from 4 experiments are shown.











































































































































Figure 5. TLR mRNA expression in cell 
subsets of the skin. A) Freshly isolated LCs and 
CD1a+ DDCs were analyzed by genome-wide 
transcriptional profiling. Shown are the transcript 
levels for the indicated Pattern recognition 
Receptor (PRR) and C-type Lectin receptor (CLR) 
genes (means from 3 separate donor samples; 
if one was negative the expression was set to 0 
to ensure bona fide expression). Open bars: LC 
transcripts; closed bars: DDC transcripts. B) Skin-
derived primary keratinocytes were profiled for 
TLR transcript expression by qRT-PCR. Transcript 
levels for TLR1-10 are indicated relative to 
GAPDH as a reference gene. C) Skin-derived 
keratinocytes were stimulated by the indicated 
TLR agonists (100ug) and again tested for TLR 
transcript expression as described under (B). 
Means ± s.e.m. are shown.
such an extent that it interfered with DC activation. In favor of the latter option, the only TLR 
agonist that did not induce elevated IL-10 release from the skin explants (i.e. Poly I:C, see Fig.3), 
was also the only agonist to consistently induce DC maturation. This elevated IL-10 release may 
also explain why intradermal injection of TLR-Ls, in contrast to GM-CSF+IL-4, did not reduce the 
migration frequency of CD14+ DDCs (Fig.1B), as we previously described IL-10 to skew migratory 
DCs in skin from a mature to this immature CD14+ phenotype (12,19). 
Transcriptional profiling of cell types isolated from dissociated healthy human skin revealed 
TLR expression in LCs and CD1a+ DDCs to be generally low, but other intracellular PRRs like 
MDA5 and NOD2 were also expressed. Keratinocytes expressed TLR2 and TLR3 and treatment of 
these cells with Poly I:C resulted in increased TLR expression, demonstrating functionality of the 
expressed TLR3. Roughly, our findings reflect the TLR expression profile previously described by 
van der Aar et al. for LCs and DDCs (8). Inconsistencies may be explained by differences in the 
employed methodologies or by differences in the isolated DC populations (notably CD1a+ DDCs 
in our study versus all CD11chiHLA-DR+ DDCs in their study). Also, the high TLR2 and -3 mRNA 
expression levels observed by us in isolated keratinocytes are in line with data from Karim et al. 
who reported high TLR2 and -3 expression as well as expression of RIG-I and MDA5 in foreskin, 
cervical, and vaginal keratinocytes (10). Importantly, these PRR expression profiles altogether 
support the observed stimulatory effects of PGN and Poly I:C on the skin-emigrated DCs, with 
PGN likely binding and activating through TLR2/NOD2 and Poly I:C through TLR3/MDA5 (7). 
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Intradermally delivered Poly I:C induced both DC maturation and an increased migration 
frequency of the mature CD1a+ DDC subset, resulting in an overall significantly increased T-cell 
stimulatory ability of the skin-emigrated DCs in an MLR with allogeneic T cells. It is not clear if 
the effect of Poly I:C on DCs is solely caused by direct activation through TLR3/MDA5, as CD1a+ 
DDCs express low levels of TLR3 but higher levels of MDA5, or indirectly. Both TLR3 and MDA5 
are also functionally expressed by keratinocytes and as such may have triggered the release of 
DC-activating cytokines that subsequently can induce DC maturation (20). Interestingly, out 
of a panel of TLR-L based adjuvants subcutaneously injected with a DEC250-targeted HIV-gag 
protein vaccine in mice, Poly I:C was identified as the superior adjuvant (21). Its observed in vivo 
adjuvanticity, effecting efficient Th1 activation, depended on the release of type-1 IFN by stromal 
cells and DCs. Indeed, both keratinocytes and fibroblasts may be the source of Poly I:C-induced 
type-1 IFN (10, 21,22). Conceivably a similar mechanism may have been at work in our skin explant 
model. Recently, selective induction of the CD8+ T cell activating co-stimulatory molecule CD70 
was reported on LCs but not on DDCs in response to viral signals (23). Indeed, intradermal 
injection of Poly I:C (a synthetic viral PAMP mimic) resulted in a subset of skin-emigrated DCs 
de novo expressing CD70 (Fig.2B). Although Langerin double staining was not performed and 
their LC identity could thus not be unequivocally confirmed, the small percentages of CD70+ 
cells correspond with the low frequencies of LCs among the skin-emigrated DCs (Fig.1B). As 
expected, CD70 was not highly up-regulated on Monocyte-derived DCs upon TLR triggering, in 
keeping with the reported exclusive up-regulation of CD70 on LCs (23).
PGN appeared to achieve a type-1 DC maturation through triggering the release of pro-
inflammatory cytokines, either through TLR2/NOD2 binding in CD1a+ DDCs or in keratinocytes 
(25).. Stimulation of T cells resulted in a Th1 polarization reflected by significantly elevated 
TNFa and IFNg release, as well as in Th17 polarization, reflected by the release of IL-17 (Fig.4B). 
This confirms findings by others, showing Th1/Th17 induction by PGN through a TLR2/NOD2-
dependent mechanism (24). Of note, the TLR2/TLR1 agonist PAM3CSK4 did not induce any DC 
maturation, in line with findings from a mouse study in vivo (21), thus confirming the likely 
involvement of the intracellular PRR NOD2 in these PGN-induced effects.
In addition, minor DC-activating effects were observed for LPS. Increased LC and CD1a+ 
DDC migration frequencies and significantly enhanced CD83 and PD-L1 expression levels 
were observed. Although low TLR4 expression in LCs, DDCs and keratinocytes was observed, 
reported TLR4 expression in dermal fibroblasts (11) may have facilitated pro-inflammatory 
cytokine release (most notably IL-1b and IL-6, see also Fig.3), leading to the observed DC 
activation. 
Remarkably, we observed no stimulatory effects for the TLR7/8 agonist R848 (Resiquimod), 
despite the fact that it emerged as an effective vaccine adjuvant –second only to Poly I:C from 
an in vivo study in humans (21). R848 was applied epicutaneously, like the closely related TLR7 
agonist Imiquimod, which has previously been recognized as a possibly effective vaccine 
adjuvant (7). Conceivably, topical application more effectively addresses low-level TLR7/8 
expressed in LCs (8). Moreover, topical application of Imiquimod has previously been described 
to lead to the recruitment of both myeloid and plasmacytoid DCs (26). Co-administration of 
systemic FLT3-L further mobilized DC precursors and enhanced the DC-stimulatory effects of 
Imiquimod (27). In line with these observations, we found R848 (like all the other TLR-Ls tested) 
to induce CCL5 release from the skin explants (although at highly variable levels, see Fig.3), 
TLR-mediated activation of dermal DC
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consistent with possible in vivo recruitment of DCs or their precursors from the blood. Clearly, 
the skin explant model employed in the current study is not suitable to address this issue.
In conclusion, Poly I:C and PGN, respectively binding TLR3/MDA5 and TLR2/NOD2, are 
attractive candidate adjuvants for intradermally delivered therapeutic vaccines targeting 
cutaneous DCs, and should be further explored as such. Based on in vivo findings from the 
Spörri and Reis e Sousa groups, direct APC activation by TLR agonists, rather than indirect 
activation through pro-inflammatory mediators released by accessory cells, ensures proper 
differentiation and long-term memory of Th1 and CD8+ effector T-cells (28,29). In view of the 
relatively high expression levels of TLR2 and NOD2 in the mature and T-cell stimulatory CD1a+ 
DDC subset and its proven ability to induce Th1 differentiation, inclusion of PGN in any TLR-
targeted adjuvant formulation seems an attractive option in this regard. Indeed, as Poly I:C and 
PGN achieve their T-cell stimulatory effects through different mechanisms (Poly I:C through 
phenotypic DC activation and PGN through pro-inflammatory cytokine release and Th1/Th17 
polarization), possible synergism through the combined administration of both deserves 
particular attention in future studies.
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Supplementary figure 1. TLR-ligands activate human monocyte derived dendritic cells. A) CD14+ isolated 
monocytes ( >95% pure) were differentiated with IL-4 and GM-CSF and analyzed at day 6 of culture by 
flowcytometry. B) mo-DC were stimulated with indicated TLR-agonists for 48 hr and analyzed by 
flowcytometry for expression of co stimulatory molecules  Open histograms: immature/unactivated DC 
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Chapter 7
Purpose: In a recent randomized phase III clinical trial in metastatic colorectal cancer patients, 
the addition of the anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb) 
cetuximab to bevacizumab and chemotherapy resulted in decreased progression-free survival, 
in particular for patients with the high-affinity FcgRIIIA.
Experimental Design: The presence of natural killer (NK) cells and type 2 (M2) macrophages 
in colorectal cancer was determined by immunohistochemistry using antibodies to lineage-
specific markers, respectively, NKp46 and CD68 with CD163. Influence of tumor-bound 
cetuximab on M2 macrophages was performed in vitro with EGFR-expressing tumor cells and 
short-term differentiated monocytes from blood donors, who were typed for the FcgRIIIA 
polymorphism (CD16). 
Results: ADCC by NK cells is generally proposed as one of the anti-tumor mechanisms of 
MAbs. We found that CD163-positive, M2 macrophages are much more abundant in colorectal 
carcinomas. In vitro analysis of M2 macrophages revealed high levels of Fc-gamma receptors 
(FcgRs) and PD-L1, and production of IL-10 and VEGF, but not IL-12. These anti-inflammatory 
and tumor-promoting mediators were released upon co-culture with EGFR-positive tumor 
cells loaded with low concentrations of cetuximab. Macrophage activation depended on EGFR 
expression on the tumor cells, FcgRs, target specificity of the MAb and mobility of antibody 
complexes. Cetuximab-induced macrophage responses were more pronounced for FCGR3A 
158-valine (high affinity) carriers.
Conclusion: These results suggest that tumor-promoting M2 macrophages are activated by the 
therapeutic MAb cetuximab in the local tumor microenvironment and argue that this immune 
mechanism should be taken into account for the application of therapeutic antibodies.
abstraCt
introduction 
Monoclonal antibodies (MAbs) have become important agents for the treatment of many 
types of malignancies. Generally, their principal mechanism of action is blocking growth factor 
pathways that are essential for tumor growth and progression. So far, all clinically applied MAbs 
contain the Fc region of human IgG, which efficiently mediates activation through Fcg receptors 
(FcgRs) on several types of immune cells. These IgG-binding receptors actually contribute to 
the clinical effect of MAbs, in addition to their direct inhibition on tumor growth  (1). The role 
of immune activation is corroborated by several studies describing an association between the 
rs396991 polymorphism (FCGR3A 158PheàVal) in the gene encoding FcgRIIIA (also known as 
CD16) and clinical outcome after treatment with the therapeutic MAbs rituximab (anti-CD20), 
trastuzumab (anti-HER2/neu) and cetuximab (anti-epidermal growth factor receptor, EGFR) 
(2-4). The high affinity valine allele has been associated with increased clinical response and 
survival in these studies, which is in line with in vitro studies indicating that antibody-dependent 
cellular cytotoxicity (ADCC) is more extensive for this allele  (5).
Recently, the addition of cetuximab to bevacizumab plus chemotherapy resulted in 
decreased progression-free survival in a large clinical trial in metastatic colorectal cancer 
(CAIRO2 study)  (6). To explain this unexpected result, we subsequently analyzed which gene 
polymorphisms were related to poor outcome in this cohort. This study revealed that patients 
expressing the high affinity allele for the FcgRIIIA (158Val) had a shorter progression-free time 
span, but only when cetuximab was added  (7). Possibly, the detrimental effect of cetuximab is a 
consequence of activation of tumor promoting immune cells, rather than triggering tumoricidal 
ADCC by NK cells. FcgRs are also expressed by macrophages, which have been demonstrated 
in colorectal carcinomas  (8, 9)Tumor-associated macrophages are characterized as M2-type 
cells and are known to possess anti-inflammatory, pro-angiogenic and tumor-promoting 
properties  (10). Recent literature even implies an active involvement of FcgRs and myeloid cells 
in carcinoma development  (11). We therefore hypothesized that therapeutic antibodies, such 
as cetuximab, might locally cross-link FcgRs on intratumoral M2-type macrophages by EGFR-
binding on tumor cells, resulting in activation and release of tumor-promoting mediators. 
Translational Relevance: In a recent clinical phase III study, the addition of the 
therapeutic MAb cetuximab was evaluated in colorectal carcinoma patients who received 
chemotherapy and bevacizumab. Surprisingly, patients with cetuximab inclusion in 
the protocol had a worse progression-free survival than those treated with standard 
treatment. This detrimental effect was more pronounced in patients with the high affinity 
Fc-binding receptor FcgRIIIA, implying a role for immune cells. In our consecutive study, 
we now show that macrophages with M2 differentiation profile are abundantly present 
in colorectal carcinomas, much more than ADCC-mediating natural killer cells. M2 
macrophages are efficiently activated by low dose cetuximab, resulting in the release of 
immune suppressive and tumor-promoting mediators. Macrophages with the high affinity 
valine-encoding FcgRIIIA displayed an enhanced activation. We conclude that therapeutic 
monoclonal antibodies, such as cetuximab, can support tumor growth via tumor associated 
macrophages in the tumor microenvironment, in addition to their direct cytostatic activity.
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These molecular interactions might explain the negative effect of the addition of cetuximab to 
bevacizumab and chemotherapy in the CAIRO2 trial.
materialS and metHodS
immunohistochemical stainings
Formalin fixed and paraffin embedded tumors from ten untreated stage III colorectal cancer 
patients, of whom the majority was moderately differentiated, 1 well and 2 were poorly 
differentiated, were selected from the pathology archive of the Leiden University Medical 
Center. All patients showed recurrent disease at follow-up. Staining for NK cells and M2 
macrophages was described before  (12). 
cell-cultures
Colorectal adenocarcinoma cell lines LoVo and HCT-15 were kindly provided by Dr. van Wezel 
(Leiden University Medical Center, the Netherlands) and epidermoid skin cancer line A431 was 
obtained from ATCC (Manassas, VA, USA). M2-type macrophages and dendritic cells (DCs) 
were differentiated from purified CD14+ monocytes (MACS, Miltenyi Biotec, Bergisch Gladbach, 
Germany) and differentiated as previously described  (12), using M-CSF (R&D, Minneapolis, USA) 
or GM-CSF (Invitrogen) with IL-4 (Invitrogen). Cells were activated by 250 ng/ml LPS (Sigma-
Aldrich, St. Louis, USA) or tumor cells with MAbs cetuximab (Erbitux®, Merck, Darmstadt, 
Germany), rituximab or bevacizumab (Mabthera® and Avastin®, respectively; Roche, Welwyn 
Garden City, UK). 
experimental conditions
At day 6 of the monocyte differentiation cultures, tumor cell lines were plated in a density of 
50.000 cells per well in 48-wells plates. After 2 h, 250 ng/ml LPS or MAbs were added together with 
M2 macrophages in a density of 100.000 cells per well. After 24 h, supernatants were collected 
and analyzed for IL-10 (Sanquin, Amsterdam, Netherlands), IL-8, VEGF (eBioscience, Vienna, 
Austria) and IL-12p70 (BD-Biosciences, Minneapolis, MN, USA) production. Macrophages 
were removed from the culture plates by scraping and stained with monoclonal antibodies 
(all purchased from BD-Biosciences, except for anti- PD1-L from eBioscience). Samples were 
recorded using a FACS Calibur with Cellquest software (BD-Biosciences). Data were analyzed 
with FlowJo software (Tree star, Ashland, USA). Macrophages were separated from tumor cell-
lines by gating for HLA-DR. 
Genotyping 
Genomic DNA was isolated from monocytes with MagnaPure Compact (Roche, Almere, 
Netherlands) and genotyping for FCGR3A c.818A>C (C_25815666_10; rs396991) was performed 
as previously described  (7). 




colon carcinomas are heavily infiltrated with type 2 macrophages, but not 
with nk cells.
To investigate immune cell infiltration of colorectal cancers, we stained ten tumors for the 
common macrophage marker CD68, and the scavenger receptor CD163, which is typically 
expressed by M2-type macrophages. All colorectal tumors were extensively infiltrated with this 
type of macrophages (figure 1a). By contrast, hardly any NK cells were observed using the NK-
lineage specific receptor NKp46. We thus envisage that cetuximab treatment might impact on 
these infiltrating macrophages, and that local ADCC via NK cells plays a minor role. 
The influence of cetuximab on macrophages was studied on freshly isolated monocytes 
that were differentiated in vitro into CD1a-CD14+CD163+ macrophages  (12). The expression of 
Fcg receptors FcgRI (CD64), FcgRII (CD32) and FcgRIIIA (CD16) and release of cytokines after 
activation by the strong TLR stimulus LPS was examined (figure 1b, c). M2 macrophages strongly 
displayed all three Fc-binding receptors and produced high amounts of the anti-inflammatory 
IL-10, as well as IL-8 and the pro-angiogenic VEGF, but not the immunostimulatory IL-12. 
Control monocyte-derived DCs displayed an opposite profile, which is in line with their 
T-cell stimulating function. These data strongly suggested that M2-type macrophages could 
potentially be stimulated by MAbs to exert an anti-inflammatory and pro-angiogenic role in 
the tumor microenvironment.   
cetuximab induces activation of type 2 macrophages
M2 macrophages were then activated by cetuximab in the presence of tumor cells. Three 








































Figure 1. Detection and characterization of M2 macrophages in colorectal cancer. A, Two representative 
examples of two color immunofluorescent staining of stage III colorectal cancers with high (left panel) and 
low (right panel) infiltration of CD68+ (green) macrophages expressing the typical type 2 marker CD163+ 
(red). B, Flow cytometry analysis of M2 macrophages and monocyte-derived dendritic cells (mDC). 
Fcg receptors are indicated by the CD nomenclature: FcgRI (CD64), FcgRII (CD32) and FcgRIII (CD16). C, 
Production of IL-10, IL-12p70, IL-8 and VEGF by mDCs and M2 macrophages after overnight stimulation 
with LPS.
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highly expressed EGFR, whereas EGFR staining of LoVo and HCT-15 was much lower (figure 
2a). Importantly, co-culture of macrophages with cetuximab-opsonized A431 tumor cells 
resulted in production of IL-10 and IL-8, whereas EGFR-low tumors LoVo and HCT-15 did not 
activate macrophages (figure 2b, suppl figure 1). Notably, the release of IL-8 upon cetuximab 
treatment exceeded that of the positive control LPS (suppl figure 1). The A431 tumor cells 
spontaneously produced VEGF, so this mediator could not be used in succeeding experiments 
to determine macrophage activation. To corroborate the notion that macrophage activation 
was the result of cross-linking Fcg receptors, we incubated tumor cells with MAbs specific for 
the non-expressed CD20 (rituximab), or the soluble VEGF (bevacizumab), both containing 
the same IgG
1
 isotype. This did not lead to IL-10 production (figure 2c), suggesting that only 
membrane-bound proteins as EGFR can efficiently trigger macrophages via FcgR. Furthermore, 
competition of Fc-binding by high concentrations of rituximab resulted in a dose-dependent 
decrease of IL-10 production (suppl figure 2). Interestingly, IL-10 was also not detected when 
cetuximab was coated on culture plates (figure 2c), suggesting that the molecular interaction 
of EGFR-cetuximab-FcgR required the flexibility of fluid membranes for proper cross-linking. 
The cetuximab mediated activation of M2 macrophages was dose-dependent (figure 3) 
and concentrations as low as 10 ng/ml were sufficient to down-regulate cell surface levels of 
CD16 and to up-regulate the inhibitory molecule PD1-L (figure 3a) and to release IL-10 and IL-8 
(figure 3b, suppl figure 1). These data showed that very low concentrations cetuximab induced 
the release of anti-inflammatory mediators from M2 macrophages through cross-linking of Fcg 
receptors. 
effect of fcGriiia polymorphism
Addition of cetuximab to bevacizumab and chemotherapy in the CAIRO2 trial decreased the 





































































Figure 2. FcgR cross-linking by cetuximab 
activates M2 macrophages. A, Flow 
cytometry analysis of EGFR expression on 
tumor cell lines A431, HCT-15 and LoVo. 
Filled histograms represent isotype control 
antibody, solid lines indicate staining with 
anti-EGFR antibody. B, IL-10 production 
by M2 macrophages upon co-culture with 
tumor cells and 1 µg/ml cetuximab (c’mab). 
Addition of LPS (250 ng/ml) served as 
positive control. C, IL-10 production by 
macrophages depends on interaction of 
macrophages and cetuximab-pulsed A431 
tumor cells. Plate-bound cetuximab (10 
µg/ml) (‘coated’) could not replace the 
EGFR-expressing tumor cells and control 
antibodies rituximab (r’mab, 1 µg/ml) or 
bevacizumab (b’mab, 1 µg/ml) could not 
replace cetuximab.
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high affinity FcgRIIIA genotype encoding the valine residue  (6, 7). We examined the influence of 
this polymorphism on the degree of M2 macrophage activation by cetuximab using 22 healthy 
donors, consisting of 12 homozygous 158-Phe and ten 158-Val carriers (figure 4). Analysis of 
IL-10 release and CD16 down-regulation on M2 macrophages showed an apparent stronger 
activation of cells with the high affinity valine allele (figure 4). These differences did not reach 
statistical significance for cytokine release, most likely due to high variation within the groups 
and very high production (figure 4a and suppl figure 1, respectively). Notably, macrophage 
activation in this system is presumably also mediated by other Fcg receptors, such as FcgRI, 
resulting in less pronounced differences between 158-Phe and 158-Val carriers. In conclusion, 
our data show that cetuximab can induce the release of anti-inflammatory mediators from M2 
macrophages and that this effect might explain the negative clinical effect of this MAb in the 
recent CAIRO2 study.  
diScuSSion
Our data show that type 2 macrophages are abundantly present in colon carcinoma and are 
activated by cetuximab-opsonized tumor cells, resulting in anti-inflammatory and tumor 
promoting mediators, including IL-10 and VEGF. M2 macrophages are known to actively 
contribute to tumor growth via angiogenesis and immune suppression  (10). Previous research 
on the immune mechanisms of therapeutic MAbs has focused on anti-tumor effects such as 




























Figure 3. Degree of M2 macrophage activation depends on cetuximab concentration. A, Flow cytometry 
analysis of PD1-L up-regulation and CD16 down-regulation on M2 macrophages upon co-culture with 
EGFR-positive A431 tumor cells and different cetuximab (c’mab) concentrations. Rituximab (r’mab) served 



































Figure 4. Activation difference 
of FCGR3A (CD16)-typed M2 
macrophages. M2 macrophages 
of twelve homozygous 158-Phe 
(solid squares) and ten 158-Valine 
allele carriers (open circles are 
heterozygous and solid circles are 
homozygous) were activated by 
cetuximab (c’mab) and EGFR-positive 
A431 tumor cells. A, CD16 down-
regulation and B, IL-10 release were 
measured. Lines represent median 
values and differences between the 
two groups at 1 µg/ml cetuximab were 
calculated by Mann Whitney test
(5, 13), however, staining for NK cells in colorectal carcinoma revealed that these cells are rare 
in colorectal cancers. Fcg receptors are also expressed by macrophages and these cells were 
abundantly present in this tumor type (figure 1). Previous studies have shown that macrophages 
are present in all stages of colon tumors and that higher numbers of macrophages are found 
in more advanced stages of disease  (8, 9). M2 macrophages are efficient in phagocytosis of 
rituximab-opsonized B cells  (14), but we question the relevance of this FcgR-mediated process 
for solid tumors like colorectal carcinoma. Based on our findings, we rather suggest that 
activation of intratumoral M2 macrophages leads to release of tumor-promoting mediators.  
The detrimental effect of cetuximab addition in the CAIRO2 trial was unanticipated  (6), 
since the combination of cetuximab and anti-VEGF therapy appeared effective in mouse models 
(15-17) However, the Fcg receptor-mediated effects by cetuximab could not be evaluated 
in these models, as the human Fc-region of cetuximab does not interact with the murine 
FcgRs. Future studies in mice expressing human FcgR might elucidate immune mechanisms of 
therapeutic MAbs and, importantly, better predict the outcome of combination studies. Our 
results indicate that the release of multiple anti-inflammatory and pro-angiogenic mediators 
by M2 macrophages could account for the decreased therapy efficacy for those patients 
that were treated with the combination of cetuximab, the anti-VEGF MAb bevacizumab and 
chemotherapy (6). The finding that M2 macrophages encoding the high affinity FcgRIIIA 
(valine-carriers) displayed a more pronounced activation (figure 4) corroborated our previous 
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observation that patients with this high affinity receptor had an even worse progression-free 
survival than those with 158-Phe homozygosity  (7). Strikingly, removal of the high-affinity 
valine-carriers from the CAIRO2 cohort revealed that the addition of cetuximab did not lead to 
worse clinical outcome, compared with the trial arm of conventional therapy. On the contrary, 
the homozygous 158-Phe FcgRIIIA patients seemed to benefit from the addition of cetuximab. 
However, this analysis was performed on the KRAS wild type patients and groups sizes were too 
small to draw firm conclusions. Notably, bevacizumab binds soluble VEGF and therefore does 
not cross-link FcgRs and activate intratumoral macrophages (figure 2). 
One intriguing question still remains: why does cetuximab mediate anti-tumor effects as a 
single agent  (18, 19), whereas its addition to bevacizumab plus chemo-therapy leads to worse 
survival? Based on our findings, we speculate that cetuximab induces local release of pro-tumor 
mediators, amongst which VEGF, and thereby neutralizes the beneficial therapeutic effect of 
bevacizumab.  Interestingly, a clinical study with cetuximab as monotherapy for metastatic 
colorectal cancers also revealed an increased progression-free survival for low-affinity carriers 
of FcgRIIIA, especially in combination with certain FCGR2A alleles  (20). Combination with 
chemotherapy might tip the balance further towards macrophage activation by up-regulation 
of EGFR expression, as shown for fluoropyrimidines and irinotecan  (21) and, importantly, also 
by recruiting immune-suppressive macrophages to the tumor site  (22). These indirect immune 
effects might then overrule the direct growth-inhibiting effect of EGFR blockade.  
In conclusion, therapeutic antibodies mediate a plethora of in vivo effector arms that reach 
beyond their on-target function or immediate complement-mediated cytotoxicity. These FcR-
dependent mechanisms are diverse in vivo and several factors determine the outcome and 
employed effector arm, including the type of tumor (solid or circulating), type of immune 
infiltrate (macrophages or NK cells) and combinations with other therapeutics. We now 
propose an adverse mechanism by which therapeutic MAbs might promote tumor growth via 
activation of infiltrated macrophages, which are known for their pro-angiogenic and immune-
suppressive functions. Clinical testing of engineered MAbs with Fc-regions with increased 
affinity to FcgRs should be performed very carefully  (1, 23), because tumor-promoting effects 
by intratumoral M2 macrophages could lead to tumor promotion instead of tumor repression. 
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Supplemental figure 1. IL-8 production upon Fc-mediated M2 macrophage activation. A, IL-8 production 
after 24 h co-culture of M2 macrophages with cetuximab (c’mab, 1 µg/ml) opsonized A431 tumor cells 
(white bars), LoVo cells (light grey bars) and HCT-15 cells (dark grey bars). Addition of LPS (250 ng/ml) 
served as positive control. B, IL-8 production by macrophages depends on interaction of macrophages 
and cetuximab opsonized tumor cells. Plate-bound cetuximab (10 µg/ml) (‘coated’) could not replace the 
EGFR-expressing tumor cells and control antibody rituximab (r’mab, 1 µg/ml) or bevacizumab (b’mab 1 
µg/ml) could not replace cetuximab. C, Overnight IL-8 production by M2 macrophages is dependent on 
the concentration of cetuximab. D, Both the phenylalanine homozygote donors (solid squares, n = 12) 
and valine allele carriers (Phe/Val [open circles] and Val/Val [solid circles] donors combined; n = 10) were 
activated by cetuximab (c’mab) and EGFR-positive A431 tumor cells.  IL-8 release was measured and lines 
represent median values.
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Supplemental figure 2. Competition for Fc-binding by 
rituximab. A431 tumor cells were loaded without cetuximab 
(c’mab 0) or with a sub-optimal dose of 0.1 mg/ml cetuximab 
(c’mab 0.1). Rituximab (r’mab) was added in higher (10 mg/ml), 
equal (0.1 mg/ml) or lower concentration and M2 macorphages 











C’mab   0       0.1     0.1     0.1     0.1
R’mab   1       10      0.1  0.001   0






the role of aPc in the activation of t cells 
In chapter 2 we analyzed the presence of HPV-specific proliferative T-cell responses in the blood 
of patients with HPV-induced cervical cancer. HPV-specific T cells were found only in a minority 
(31%) of the patients. T-cell responses were more often detected in patients presenting with a 
tumor that deeply invaded the surrounding tissue, which is on its own a bad prognostic sign. 
At that time we hypothesized that by the infiltration of healthy tissue, tumor antigens were 
delivered to APC not tolerized by the tumor milieu and, therefore, able to appropriately instruct 
T cells. However in view of the results presented in chapter 5, in which we showed that CxCa 
can induce macrophage differentiation, I would like to propose an alternative explanation. 
Macrophages contribute to tumor invasion by the production of metallo proteinases (MMP) 
which brake down collagen and facilitate infiltration by tumor cells in the surrounding tissue. 
Therefore, the deeply invading tumors described in chapter 2 could be the tumors that 
harbour high numbers of MMP-producing M1 or M2 macrophages. In chapter 2 we describe 
that half of the patients with deeply invading tumors have proliferating HPV specific T cells in 
the blood. After uptake of tumor cells or cell debris macrophages can present tumor-specific 
antigens to T cells and elicit T-cell responses. Analysis of the H&E staining of these deeply 
invading tumors showed that the patient group with T-cell proliferation in the blood had high 
immune cell-infiltrate in the tumor (Table 1). This suggest the presence of pro-inflammatory M1 
macrophages, contributing to local invasion of the tumor  but also inducing inflammation and 
T-cell responses. 
In contrast, patients without HPV-specific proliferation in the blood predominantly lacked 
immune-cell infiltrate in the tumor.  One can envisage that the patients without  T-cell responses 
in the blood and low infiltrate density in the tumor (table 1)  harbour M2 type macrophages 
in the tumor. These macrophages are not attracting or inducing T cells but promote tumor 
invasion and this correlates with the poor prognosis found for this group (chapter 2).
We showed that when HPV-specific T cells were present in the tumor, the T-cell reaction 
of a wide diversity and involved several CD4+ as well as CD8+ T-cell clones (chapter 3). Ex-vivo, 
these T cells recognized HPV but not all responding cells produced  type 1 cytokines. Addition 
of TLR-agonist PAM3CSK4 and Poly I:C during antigen-specific stimulation of the T cells 
increased their production of IFNg in primary cultures. To stimulate the T cells with antigen 
we made use of B-LCL as antigen presenting cell. Although B cells can present antigen, they 
are not as the specialized as DC and, therefore, these assays may not have been optimal for 
testing T-cell function. How important the type of APC is for the strength of activation in 
antigen-experienced cells is not  clear, although it is known that the type of co stimulatory 
molecules present influence cytokine production [1]. Furthermore, we showed in chapter 5 
that naïve responder T cells failed to produce high levels of IFNg when stimulated with less 
well differentiated DC or macrophages – obtained when monocytes were cultured in the 
presence of tumor supernatant -  as compared to T cell stimulated with fully differentiated DC. 
In addition, we observed that established HPV-specific T-cell clones produced less IL-2 upon 
activation with the above mentioned non-optimal APC (unpublished observations). Apparently 
the type of antigen presenting cell is important for the activation of naïve but also antigen 
experienced T cells. Finally, experiments on T-cell activation by peptide loaded monocytes 




et al, manuscript submitted). Hence, conclusions concerning the functionality of T cells (e.g. 
like we have called the T cells that did not produce cytokines ‘poised’ in chapter 3) should be 
drawn with great care.
tlr-agonists to boost inflammation?
Addition of TLR-agonists boosted the IFNg production of the aforementioned cultures 
described in chapter 3 but not to the same extent in all patients. PAM3CSK4 and Poly I:C were 
the most promising adjuvant. In these cultures the exact cell type (APC, T cells and in lymph 
node tissue also B cells) that responded to the TLR-agonist was not dissected. 
Several studies report that stimulation of TLR modulates T-cell responses after TCR 
triggering [2]. At the T-cell population level, TLR-stimulation enhanced IFNg production by T 
cells but also abolished regulatory T-cell function [2]. So far, these studies were performed on 
unselected CD4+ T cell populations. In our study on functional TLR expression by T cells we made 
use of isolated HPV-specific T cell clones and conducted many in vitro experiments. Analysis 
of TLR expression by patient derived tumor-antigen specific CD4+ T-cell clones -including 
helper and regulatory T-cell clones- revealed that human T cells express a number of different 
TLRs at the mRNA level and that the TLR expression pattern differed per CD4+ T-cell clone, 
independent of their function. When these CD4+ T-cell clones were tested in various activation 
(proliferation, cytokine production) and suppression assays no consistent gain (proliferation/
IFNg production) or loss in function was observed due to the presence of TLR-agonists. This 
suggests that TLR may not play a major role in direct stimulation of antigen experienced and 
fully polarized CD4+ T cells (unpublished observations).
The effect of several TLR-agonists on the activation of purified APC was investigated in 
vitro in chapter 5. Interestingly, the two agonists PAM3CSK4 and Poly I:C - showing the most 
promising activation of T-cell cultures in chapter 3 - were the least promising agonists in these 
assays (chapter 5a, figure 2 and not shown).  Addition of TLR-agonists to mo-DC resulted in 
upregulation of co-stimulatory molecules at the cell surface, but Poly I:C as well as PAM3CSK4 
failed to induce the production of IL-12. However, when Poly I:C was added to a less pure culture 
of mo-DC (derived by plastic adherence) splendid production of IL-12 was detected. These 
cultures are contaminated with T cells which may have provided additional signals via CD40-L 
or IFNg [3,4] suggesting that Poly I:C in the presence of a second signal  is a strong agonist 
(unpublished data).  
This notion is sustained by our studies using skin-explant cultures as described in chapter 
6. Poly I:C proves to be the strongest activator of dermal APC. Here too, other cell types are 
present that can provide synergistic signals to the local APC. Interestingly, R848 -the agonist of 
TLR7 and closely related to Imiquimod- did not induce any measurable activation or migration 
in the skin-explant model described in chapter 6. Keratinocytes, which functionally display 
TLR3 but not TLR7 may have supported the activation of APC by the production of IL-1, type I 
IFN and other factors ([5] and unpublished observations).  Based on chapter 3 and 6,  Poly I:C 
may form an attractive compound to apply locally on tumors or neoplastic lesions. Especially 
for HPV+ oropharyngeal tumors this could be a good alternative or adjuvant treatment. These 
tumors develop within a lymphoid structure and thus consist of lymphoid tissue and epithelial 
cells (e.g. keratinocytes). Since many HPV+ oropharyngeal tumors are infiltrated with tumor-
antigen specific T cells, stimulation of local inflammation might tip the balance in favor of an 
anti-tumor response (chapter 4). 
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m2 and myeloid derived suppressor cells (mdSc)
Tumors attract myeloid antigen presenting cells and interfere with their differentiation. 
Gabrilovich et al showed in mouse models that tumor-induced myeloid cells suppressed 
surrounding T cells. These MDSC express GR1+ as well as CD11b, produce iNOS and arginase 
and are of pre-mature undifferentiated state [6]. MDSC are also found in humans, although the 
phenotype is less clear and there is a great variety between individuals and tumor types. Human 
MDSC express CD33, CD11b and IL4Ra, CD15, CD14 although the last 3 markers are not always 
reported [7]. In chapter 5 we showed that soluble factors produced by CxCa cell lines influence 
myeloid cell differentiation despite the presence of IL-4 and GM-CSF. Some cell lines only 
hampered DC differentiation but other cell lines clearly induced a macrophage phenotype. The 
APC differentiated in the presence of supernatant of CASKI cells expressed less CD1a and higher 
mannose receptor. Other markers like CD14 or IL-4Ra were not clearly expressed and, therefore, 
it was difficult to nail down the exact cell phenotype that was induced. The differentiation of 
these cells into DC was completely restored when IL-6 was blocked. Thus in our experiments 
IL-6 only hampered DC differentiation and induced higher IL-10 production but did not skew 
cell differentiation towards macrophages or MDSC. 
Furthermore, we showed in chapter 5 that CxCa-produced PGE2 skewed mo-DC 
differentiation towards APC expressing CD14, CD163 and high levels of the mannose receptor. 
Based upon receptor expression profile and functional characteristics we called these cells 
type 2 macrophages. Similarly, Obermajer et al. recently published that the addition of PGE2 to 
mo-DC cultures induced suppressive cells which they called MDSC [8].  This is a clear example 
of the confusion and debate that is currently ongoing about the phenotype, function and role 
of myeloid subsets in human cancers. To complicate matters even further, we clearly found that 
activation with TLR-agonists or CD40-L of M2 macrophages resulted in phenotypic changes 
leading to loss of the typical M2 marker phenotype but exertion of their M2 function (chapter 5a 
supplementary. fig. 1). Thus the phenotype of APC is not always representing the function of the 
cell, even more because myeloid cells show great plasticity depending on the type of stimulus. 
Finally, tumors harbour distinct microenvironments that instruct locally present myeloid cells 
and results in heterogenic populations of  myeloid cells within one tumor, both in mice and 
men [9-11]. These data plead for a less stringent separation of myeloid cell subsets. MDSC or 
macrophages are not different cell subsets but rather resemble a state of differentiation and 
activation of developing myeloid cells. 
chemotherapeutics induce immunological effects
Chapter 5b describes the preliminary data of studies in which tumor cell lines known to skew 
monocytes to M2 macrophages are treated with cisplatin or carboplatin. Treatment of these 
tumor lines with physiological but non-lethal doses of cisplatin resulted in an increased 
production of PGE2 and IL-6 by the tumor cells and augmented the skewing of monocytes to 
M2 macrophages. This illustrates that the quantity and the sum of factors released by the tumor 
cells bears impact on the final outcome.  Possibly other factors are produced by the CxCa cell 
lines as well and contribute to the observed effects. The fact that COX-inhibition in tumor cells 
prevented the skewing to M2 macrophages illustrates that PGE2 is a key factor in this network. 
If patients receive chemotherapy treatment it is likely that a peak dose emerges in the 




the results of chapter 5b, one can envisage that if tumor cells are resistant and survive they 
might actually contribute to an increase in the number of local M2 macrophages and as such 
promote tumor growth. Ferrandina et al. performed a clinical study in patients with advanced 
CxCa and found that over-expression of COX-2 in the tumor correlated with a poor prognosis 
upon chemo radiation. This was explained by the fact that COX-2 expression in the tumor 
made the cells more resistant to apoptosis and thereby to chemotherapeutic treatment [12-15]. 
However the data of chapter 5b advocates an alternative explanation. An important predictor 
of response to therapy in several human tumor types is the number and type of T cells present 
in the tumor [16-21]. Maybe in cervical cancer these two known prognostic factors are related 
because the type and number of T cells infiltrating could reflect the type of macrophages that 
are present. High numbers of M2 macrophages correlate with more regulatory T cells infiltrate 
in human ovarian and GIST tumors [22,23]. Therefore the tumor expressing high regulatory 
T cell numbers is likely to be the COX+ tumor that induced the differentiation of M2 cells via 
elevated levels of PGE2 and IL-6 in its micro milieu. Besides the tumor promoting activity of 
the M2 macrophages, increased suppression of locally present T cells – either directly by the 
production of IL-10 by M2 macrophages or by the attraction of regulatory T cells - will occur 
and this is enhanced upon treatment with cisplatin (chapter 5b). This notion is sustained by 
a study in mice bearing lung tumors. Here, treatment with COX-inhibiting drugs resulted in 
marked T-cell infiltration in the tumor and delayed tumor outgrowth. The tumor infiltrating 
APC produced less IL-10 and more IL-12 upon treatment. This indicates that local PGE2 levels 
altered the APC type in the tumor with effects on T-cell infiltration [24]. Interestingly in lung 
cancer a poor response to cisplatin therapy is associated with activation of STAT3 protein.  IL-6 
signaling is known to activate STAT3, suggesting that cisplatin-mediated increase of factors like 
IL-6 – known to affect DC differentiation - might play a role in the poor response to cisplatin of 
these patients as well [25].
Unfortunately studies on the simultaneous presence of different T cells types in relation to 
the infiltrating APC on human tumors are scarce. This makes it difficult to find data corroborating 
above mentioned hypothesis. Studies in which these parameters are combined may reveal 
a relationship between these players, especially when analyzed before and after treatment. 
Currently, mouse tumor models are explored to further dissect the exact role of infiltrating APC 
and T cells upon in relation to treatment. A major drawback of such models is that only a few 
tumor lines are suitable to study this. As we have shown in chapter 5, pronounced differences 
between cell lines exist with respect to their capacity to influence immune cells.  Mouse studies 
using tumor cell lines will poorly reflect the great variety in human tumors and thus their 
interplay with immune cells. 
Notably, platinum based chemotherapeutics can have positive immune-related side 
effects. In a mouse model, Apetoh et al.showed that oxaliplatin induced immunogenic cell 
death via calreticulin exposure on tumor cells, thereby, stimulating the induction of an anti 
tumor T-cell response. Oxaliplatin and cisplatin induced release of HMGB-1 in dying tumor cells 
that activated APC via stimulation of TLR-4 [26,27].However, most of these experiments were 
done with only a few tumor-cell lines and intra-tumoral injection of chemotherapeutics or 
ex-vivo treatment of the tumor which does not resemble the clinical practice. This mechanism 
might be relevant in human cancer though since patients with breast cancer carrying  a loss-of-
function TLR-4 mutation relapsed more quickly after radiotherapy combined with (non-platin 
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based) chemotherapy [26], arguing for immune-dependent effects of chemotherapy. The data 
in chapter 5 shows that tumor induced macrophages respond to TLR-4 agonists, as reflected 
by the production of IL-10. Therefore, it is highly likely that chemotherapy-mediated release 
of HMGB-1 may not only activate DC but activate locally tumor-promoting macrophages as 
well. Activation of macrophages would add to the immune-suppressive tumor-promoting 
micro milieu in the tumor. Thus, platinum-based chemotherapy of solid tumors may both 
have positive and negative effects on the local anti-tumor immune response. The outcome 
is likely to depend on the constitution of the population of different APCs present within the 
tumor. Finally, most patients are treated with a combination of radiotherapy and chemotherapy 
but the combination of these two treatments is yet not addressed in the former and our own 
studies. Radiotherapy enhances antigen presentation by tumor cells, induction of tumor 
antigen specific antibodies and inflammation [28-30] and is, therefore, likely to contribute to 
the overall immune response as well. 
blocking coX-2 or il-6 during treatment
Blocking the production of PGE2 with COX-inhibitors prevented the induction of tumor 
promoting macrophages in vitro (chapter 5) and, therefore, patients with COX overexpressing 
tumors may benefit from blocking these enzymes during therapy. A number of studies were 
performed in several solid cancers in which patients were treated with a COX-2 inhibiting drug 
during standard therapy. In a recent phase II study COX-2 inhibition favored the clinical  outcome 
in patients with ovarian cancer [31]. Also a daily dose of celexocib (most clinically used COX-2 
inhibitor) effectively prevented (pre-cancerous) colorectal polyp formation. Unfortunately, 
the latter trial was aborted because of serious adverse cardiovascular effects when patients 
were treated for several years [32].  Also in non-small-cell lung cancer the addition of celexocib 
during a shorter time period to chemotherapy was studied. Although no adverse cardiovascular 
side effects were reported also no survival benefit was found in two independent studies [33,34]. 
COX-inhibition in patients with neoplastic lesions was already advocated because the increased 
chemo-sensitivity of the tumor cells [13-15]. We provide with chapter 5b an immunological 
rationale for the addition of a COX-inhibitor to standard treatment. Also in combination with 
therapeutic vaccination, inhibition of COX-enzymes may contribute to a less hostile  tumor 
microenvironment that is more vulnerable for the attack by T cells.
A second strategy to change the tumor microenvironment into an attractive place for 
pro-inflammatory macrophages and cytotoxic T cells is blocking IL-6. We found that cancer 
cell derived IL-6 skews DC differentiation towards APC that produce more IL-10 (chapter 4) as 
well as displayed elevated levels of activated STAT-3 (data not shown). Recently, a study was 
reported in which chemo resistant end-stage ovarian cancer patients were treated with an 
antibody to IL-6 (siltuximab). Stable disease was observed in some patients [35]. Concordantly, 
in a xeno-graft ovarian cancer mouse model blocking of IL-6 resulted in less macrophages 
infiltrating the tumor [35], indicating that  tumor-rejection associated immune-effects can 
be achieved by blocking IL-6 signalling. In rheumatoid arthritis, a monoclonal antibody to IL-
6Receptor is used with great clinical benefit by stopping inflammation upon treatment [36]. 
Treatment with blocking antibodies to IL-6 can break the autocrine supportive loop of IL-6 
producing tumor cells as well as IL-6-mediated suppression of DC differentiation or induction 
of M2 macrophages. Therefore, addition of IL-6 blocking antibodies to standard treatment or 




monoclonal antibody can activate any type of local macrophage
In chapter 7 we describe that blocking growth receptors on tumors as anti-tumor therapy may 
have unwanted immunological side effects. We showed that tumor promoting M2 macrophages 
are activated by tumor bound cetuximab although this monoclonal antibody  that targets EGFR 
on tumor cells was optimized to bind FcgReceptors on NK cells. For this, we used an in vitro 
culture system to differentiate monocytes into M2 macrophages by M-CSF. These macrophages 
responded to tumor bound antibodies with the production of the immune suppressive IL-10 
and IL-8. Although M-CSF is widely used to differentiate human M2 macrophages in vitro, 
these might not resemble the tumor-supernatant induce M2 as described in chapter 5b. To 
study the differences, we analyzed M2 macrophage cultures derived by culture protocols with 
distinct cytokines (chapter 5b). Although these macrophages expressed similar phenotype, 
the response to stimuli was not equal.  For example the cytokine production upon CD40-
ligation was poor in the M-CSF cultures whereas the IL-6+PGE2 induced cultures (resembling 
CxCa cell line supernatant) produced high amounts of IL-10 upon this activation. Taken 
these together, the experiments described in chapter 7 might  not resemble the real tumor 
associated macrophages as induced by CxCa cell lines (chapter 5b). However (unpublished) 
control experiments showed that TSN-M2 macrophages -as described in chapter 5- are also 
activated by tumor-bound cetuximab and not by control antibody, indicating that M-CSF 
derived M2 macrophages were appropriate cells for these proof-of-principle tests. Of note, if 
M1 macrophages, that also express FcReceptors, are present in the tumor they will get activated 
as well and engulfe or kill the cells upon binding cetuximab opsonized tumor cells. Therefore, 
the net outcome of a treatment may again be determined by the immune-cell repertoire that is 
present in each individual tumor. Based on the results with cetuximab, targeting the cell surface 
expressed IL6receptor by tocilizumab may also result in macrophage activation. Although it has 
been shown that this MAb did not activate DCs, no specific experiments with the MAb bound 
to IL-6R-expressing cells have been reported [37]. 
repolarization of macrophages – a way to treat cancer?
The treatment of cancer may take advantage of therapies that interfere with M2 macrophages, 
if combined with standard or immunotherapeutic regimens. Therapeutic modalities may attack 
at several levels; the attraction, the differentiation or the activation of macrophages. 
One therapeutic option is to interfere at the level of macrophage attraction and 
differentiation by abrogation of the PGE2 and the IL-6 and STAT-3 activation loop or other 
tumor produced cytokines [38,39]. This indirectly affects tumor growth and limits the induction 
of tolerogenic macrophages as described earlier. It might prove difficult to reach high enough 
antibody titers to block cytokine levels locally in the tumor, as they often are poorly vascularized 
at area’s where macrophages tend to accumulate [40]. Care should be taken since as membrane 
bound antibodies may activate macrophages via cross linking of the FcgReceptors and thereby 
activate inflammatory cascades (chapter 7). 
IFNg in combination with the CD40-CD40L APC-activation signal effectively reprograms 
tumor-induced M2-like macrophages into activated IL-12 producing M1 cells (chapter 4). For 
this to occur in the tumor-microenvironment, it is essential that CD4+ Th1 cells are locally 
present. The capacity of tumor-specific Th1 cells to directly alter the tumor microenvironment 
has also been recognized in studies on tissue-infiltrating CD8+ T cells in mouse models. Th1 cells 
were essential for successful recruitment, local expansion and full effector function of large 
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numbers of CTL by modulation of the local environment [41,42], and this may have included 
the repolarization of macrophages. In order to obtain sufficient numbers of tumor-specific 
CD4+ Th1 cells one may make use of adoptive T-cell transfer protocols or apply strong vaccines 
[43-46]. These therapies should not only induce cytotoxic T cells but also type 1 polarized 
helper cells to help shifting the local tumor micromilieu from tumor-promoting and immune 


























COX-inhibitor IL-6/6R MAb Vaccines / ACT
Figure  1. Modulation of tumor associated macrophages. Monocytes leaving the bloodstream and 
entering the tissue differentiate in APC but this is hampered by tumor produced soluble factors. In the 
proximity of a PGE2 and IL-6 producing tumor their differentiation is skewed towards M2 macrophages. 
These macrophages produce VEGF and MMP which support tumor growth but also high IL-10 and low 
IL-12 suppressing T-cell function and precluding type 1 T-cell induction. However if this M2 macrophage 
interacts with an IFNg producing CD40-L expressing CD4+ T cell it can revert into a IL-12 producing 
macrophage capable of inducing type 1 T cells. Cisplatin or carboplatin treatment of a tumor that produce 
PGE2 and IL-6 (likely to be a COX-2 positive tumor) can induce higher levels of these factors and results in 
more M2 skewing. M2 induction by the tumor can be avoided by treating the patient with drugs that block 
COX-2 enzymes thereby preventing PGE2 production or blocking of the tumor produced IL-6 with MAb 
to IL-6 or IL-6Receptor. Induction of tumor specific IFNg producing T cells by therapeutic vaccination or 
adoptive T cell transfer (ACT) can shift the balance in the tumor towards anti-tumor inflammation by T-cell 
mediated activation of the local APC. Therapeutic options are depicted in the blue boxes.
immunogenic HPV16+ oropharyngeal tumors
Intriguingly, the incidence of HPV related cancers of the head and neck region are rapidly 
increasing. Another unresolved issue is how this virus can persist and cause cancer in an 




of lymphoid follicles that are covered with squamous epithelium that form crypts [47,48]. The 
reticulated crypt epithelium, also called lymphoepithelium plays a key role in the initiation 
of immune responses in the palatine tonsils. Luminal antigens are taken up in the crypts and 
transported to sub epithelial spaces where they come in contact with lymphoid cells. Not only 
HPV virus can settle in these crypts and infect basal cells of the epithelium but also a high load 
of fungi, bacteria and other viruses pass by this tissue at daily basis [47]. 
In chapter 4 we describe that in 6 out of 8 HPV16+ oropharyngeal cancer patients HPV 
specific T cells were present in tumors or LN. Although the cohort is very small and the results 
need to be validated in a bigger cohort, these data suggest that local HPV-specific T cells are 
more often present or less suppressed compared to HPV16+ cervical cancer [49]. In two patients 
HPV-specific proliferating and IFNg producing TIL could be readily detected in a direct ex-vivo 
analysis of a single cell suspension from  a fresh biopsy (without the need for a homeostatic 
proliferation period). This indicates that a strongly activated tumor-antigen specific T-cell 
population is present within these tumors (data not shown). In the tonsil, local APC can take 
up tumor antigens but in parallel may get activated through stimulation of their pattern 
recognition receptors by normal bacterial and viral flora entering the body. This concomitant 
activation results in stronger signal 2 and 3 delivery of APC to T cells. We hypothesize that 
infection and inflammation caused by other pathogens may appropriately activate APC in this 
lymphoid structure to prime HPV16-specific T cells resulting in the strong T cell response found 
in these (few) patients. Furthermore I speculate that the type of pathogen co-infecting  the 
tonsil at the moment of T-cell priming might be of importance for the T-cell response that is 
subsequently induced. This because we showed in chapter 5 and 6 that different TLR-agonists 
show unique activation patterns in APC resulting in different T cell stimulating abilities. 
Lesions in the oral cavity known as leucoplakia progresses in 20% to cancer and studies 
on the presence of HPV in these lesions showed conflicting results. Although HPV was more 
often detected in lesions compared to healthy control tissue is was not exclusively detected in 
lesions. Furthermore the prevalence of HPV in lesions varied from 17%- 68% between studies 
(reviewed by [50,51]. Whether these lesions are caused by the virus or that the virus just 
better persists in ulcerated tissue and therefore is more often detected, is not known. Also 
pre-cancerous lesions of the Tonsil are not studied yet and this is the localization where HPV+ 
HNSCC develops. Thus whether oropharyngeal neoplasias develop in the same way as cervical 
neoplasias (progression of CINI, II, III to malignant carcinoma) remains an open question. 
Studies on the presence of pre-malignant lesions in combination with determination of the 
present flora in the tonsil and a detailed analysis of local T-cell infiltrate and specificity might 
elicit some answers to the previous mentioned discrepancies between HPV-induced CxCa and 
HPV induced oropharyngeal carcinoma.
We described that circulating HPV specific T cells in HPV+ CxCa (chapter 2) as well as 
HPV16+ oropharyngeal cancer (chapter 4) proliferate but often lack detectable cytokine 
production when stimulated in vitro. In contrast to the circulating T cells, HPV-specific tumor 
infiltrating T cells of most HPV+ oropharyngeal tumors produce type 1 cytokines upon peptide 
recognition (chapter 4). Also here, the design of the study and the APC used for the test might 
have influenced the results. However in both test monocytes have presented the peptides 
and in the patients with HPV-negative tumors 4 out of 7 responses were accompanied by IFNg 
showing that monocytes can activate the T cells properly in these experiments.  
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Oropharyngeal tumor-derived TIL were able to respond to HPV oncoproteins with the 
production of type 1 cytokines when directly tested after isolation from a digested biopsy 
(n=2, data not shown) or short culture period (chapter 4). On the other hand we also showed 
that in addition to HPV16-specific IFNg and TNFa producing Th1 cells also HPV16 specific IL-5 
producing CD4+ Th2 cells, Treg and FoxP3 expressing CD8+ T cells could be isolated out of an 
oropharyngeal tumor. To understand why these patients, despite the presence of functional 
tumor-antigen specific T cells, can not fully control their growing HPV16+ tumors also the other 
tumor-infiltrating immune cells must be analyzed. For instance, one explanation could be that 
–similar to what is found in breast cancer [16] - CD4+ T cells promote pro-tumor inflammation 
by M2 macrophages in oropharyngeal tumors. Therefore, in depth analysis of the ex-vivo TIL 
population as described in chapter 3 for CxCa TIL should be performed including the analysis 
of Th2 and Th17 populations in this patients with oropharyngeal cancer. Furthermore, single 
cell suspensions of these tumors could be analyzed not only for lymphocytes but also for the 
presence and phenotype of the  myeloid cells. Finally, analysis of T cells isolated from regressing 
lesions after therapy might shed light on the role of these cells in the better disease free survival 
that HPV+ HNSCC patients display.
For the treatment of HPV16+ high grade vulvar intra-epithelial neoplasia (VIN), promising 
results were obtained with a synthetic long peptide (SLP) vaccine that induced strong and 
broad Th1 type T cell immunity to E6 and E7 [52,53]. Although patients with HPV16+ HNSCC 
carcinoma respond surprisingly well to radiotherapy this heavy treatment is not without side 
effects. It is suggested that the immunogenic properties  of these virally induced HPV16+ 
oropharyngeal tumors contribute to the good response to treatment ([54] further supported 
by the data of chapter 4).   Therapeutic vaccination aiming to reinforce the T-cell response 
to the HPV16 oncoproteins, thus may form a promising treatment modality. Schiering et al. 
recently published that tumor specific CD4+ T cells that spontaneously had developed in 
mice, suppressed the induction of new T cells by vaccination [55]. In view of our data showing 
that HPV specific T cell responses are present in the majority of the circulating T-cell and 
TIL- populations of patients with HPV16+ oropharyngeal tumors (chapter 4), vaccination may 
predominantly lead to boosting of already existing HPV16-specific T-cell responses and increase 
the number of HPV16-specific Th2 cells and regulatory T cells [56].  Therefore a prospective 
study on the presence of HPV-oncoprotein specific immunity, the correlation with survival and 





1. Schwartz RH: Costimulation of T 
lymphocytes: the role of CD28, CTLA-4, 
and B7/BB1 in interleukin-2 production and 
immunotherapy. Cell 1992, 71: 1065-1068. 
2. Kabelitz D: Expression and function of Toll-
like receptors in T lymphocytes. Curr Opin 
Immunol 2007, 19: 39-45. 
3. Caux C, Massacrier C, Vanbervliet B, Dubois 
B, Van Kooten C, Durand I et al.: Activation of 
human dendritic cells through CD40 cross-
linking. J Exp Med 1994, 180: 1263-1272. 
4. Stout RD: Macrophage activation by T cells: 
cognate and non-cognate signals. Curr Opin 
Immunol 1993, 5: 398-403. 
5. Karim R, Meyers C, Backendorf C, Ludigs K, 
Offringa R, van Ommen GJ et al.: Human 
papillomavirus deregulates the response of 
a cellular network comprising of chemotactic 
and proinflammatory genes. PLoS One 2011, 6: 
e17848. 
6. Youn JI, Gabrilovich DI: The biology of 
myeloid-derived suppressor cells: the 
blessing and the curse of morphological and 
functional heterogeneity. Eur J Immunol 2010, 
40: 2969-2975. 
7. Ostrand-Rosenberg S: Myeloid-derived 
suppressor cells: more mechanisms for 
inhibiting antitumor immunity. Cancer 
Immunol Immunother 2010, 59: 1593-1600. 
8. Obermajer N, Muthuswamy R, Lesnock J, 
Edwards RP, Kalinski P: Positive feedback 
between PGE2 and COX2 redirects the 
differentiation of human dendritic cells 
towards stable myeloid-derived suppressor 
cells. Blood 2011. 
9. Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, 
Zheng L: Activated monocytes in peritumoral 
stroma of hepatocellular carcinoma promote 
expansion of memory T helper 17 cells. 
Hepatology 2010, 51: 154-164. 
10. Movahedi K, Laoui D, Gysemans C, Baeten 
M, Stange G, Van den Bossche J et al.: 
Different tumor microenvironments contain 
functionally distinct subsets of macrophages 
derived from Ly6C(high) monocytes. Cancer 
Res 2010, 70: 5728-5739. 
11. Pettersen JS, Fuentes-Duculan J, Suarez-
Farinas M, Pierson KC, Pitts-Kiefer A, Fan L 
et al.: Tumor-associated macrophages in 
the cutaneous SCC microenvironment are 
heterogeneously activated. J Invest Dermatol 
2011, 131: 1322-1330. 
12. Ferrandina G, Lauriola L, Distefano MG, 
Zannoni GF, Gessi M, Legge F et al.: Increased 
cyclooxygenase-2 expression is associated 
with chemotherapy resistance and poor 
survival in cervical cancer patients. J Clin 
Oncol 2002, 20: 973-981. 
13. Hida T, Kozaki K, Ito H, Miyaishi O, Tatematsu 
Y, Suzuki T et al.: Significant growth inhibition 
of human lung cancer cells both in vitro and 
in vivo by the combined use of a selective 
cyclooxygenase 2 inhibitor, JTE-522, and 
conventional anticancer agents. Clin Cancer 
Res 2002, 8: 2443-2447. 
14. Noordhuis MG, Eijsink JJ, Roossink F, de GP, 
Pras E, Schuuring E et al.: Prognostic cell 
biological markers in cervical cancer patients 
primarily treated with (chemo)radiation: a 
systematic review. Int J Radiat Oncol Biol Phys 
2011, 79: 325-334. 
15. Souza RF, Shewmake K, Beer DG, Cryer 
B, Spechler SJ: Selective inhibition of 
cyclooxygenase-2 suppresses growth and 
induces apoptosis in human esophageal 
adenocarcinoma cells. Cancer Res 2000, 60: 
5767-5772. 
16. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell 
B, Shiao SL, Madden SF et al.: Leukocyte 
Complexity Predicts Breast Cancer Survival 
and Functionally Regulates Response to 
Chemotherapy. Cancer Discovery 2011. 
17. Denkert C, Loibl S, Noske A, Roller M, Muller 
BM, Komor M et al.: Tumor-associated 
lymphocytes as an independent predictor 
of response to neoadjuvant chemotherapy 
in breast cancer. J Clin Oncol 2010, 28: 105-113. 
18. Fridman WH, Galon J, Pages F, Tartour E, 
Sautes-Fridman C, Kroemer G: Prognostic and 
predictive impact of intra- and peritumoral 
immune infiltrates. Cancer Res 2011, 71: 5601-
5605. 
19. Jordanova ES, Gorter A, Ayachi O, Prins F, 
Durrant LG, Kenter GG et al.: Human leukocyte 
antigen class I, MHC class I chain-related 
molecule A, and CD8+/regulatory T-cell ratio: 
which variable determines survival of cervical 
cancer patients? Clin Cancer Res 2008, 14: 
2028-2035. 
20. Piersma SJ, Jordanova ES, van Poelgeest MtIE, 
Kwappenberg KMC, van der Hulst JM, Drijfhout 
JW et al.: High Number of Intraepithelial 
CD8+ Tumor-Infiltrating Lymphocytes Is 
Associated with the Absence of Lymph Node 
Metastases in Patients with Large Early-Stage 
Cervical Cancer. Cancer Res 2007, 67: 354-361. 
21. Zitvogel L, Kepp O, Kroemer G: Immune 
parameters affecting the efficacy of 
chemotherapeutic regimens. Nat Rev Clin 
Oncol 2011, 8: 151-160. 
22. Kryczek I, Wei S, Zhu G, Myers L, Mottram P, 
Cheng P et al.: Relationship between B7-H4, 
Regulatory T Cells, and Patient Outcome in 
154
Human Ovarian Carcinoma. Cancer Res 2007, 
67: 8900-8905. 
23. van Dongen M, Savage ND, Jordanova ES, 
Briaire-de Bruijn IH, Walburg KV, Ottenhoff 
TH et al.: Anti-inflammatory M2 type 
macrophages characterize metastasized 
and tyrosine kinase inhibitor-treated 
gastrointestinal stromal tumors. Int J Cancer 
2010, 127: 899-909. 
24. Stolina M, Sharma S, Lin Y, Dohadwala M, 
Gardner B, Luo J et al.: Specific inhibition 
of cyclooxygenase 2 restores antitumor 
reactivity by altering the balance of IL-10 and 
IL-12 synthesis. J Immunol 2000, 164: 361-370. 
25. Yin Z, Zhang Y, Li Y, Lv T, Liu J, Wang X: 
Prognostic significance of STAT3 expression 
and its correlation with chemoresistance 
of non-small cell lung cancer cells. Acta 
Histochem 2011. 
26. Apetoh L, Ghiringhelli F, Tesniere A, Obeid 
M, Ortiz C, Criollo A et al.: Toll-like receptor 
4-dependent contribution of the immune 
system to anticancer chemotherapy and 
radiotherapy. Nat Med 2007, 13: 1050-1059. 
27. Tesniere A, Schlemmer F, Boige V, Kepp O, 
Martins I, Ghiringhelli F et al.: Immunogenic 
death of colon cancer cells treated with 
oxaliplatin. Oncogene 2010, 29: 482-491. 
28. Demaria S, Bhardwaj N, McBride WH, 
Formenti SC: Combining radiotherapy and 
immunotherapy: a revived partnership. Int J 
Radiat Oncol Biol Phys 2005, 63: 655-666. 
29. Nesslinger NJ, Sahota RA, Stone B, Johnson K, 
Chima N, King C et al.: Standard treatments 
induce antigen-specific immune responses 
in prostate cancer. Clin Cancer Res 2007, 13: 
1493-1502. 
30. Reits EA, Hodge JW, Herberts CA, Groothuis 
TA, Chakraborty M, Wansley EK et al.: 
Radiation modulates the peptide repertoire, 
enhances MHC class I expression, and induces 
successful antitumor immunotherapy. J Exp 
Med 2006, 203: 1259-1271. 
31. Legge F, Paglia A, D’Asta M, Fuoco G, Scambia 
G, Ferrandina G: Phase II study of the 
combination carboplatin plus celecoxib in 
heavily pre-treated recurrent ovarian cancer 
patients. BMC Cancer 2011, 11: 214. 
32. Bertagnolli MM, Eagle CJ, Zauber AG, Redston 
M, Solomon SD, Kim K et al.: Celecoxib for the 
prevention of sporadic colorectal adenomas. 
N Engl J Med 2006, 355: 873-884. 
33. Groen HJ, Sietsma H, Vincent A, Hochstenbag 
MM, van Putten JW, van den Berg A et al.: 
Randomized, Placebo-Controlled Phase III 
Study of Docetaxel Plus Carboplatin With 
Celecoxib and Cyclooxygenase-2 Expression 
As a Biomarker for Patients With Advanced 
Non-Small-Cell Lung Cancer: The NVALT-4 
Study. J Clin Oncol 2011, 29: 4320-4326. 
34. Koch A, Bergman B, Holmberg E, Sederholm C, 
Ek L, Kosieradzki J et al.: Effect of celecoxib on 
survival in patients with advanced non-small 
cell lung cancer: a double blind randomised 
clinical phase III trial (CYCLUS study) by the 
Swedish Lung Cancer Study Group. Eur J 
Cancer 2011, 47: 1546-1555. 
35. Coward J, Kulbe H, Chakravarty P, Leader D, 
Vassileva V, Leinster DA et al.: Interleukin-6 
as a Therapeutic Target in Human Ovarian 
Cancer. Clin Cancer Res 2011, 17: 6083-6096. 
36. Choy E: Inhibiting interleukin-6 in rheumatoid 
arthritis. Curr Rheumatol Rep 2008, 10: 413-417. 
37. Betts BC, St Angelo ET, Kennedy M, Young 
JW: Anti-IL6-receptor-alpha (tocilizumab) 
does not inhibit human monocyte-derived 
dendritic cell maturation or alloreactive T-
cell responses. Blood 2011, 118: 5340-5343. 
38. Dalwadi H, Krysan K, Heuze-Vourc’h N, 
Dohadwala M, Elashoff D, Sharma S et al.: 
Cyclooxygenase-2-dependent activation 
of signal transducer and activator of 
transcription 3 by interleukin-6 in non-small 
cell lung cancer. Clin Cancer Res 2005, 11: 7674-
7682. 
39. Yu H, Pardoll D, Jove R: STATs in cancer 
inflammation and immunity: a leading role for 
STAT3. Nat Rev Cancer 2009, 9: 798-809. 
40. Murdoch C, Giannoudis A, Lewis CE: 
Mechanisms regulating the recruitment of 
macrophages into hypoxic areas of tumors 
and other ischemic tissues. Blood 2004, 104: 
2224-2234. 
41. Bos R, Sherman LA: CD4+ T-cell help in the 
tumor milieu is required for recruitment and 
cytolytic function of CD8+ T lymphocytes. 
Cancer Res 2010, 70: 8368-8377. 
42. Nakanishi Y, Lu B, Gerard C, Iwasaki A: CD8(+) 
T lymphocyte mobilization to virus-infected 
tissue requires CD4(+) T-cell help. Nature 
2009, 462: 510-513. 
43. Hunder NN, Wallen H, Cao J, Hendricks DW, 
Reilly JZ, Rodmyre R et al.: Treatment of 
metastatic melanoma with autologous CD4+ 
T cells against NY-ESO-1. N Engl J Med 2008, 
358: 2698-2703. 
44. Melief CJ, van der Burg SH: Immunotherapy 
of established (pre)malignant disease by 
synthetic long peptide vaccines. Nat Rev 
Cancer 2008, 8: 351-360. 
45. Verdegaal EM, Visser M, Ramwadhdoebe TH, 
van der Minne CE, van Steijn JA, Kapiteijn E 
et al.: Successful treatment of metastatic 
melanoma by adoptive transfer of blood-
derived polyclonal tumor-specific CD4+ 




dose interferon-alpha. Cancer Immunol 
Immunother 2011, 60: 953-963. 
46. Welters MJ, Kenter GG, de Vos van Steenwijk PJ, 
Lowik MJ, Berends-van der Meer DM, Essahsah 
F et al.: Success or failure of vaccination for 
HPV16-positive vulvar lesions correlates with 
kinetics and phenotype of induced T-cell 
responses. Proc Natl Acad Sci U S A 2010, 107: 
11895-11899. 
47. Nave H, Gebert A, Pabst R: Morphology and 
immunology of the human palatine tonsil. 
Anat Embryol (Berl) 2001, 204: 367-373. 
48. Perry ME: The specialised structure of crypt 
epithelium in the human palatine tonsil and 
its functional significance. J Anat 1994, 185 ( Pt 
1): 111-127. 
49. Piersma SJ, Welters MJ, van der Hulst JM, Kloth 
JN, Kwappenberg KM, Trimbos BJ et al.: Human 
papilloma virus specific T cells infiltrating 
cervical cancer and draining lymph nodes 
show remarkably frequent use of HLA-DQ 
and -DP as a restriction element. Int J Cancer 
2008, 122: 486-494. 
50. Syrjanen S, Lodi G, von B, I, Aliko A, Arduino P, 
Campisi G et al.: Human papillomaviruses in 
oral carcinoma and oral potentially malignant 
disorders: a systematic review. Oral Dis 2011, 
17 Suppl 1: 58-72. 
51. Campisi G, Panzarella V, Giuliani M, Lajolo C, Di 
FO, Falaschini S et al.: Human papillomavirus: 
its identity and controversial role in oral 
oncogenesis, premalignant and malignant 
lesions (review). Int J Oncol 2007, 30: 813-823. 
52. Kenter GG, Welters MJ, Valentijn AR, Lowik 
MJ, Berends-van der Meer DM, Vloon AP et al.: 
Vaccination against HPV-16 oncoproteins for 
vulvar intraepithelial neoplasia. N Engl J Med 
2009, 361: 1838-1847. 
53. Welters MJ, Kenter GG, Piersma SJ, Vloon AP, 
Lowik MJ, Berends-van der Meer DM et al.: 
Induction of tumor-specific CD4+ and CD8+ 
T-cell immunity in cervical cancer patients 
by a human papillomavirus type 16 E6 and E7 
long peptides vaccine. Clin Cancer Res 2008, 
14: 178-187. 
54. Chung CH, Gillison ML: Human papillomavirus 
in head and neck cancer: its role in 
pathogenesis and clinical implications. Clin 
Cancer Res 2009, 15: 6758-6762. 
55. Schiering C, Guarnerio J, Basso V, Muzio L, 
Mondino A: Antigen-experienced CD4(+) T 
cells limit naive T-cell priming in response to 
therapeutic vaccination in vivo. Cancer Res 
2010, 70: 6161-6170. 
56. Welters MJ, de JA, van den Eeden SJ, van der 
Hulst JM, Kwappenberg KM, Hassane S et al.: 
Frequent display of human papillomavirus 
type 16 E6-specific memory t-Helper cells in 
the healthy population as witness of previous 









Ons afweersysteem bestaat uit twee samenwerkende delen: een aspecifiek deel dat snel kan 
reageren op signalen uit de omgeving en een specifiek deel dat unieke delen van eiwitten 
afkomstig van ziekteverwekkers (virus, bacterie etc.) of van afwijkende cellen (kanker) 
herkent en hier tegen geheugen op kan bouwen. Macrofagen behoren tot het eerstgenoemde 
aspecifieke deel.  Dendritische Cellen (DC) vormen een brug tussen beide delen van het 
afweersysteem. Beiden zijn antigeen presenterende cellen (APC) wat inhoudt dat zij eiwitten 
van de ziekteverwekkers of kankercellen kunnen opeten en dan kleine stukjes hiervan 
(peptiden) in de context van zogenoemde MHC moleculen presenteren aan het specifieke 
deel van het afweersysteem, de T cellen. Macrofagen en DC hebben allerlei receptoren op hun 
celoppervlak die ervoor kunnen zorgen dat ze geactiveerd raken. Toll like receptoren zijn een 
voorbeeld hiervan; deze receptoren herkennen delen van bacterien en virussen. Het resultaat 
van herkenning via deze receptoren is dat de APC extra co-stimulatoire moleculen op het 
celoppervlak brengen en dat er bepaalde stoffen worden uitgescheiden zoals cytokines. T cellen 
die  het MHC-peptide complex herkennen zullen door de aanwezige co-stimulatoire moleculen 
en cytokines geïnstrueerd worden om te gaan delen en een bepaalde functie uit te oefenen. 
In het geval van een ziekteverwekker zullen zij ten strijde trekken om de ziekteverwekker te 
vernietigen. Nadat de taak van de T cellen erop zit, blijft een kleine groep over, deze vormen 
een poel van reservekrachten die snel kunnen reageren mocht de ziekteverwekker opnieuw 
in het lichaam aanwezig zijn. De cellen van het afweercellen kunnen uitrijpen tot  cellen met 
verschillende functies naar gelang het type activeringsignaal. Macrofagen rijpen uit in grofweg 
2 types; type 1 pro-inflammatoire macrofagen stimuleren een ontsteking (inflammatie)  en het 
specifieke deel van het afweersysteem.  Type 2 macrofagen zijn betrokken bij wondheling, 
bloedvatvorming en de onderdrukking van T cel reacties. Ook T cellen ontwikkelen zich in 
verschillende typen. Type 1 cytotoxische (CD8+) en helper (CD4+) T cellen kenmerken zich 
onder andere door productie van IFNg en hun vermogen om zieke of geïnfecteerde cellen aan 
te vallen en dood te maken. Wanneer CD4+ cellen (T helpers) een MHC-peptide complex op 
een APC herkennen zullen zij via CD40-CD40-L interacties een APC sterk activeren en hiermee 
helpen zij  een specifieke immuunrespons op gang te houden. Daarnaast zijn er ook regulatoire 
T cellen die de ontwikkeling en functie van andere afweercellen kunnen onderdrukken.
Tumoren proberen een afweerreactie van T cellen te vermijden door middel van 
verschillende strategieën. Eén manier is om verschillende, voor de afweerreactie van belang 
zijnde, molekulen op het oppervlakte van de tumorcel aan te passen. Een tweede manier is 
factoren uitscheiden die T cellen onderdrukken. Ook gebruiken ze type 2 macrofagen om 
nieuwe bloedvaten te genereren en om T cel reacties te onderdrukken.
In verschillende diermodellen en in studies van menselijk materiaal is aangetoond dat een 
hoog aantal CD8 cellen en een laag aantal regulatoire T cellen in de tumor voorspellend is 
voor een betere overleving in patiënten met kanker. De aanwezigheid van een hoog aantal 
type 2 macrofagen in de tumor voorspelt een slechtere overleving. Dit duidt erop dat het 
afweersysteem een belangrijke rol speelt in controle van de tumor groei.
Het Humaan Papilloma Virus (HPV) is een DNA virus dat basale epitheel cellen infecteert. 
De tumorveroorzakende typen HPV (voornamelijk HPV 16 en 18) veroorzaken afwijkingen 
aan o.a. de baarmoederhals die uiteindelijk kunnen leiden tot baarmoederhalskanker. 
Nadat het virus een huidcel heeft geïnfecteerd komen virale eiwitten tot expressie in de cel. 
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Enkele virale eiwitten, genaamd E6 en E7, induceren ongecontroleerde celdeling en maligne 
transformatie en zijn verantwoordelijk voor het ontstaan en in stand houden van kanker. In een 
getransformeerde cel zijn dus altijd de eiwitten E6 en E7 aanwezig en omdat dit virale eiwitten 
zijn kan er een specifieke (T cel gecontroleerde) afweerreactie ontstaan. In dit proefschrift 
onderzoeken we T cellen die specifiek deze eiwitten herkennen.
Ruim de helft van de mensen die seksueel actief zijn wordt geïnfecteerd met een 
tumorveroorzakend type van HPV. Bijna alle geïnfecteerde vrouwen maken een afweerreactie 
en ruimen het virus weer op. Bij enkele mensen is het virus toch in staat om te blijven zitten en 
in de loop van de jaren kan dit tot kanker leiden. Waarom niet alle vrouwen het virus opruimen 
en enkelen toch een tumor ontwikkelen is nog steeds niet opgehelderd. Wel is er gevonden 
dat in voorstadia van een ontwikkelende tumor de T cellen een belangrijke rol spelen in het 
voorkomen van ernstige ziekte. In gezonde vrouwen worden sterke tegen HPV reagerende T 
cel reacties gevonden maar in vrouwen met een persisterende HPV infectie werden geen of 
zwakkere T cel reacties gemeten.
Nieuw is dat HPV (voornamelijk HPV16) steeds vaker wordt gevonden in tumoren van het 
hoofd-hals gebied, met name  in de oropharynx (voornamelijk de amandelen). Hoewel er nog 
niet veel bekend is over de rol van het virus in deze tumoren, of de afweerreactie hiertegen, is 
het wel duidelijk dat patiënten met een tumor die HPV positief is veel beter reageren op (radio)
therapie dan patiënten die een tumor in dit gebied hebben die niet veroorzaakt wordt door HPV. 
De standaard behandeling voor tumoren is nog altijd chirurgie en het verwijderen van 
de tumor. Terugkerende baarmoederhalskanker wordt behandeld met platina houdende 
chemotherapie, zoals cisplatinum. Helaas reageert maar een klein deel van de patiënten 
goed op deze therapie (30%). Behandeling van tumoren met chemotherapie is gericht op 
destructie van de delende tumorcellen. Het is nog niet goed onderzocht wat de bijeffecten 
zijn van verschillende chemotherapeutica op de locale afweercellen.  Een relatief nieuwe vorm 
van therapie voor kanker is de immunotherapie, het behandelen van kanker door (delen van) 
het afweersysteem te gebruiken. De eerste vorm van immunotherapie die in de kliniek als 
behandeling wodt gebruikt is monoklonale antilichamen. Dit zijn antistoffen die bijvoorbeeld 
een specifieke factor of receptor op tumorcellen binden en daarmee de groeifactoren van 
tumoren weg nemen. Een nieuwere vorm van immunotherapie is het gebruik van zogenoemde 
therapeutische vaccins. Deze vaccins hebben als doel de tegen de tumor gerichte CD4 en CD8 
T cel reactie zodanig te versterken dat de tumorgroei onder controle komt.
In dit proefschrift zijn verschillende aspecten van de afweerreactie tegen (door HPV 
veroorzaakte) tumoren onderzocht. Door meer kennis van de locale afweerrespons te krijgen 
kunnen we immunotherapeutische strategieën gebaseerd op therapeutische vaccinatie beter 
ontwikkelen en toepassen.
In hoofdstuk 2 hebben we de HPV-specifieke T cel reactie in het bloed van een grote groep 
baarmoederhalskanker patiënten prospectief geanalyseerd. Maar 31% van deze patiënten 
had circulerende HPV-specifieke T cellen. Een positieve T-cel reactie werd vaker gezien in de 
groep patiënten met diep infiltrerende tumoren. Hoewel diepe infiltratie van de tumor in het 
gezonde weefsel een slecht prognostisch teken is, bleek dat die patiënten die daarbij ook een 
circulerende HPV-specifieke T cel reactie hadden een betere 3-jaars overleving hadden dan de 
patiënten waarin zo’n reactie niet aangetoond kon worden.
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Eerder is gepubliceerd dat  in 30% van de HPV veroorzaakte baarmoederhals tumoren  T 
cellen tegen dit virus in de tumor te vinden zijn. In hoofdstuk 3 beschrijven wij een uitgebreide 
analyse van de breedte en het type respons van  T cel populaties in de tumor of uit de tumor-
drainerende lymfeklier. Als patiënten een HPV-specifieke reactie hadden dan was deze vaak 
verassend breed (meerdere eiwitdelen herkend, meerdere clonale T cel populaties). Een deel 
van de HPV-specifieke T cellen maakte niet de gewenste  cytokines interferon-g en IL-2. De 
toevoeging van APC-activerende signaalstoffen die aan de op APC aanwezige toll-like receptoren 
(TLR) binden resulteerde in hogere cytokine productie door de HPV-specifieke T cellen.
Niet alleen in de ano-genitale regio maar ook in de keel is HPV terug te vinden. Hoofdstuk 
4 beschrijft een eerste studie naar de HPV-specifieke T cellen in patiënten met kanker in de 
hoofd-hals regio. HPV16 DNA werd alleen gevonden in tumoren van de amandelen/oropharynx 
maar niet op andere locaties in dit gebied. We vonden in het bloed van verschillende patiënten 
HPV-specifieke T cellen terug, wat duidt op een eerdere infectie of een infectie die nog 
aanwezig is. In HPV16-positieve tumoren vonden we verrassend vaak HPV-specifieke T cellen. 
Dit zou een verklaring kunnen zijn waarom deze patiënten een grotere kans op overleving 
hebben op therapie; er is immers al een leger van afweercellen aanwezig die specifiek tumor 
antigeen herkent. Verder onderzoek naar de andere aanwezige afweercellen in deze tumoren 
moet uitwijzen waarom de tumor toch groeit ondanks sterke locale T cel reactie.
Het tekort aan HPV specifieke T cellen in patiënten met baarmoederhalskanker zou 
kunnen komen doordat ze een goede stimulatie door DC missen. In hoofdstuk 5a hebben we 
onderzocht of tumoren de uitrijping van monocyten naar DC kunnen beinvloeden. Meerdere in 
het laboratorium gekweekte tumorcellijnen bleken factoren te produceren die de ontwikkeling 
van DC verstoorde. Enkele tumorcellijnen dreven de uitrijping van monocyten in de richting van 
type 2 macrofagen. De type 2 macrofagen produceerden na stimulatie veel IL-10 en weinig IL-12 
en waren daardoor slecht in staat een type 1 T cel reactie te induceren. De verantwoordelijke 
factoren voor de uitrijping van macrofagen waren de door tumorcellen uitgescheiden stoffen 
prostaglandine E2 (PGE2) en IL-6. Behandeling van de tumorcellen met COX-remmers (COX-
enzymen vormen o.a. PGE2) resulteerde in restauratie van de ontwikkeling van DC. Interactie 
met interferon-g producerende type 1 T cellen, via CD40- CD40-L interacties, is een sterk 
activerende stimulus voor dendritische cellen en macrofagen. In dit hoofdstuk laten we ook 
zien dat stimulatie van type 2 macrofagen via CD40 en de IFNg receptor  (via CD40-L positieve 
cellen en de toevoeging van IFNg zoals zou worden geleverd door type 1 T-helper cellen) sterk 
genoeg is om deze te veranderen in geactiveerde type 1 macrofagen. Dit suggereert dat het 
remmen van COX-enzymen en IL-6 en daarnaast het verhogen van de aanwezigheid van type 1 
T cellen een gunstig effect heeft op de lokale ontstekingsreactie in de tumor.
Als baarmoederhalskanker weer terug komt ondanks therapie worden patiënten vaak 
behandeld met platinum houdende chemotherapie. Het effect van chemotherapie op de lokale 
afweercellen is nog niet goed onderzocht. In hoofdstuk 5b onderzoeken we de immuun-
modulerende effecten van cisplatinum op tumor cellen en de uitrijping van monocyten naar 
DC. Verrassend genoeg bleek dat de behandeling van tumorcellen met een fysiologische 
dosis cisplatinum de productie van PGE2 en IL-6 door tumorcellen verhoogt. Dit resulteerde 
in een toename van het percentage monocyten dat tot type 2 macrofagen was uitgerijpt. 
Deze macrofagen  dragen niet bij aan de afweerreactie tegen tumoren maar produceren wel 
groeifactoren voor de tumor. Dit betekent dat een behandeling met cisplatinum van een 
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tumor waarvan niet alle cellen doodgaan maar wel M2 macrofagen kunnen induceren mogelijk 
averechts kan werken voor de patient. Dit mechanisme kan een alternatieve verklaring  zijn voor 
een eerder beschreven observatie dat patiënten met een tumor die hoog COX-2 tot expressie 
brengt een slechtere respons op chemotherapie hebben. In dit hoofdstuk onderzoeken we ook 
of andere CD4 cellen die andere cytokinen dan interferon-g produceren in staat zijn om type 
2 macrofagen te veranderen naar een ander type macrofagen net zoals type 1 CD4+ T-helper 
cellen dat kunnen. 
Er wordt momenteel veel geïnvesteerd in onderzoek naar therapeutische vaccinatie voor 
de behandeling van chronische infecties en kanker met het doel om beschermende T cel 
immuniteit te genereren. Het gebruikte adjuvant en de route van toedienen zijn belangrijk voor 
het type van de geïnduceerde T-cel respons. Intra-dermale injectie lijkt een goede methode om 
de afweer te stimuleren tegen ziekten die zich ontwikkelen in de huid,  zoals melanoom en HPV 
geïnduceerde tumoren, omdat de geïnduceerde T cellen dan geïnstrueerd worden om naar de 
huid te migreren. In hoofdstuk 6 bekijken we het effect van verschillende TLR stimulerende 
stoffen (agonisten) op de activering  van uit de huid migrerende APC in een menselijk ex-vivo 
huid model. Het blijkt dat maar enkele TLR-agonisten activatie van in de huid aanwezige APC 
induceren in tegenstelling tot de in-vitro resultaten met zulke cellen zoals beschreven in de 
literatuur en dit kan implicaties hebben voor de keuze van adjuvant in vaccinatie strategien.
De behandeling van patiënten met uitgebreid colorectaal kanker bestaat momenteel uit 
chemotherapie samen met een monoklonaal antilichaam dat een tumorgroeifactor wegvangt 
(bevacizumab). Toevoeging aan dit regime van een tweede antilichaam dat de groeireceptor 
EGFR blokkeert op de tumor cellen (cetuximab), en daardoor verder de groei van deze cellen 
remt,  resulteerde niet in de verwachte extra overleving (CAIROII studie). Verdere analyse liet 
zien dat patiënten met een bepaald polymorfisme in het gen voor FCGR3A (FcgRIIIa is een 
receptor die de staart van antilichamen bindt) het significant slechter deden als cetuximab 
was toegevoegd aan het regime. Dit polymorfisme geeft een hogere bindingsaffiniteit voor 
antilichamen aan deze receptor. Omdat macrofagen vaak aanwezig zijn in colorectale tumoren 
testen wij in hoofdstuk 7 de hypothese dat aan tumorcel gebonden cetuximab de tolerogene, 
tumor geassocieerde type 2 macrofagen, die sterk FcgRIIIa positief zijn, activeert. Activering 
van deze tumorbevorderende macrofagen zou een verklaring kunnen zijn voor de slechtere 
overleving in de groep met cetuximab in de eerder beschreven studies. Onze in-vitro proeven 
laten zien dat inderdaad de type 2 macrofagen geactiveerd kunnen worden door dit antilichaam 
wanneer het gebonden is aan het oppervlak van tumor cellen en dit lijkt ook meer efficiënt 
te gebeuren in donoren met een receptor die een hogere bindingsaffiniteit voor antistoffen 
hebben. Dit heeft implicaties voor de toekomstige ontwikkeling van antilichamen die vaak 
extra geoptimaliseerd worden om aan de FcgRIIIa te binden. Dit omdat men de activatie van 
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